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 i 
Abstract 
 
This translational research evaluates a novel, custom-built Raman probe for potential 
application as an in vivo diagnostic tool in the oesophagus. Raman spectroscopy (RS) is a 
well established analytical technique which is capable of probing the biochemical changes 
associated with neoplastic progression in oesophageal tissue. RS relies on measurement of 
subtle inelastic scattering signals following monochromatic laser excitation. 
 
Clinical utilisation of RS within hollow organs requires accurate collection and transmission 
of signal through fibre-optic cables. This research aims to evaluate the ability of a custom 
built fibre-optic Raman probe, in conjunction with multivariate classification models, to 
differentiate between benign and neoplastic oesophageal pathologies ex vivo. The need for 
spectral stability and reproducibility are addressed, as are difficulties associated with multi-
system reliability. In addition, the biochemical basis of spectral classification is evaluated and 
discussed. 
 
Seven hundred and ninety-eight 1 s Raman probe spectra were acquired from 673 ex vivo 
oesophageal tissue samples from 62 patients. 5 s and 0.1 s spectra were also recorded for 
comparison. Principal component fed linear discriminant analysis was used to calculate probe 
accuracy by reference to a consensus histopathological ‘gold standard’ diagnosis. All results 
were statistically cross validated. 
 
Based on characteristic spectral signatures, high-grade dysplasia and adenocarcinoma could 
be discriminated from Barrett’s oesophagus, low-grade dysplasia and normal squamous 
oesophagus with a sensitivity of 86% and a specificity of 88%. The ability to detect early 
superficial mucosal disease, including discrimination between low-grade and high-grade 
dysplasia, was also demonstrated despite short, clinically applicable (1 s) spectral acquisition 
times. Background subtraction and green glass correction algorithms were not shown to 
enhance diagnostic performance. However, improved diagnostic accuracy was demonstrated 
using longer acquisition times. 
 
A single probe was shown to measure consistent spectra over a 20 month period. In addition, 
a potential algorithm for multi-system spectral classification was defined, and consistent 
measurements were recorded by two independent operators using two identically built 
 ii 
probes. The potential for bimodal diagnosis using a combination of RS and narrow band 
imaging was also demonstrated. No single incident of thermal tissue injury was reported. 
 
The ability for rapid, accurate, objective diagnosis of a range of oesophageal pathologies 
using a novel endoscopic Raman probe has been demonstrated. RS has the potential to aid 
targeting of high-grade dysplasia and intramucosal cancer during endoscopic resection in 
order to maximise R0 resection rates. A potential barrier to clinical application of RS will be 
the transferability and repeatability of spectral measurements acquired with different Raman 
systems. This will require further evaluation following the construction of multiple probes. 
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CHAPTER 1 
 
1 Introduction: Research Context and Objectives 
 
Barrett’s oesophagus is known to progress through a series of histologically identifiable 
dysplastic changes to oesophageal adenocarcinoma and confers an increased risk of 
malignancy. However, endoscopic detection of high grade dysplasia (HGD) (the 
premalignant lesion) and early intramucosal cancer (T1a) within Barrett’s segments is 
unreliable, even for experienced endoscopists.[1-6] British Society of Gastroenterology 
guidelines therefore recommend random quadrantic biopsies every 2cm of Barrett’s 
oesophagus.[7] This gold standard biopsy regimen samples <5% of the oesophageal mucosa 
and may fail to diagnose up to 57% of dysplastic lesions.[8] In addition, patients with 
confirmed HGD have a significant risk of occult invasive malignancy (around 35%) which 
may be missed by random biopsy.[9-26] 
 
The early detection of premalignant breast, colon and cervical neoplasia has facilitated timely 
intervention in patients with these tumours leading to decreased cancer-related mortality.[27] 
However, despite the recognition of Barrett’s oesophagus as a significant risk factor for 
oesophageal adenocarcinoma, and a variety of novel techniques to resect and ablate early 
neoplastic lesions, five year survival rates remain dismal (8-15%).[28-30] 
 
The relative lack of progress in terms of mortality outcomes stems partly from difficulties in 
predicting the small cohort of patients with non-dysplastic Barrett’s oesophagus who will 
eventually progress to cancer. It also reflects difficulties in identifying neoplastic lesions 
endoscopically and the absence of a non-endoscopic screening test. 
 
Recently improved therapeutic strategies for treating HGD / T1a disease, including 
endoscopic resection and radiofrequency ablation, have created a profound clinical need for a 
safe and accurate test to endoscopically diagnose and grade early Barrett’s-associated 
neoplasia. Since patients with Barrett’s oesophagus are at an increased risk of malignant 
progression, this cohort are currently kept under close endoscopic surveillance. However, 
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improved endoscopic diagnostic techniques are required to: target areas of dysplasia for point 
biopsy (minimising missed neoplasia and the risks of bleeding/perforation); assess resection 
margins intra-operatively; and ultimately enable instant diagnosis of dysplasia and 
intramucosal cancer in order to facilitate early targeted endoscopic resection with meticulous 
endoscopic margin assessment. 
 
Raman spectroscopy is an optical diagnostic technique which has shown considerable 
potential for early diagnosis of a variety of malignant disease states.[31-51] Raman 
spectroscopy measures the molecular-specific, inelastic scattering of laser light within tissue, 
producing a molecular ‘fingerprint’ unique to that tissue. Normal and abnormal tissue has 
differing biochemical cellular components leading to characteristic spectral differences which 
can be analysed. Laboratory based Raman spectrometers have previously been shown to be 
capable of discriminating eight pathological tissue types in the distal oesophagus (including 
Barrett’s metaplasia, HGD and adenocarcinoma) with high sensitivities and specificities.[49] 
 
The objective of this Doctorate is to facilitate the translation of this laboratory technique into 
a clinical tool which can be used endoscopically in patients with Barrett’s oesophagus. 
Raman spectroscopy has clear potential as a medical diagnostic tool, it is exquisitely sensitive 
to minute biochemical changes; objective; rapid; safe; suitable for analysis of fresh un-
prepared tissue; and feasible for use in conjunction with specialised fibre-optics to enable 
hollow organ assessment. 
 
Following a multi-unit collaboration a novel fibre-optic Raman probe has been designed and 
built at the Analysis Interface Centre at Bristol University. The probe, which has been 
specifically designed to fit through the instrument channel of a gastroscope, is novel in its 
design which aims to facilitate interrogation of the epithelial surface so potentially enabling 
detection of early pre-malignant neoplasia. In addition, the probe has been engineered for 
direct contact with oesophageal epithelium. 
 
This Doctorate aims to evaluate the potential of this novel Raman probe to discriminate 
clinically relevant oesophageal pathologies. The probe has been coupled to a near-infrared 
monochromatic laser source and a Renishaw system 100 spectrometer (Renishaw Plc., 
Wotton-under-Edge, Gloucestershire, UK). Initial proof of concept experiments have been 
conducted using laboratory standards and porcine tissue phantoms. Further evaluation has 
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used fresh human oesophageal tissue to evaluate the diagnostic potential of this technique 
with the aim of supporting a future application for an in vivo clinical trial. Probe performance 
has been evaluated from a translational standpoint, ensuring clinically applicable laser power 
at the probe tip and short spectral acquisition times which will be feasible during routine 
oesophagoscopy. Besides diagnostic accuracy, other translational aspects have also been 
addressed including inter-user variability, consistency of spectral acquisition over a 
prolonged (18 month) time period, compatibility with narrow band imaging, variation of 
accuracy with spectral acquisition times, and reproducibility and transferability of data 
measured using independent (optically identical) probes and using different spectrometers. 
 
This is a translational research project with huge clinical significance. All data has been 
collected safely and meticulously using rigorous scientific standards in order to generate 
robust, reproducible and clinically relevant results. The data has been carefully and 
thoroughly evaluated so as to present an accurate, rather than over-optimistic, description of 
probe performance in order to truly establish potential for future clinical use. 
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CHAPTER 2 
 
2 Literature Review: Barrett’s Oesophagus 
 
2.1 Oesophageal cancer – Epidemiology and Clinical Significance 
 
Over the past 40 years the incidence of oesophageal adenocarcinoma has increased more 
rapidly than any other solid tumour in the Western world (Figure  2-1). Oesophageal cancer 
has become the ninth most prevalent cancer in the UK[52] and now represents a major public 
health problem. 
 
Figure  2-1. Oesophageal adenocarcinoma incidence ratio relative to 1975. Reproduced 
from the National Cancer Institute’s Surveillance, Epidemiology, and End Results 
database.[30] 
The other common pathological type of oesophageal cancer, squamous cell carcinoma (SCC), 
has by contrast declined by around 2% per year over the past decade, and adenocarcinoma 
now accounts for more than 50% of cases.[52][28]   This trend is likely to result from the 
changing pattern of risk factors which influence the development of the two diseases. Rates 
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of smoking - a major risk factor for SCC - are declining, and rates of gastro-oesophageal 
reflux, the principal risk factor for adenocarcinoma, have increased dramatically. 
The rapid increase in incidence of oesophageal adenocarcinoma is given a greater 
significance when survival figures are considered. Between 1993 and 1997 pooled data from 
the United States illustrated a one year survival of 44% with a 5 year survival of just 
13%.[53] Figures from the Office for National Statistics quoted UK survival rates from 2001 
as just 28% and 8% respectively.[29] More recently the National Oesophagogastric Cancer 
Audit reported a 5 year age-adjusted survival rate of 10%.[28] In addition the audit reported a 
1 year survival of just 76% in those patients who underwent oncological and surgical therapy 
with curative intent.[28] Five year survival rates following surgery with curative intent 
remain between 25% and 40%. 
It is clear that oesophageal cancer outcomes have lagged hugely behind those for other 
common malignancies including bowel, breast, and cervical cancer and there is now a 
pressing clinical need to diagnose oesophageal cancer earlier, and to identify and treat 
dysplastic changes in the oesophagus in order to prevent progression to malignancy. 
 
2.2 Barrett’s Oesophagus – definition, epidemiology, significance 
2.2.1 Definition: 
 
Barrett’s oesophagus is a well known risk factor for the development of oesophageal 
adenocarcinoma.[54; 55] Barrett’s oesophagus is defined by the American College of 
Gastroenterology as “a change in the distal oesophageal epithelium of any length that can 
be recognised as columnar type mucosa at endoscopy and is confirmed to have intestinal 
metaplasia by biopsy of the tubular oesophagus”.[56] The need for recognition of 
intestinal metaplasia (IM), as opposed to two other histologically distinct types of columnar 
metaplasia: cardiac (CM) and fundic (FM), reflects the fact that it is IM which has been 
shown to have significant malignant potential.[54; 57-61] IM can be easily recognised 
histologically by the presence of goblet cells occurring in association with columnar 
epithelium (Figure  2-5). 
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However, both British and Japanese guidelines on Barrett’s oesophagus exclude the need for 
goblet cells in their definitions. The British Society of Gastroenterology prefers the term 
‘columnar-lined oesophagus’ (CLO) and defines Barrett’s oesophagus as “an oesophagus in 
which any portion of the normal squamous lining has been replaced by a metaplastic 
columnar epithelium which is visible macroscopically. In order to make a positive 
diagnosis of “Barrett’s oesophagus”, a segment of columnar metaplasia of any length 
must be visible endoscopically above the oesophago-gastric junction and confirmed or 
corroborated histologically.”[7] The explanation for the difference in definitions is that UK 
pathologists consider that goblet cells can always be identified within a Barrett’s segment 
provided sufficient biopsies are taken over an adequate time-scale.[7] 
 
In the UK, the definition of Barrett’s oesophagus is therefore regarded as a 
clinicopathological construct from both endoscopic and histopathological findings. 
 
2.2.2 Epidemiology 
 
The exact population prevalence of Barrett’s oesophagus is unclear. Reports from endoscopic 
series range from 0.9% to 5.6% depending on the precise definition used and the type of 
study.[62; 63] A well designed population based study recruited a representative sample of 
1000 people from two communities in Northern Sweden to undergo upper endoscopy and 
confirmed the presence of intestinal metaplasia in 1.6% of the population studied.[64] 
 
When extrapolated to the UK and US populations, conservative estimates of prevalence are 
approximately 1 million and 4 million affected individuals respectively.[26; 65] 
 
There is also evidence that the incidence of Barrett’s oesophagus is increasing by around 2% 
per year.[63; 64; 66; 67] Although this may be due in part to improved endoscopic 
recognition, it is likely that there has been some true increase in incidence - data from 
Holland reported an increase in the number of cases of Barrett’s oesophagus despite a 
decrease in the number of endoscopies being performed over the same period, suggesting a 
true increase in incidence.[26; 67] 
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The prevalence of Barrett’s oesophagus increases with age, the mean age at diagnosis being 
approximately 62 years for men and 68 years for women. The condition predominantly 
affects Caucasians[68] with a male to female ratio of approximately 1.7:1.[69] 
 
2.2.3 Risk Factors for Developing Barrett’s Oesophagus 
 
The chief risk factor for the development of Barrett’s oesophagus is chronic gastro-
oesophageal reflux disease (GORD). Between 8% and 30% of all adults are affected by 
GORD and 5% to 12% of these may subsequently develop Barrett’s oesophagus.[64; 70-72] 
Evidence suggests that symptom frequency and symptom chronicity are better predictors of 
the presence of Barrett’s oesophagus than symptom severity at any given time.[64; 70; 73; 
74] 
 
In addition to GORD, other causes of oesophageal inflammation have also been linked to 
Barrett’s oesophagus formation including viral infections, chemotherapy and non-steroidal 
anti-inflammatory drugs. There is also evidence that smoking, high alcohol intake, high BMI 
and centripetal obesity are linked to Barrett’s and an increased risk of progression to 
adenocarcinoma (although smoking is much more commonly associated with squamous cell 
carcinoma).[75] [76; 77] 
Eradication of gastric H. Pylori has also been shown to predispose to the development of 
Barrett’s oesophagus.[78] H. pylori bacteria produce the enzyme urease which catalyses the 
breakdown of urea, releasing ammonia which neutralises acid produced by gastric parietal 
cells. Gastritis caused by H. pylori infection also causes destruction of parietal cells, further 
decreasing gastric acid production.[78] The presence of H. pylori has been shown to diminish 
the prevalence of complications secondary to GORD, including the development of Barrett’s 
oesophagus. 
 
2.2.4 Pathogenesis and Natural History of Barrett’s Oesophagus and 
Adenocarcinoma 
Understanding the pathogenesis and natural history of Barrett’s oesophagus is vital to 
understanding and identifying which patients will progress to oesophageal adenocarcinoma. 
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Barrett’s oesophagus develops as an adaptive response to increased cell loss as a result of 
chronic inflammation, secondary to the synergistic effect of longstanding pulsatile reflux of 
acid and bile.[79; 80] Metaplasia appears to originate from stem cells located in the 
oesophageal gland squamous ducts which undergo point mutations in tumour suppressor 
genes (TSG), typically p16 and p53, in response to chronic reflux.[81] 
Although traditionally thought of as an acquired condition, inherited genetic factors may have 
an influence in a subset of patients who develop Barrett’s oesophagus. Family and twin 
studies suggest that certain individuals with a strong familial history of Barrett’s oesophagus 
are at an increased risk.[82; 83] For example, a family in the UK has been identified with a 
male index case with oesophageal adenocarcinoma, three siblings with neoplastic metaplasia, 
and six children with non-dysplastic metaplasia.[26; 84] 
 
Although Barrett’s oesophagus and oesophageal adenocarcinoma appear to be polygenic 
conditions, it is hoped that results from on-going genome-wide association studies, and whole 
genome sequencing studies, will direct further investigation towards particular loci of 
interest.[85] 
Following the initial trigger, commonly a point mutation, competing populations of distinct 
metaplastic clones colonise the Barrett’s segment. Subsequently, in order for neoplasia to 
develop the metaplastic oesophageal epithelial cells must undergo a series of molecular 
changes which classically give rise to cancer via the metaplasia-LGD-HGD-adenocarcinoma 
sequence.[86] 
Several of these molecular changes have been defined (mostly those necessary for the 
development of Barrett’s oesophagus and early changes in the pathogenesis of dysplasia) but 
most of the key steps that enable cells to become cancerous remain unclear. It appears that 
mutations in genes responsible for DNA repair, chemical processing and the inflammatory 
response may all have a role.[87-89] 
p53 abnormalities have been detected in up to 95% of Barrett’s associated cancers and studies 
have shown that Barrett’s patients with p53 mutations are at a far higher risk of malignant 
progression than those patients with Barrett’s oesophagus that lack the mutation. Another 
tumour suppressor gene p16 has also been shown to be important in the development of 
Barrett’s cancers. Like p53, p16 prevents progression of abnormal cells from G1 to the S 
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phase. p16 mutations are the earliest detected genetic alterations in patients with Barrett’s 
oesophagus and are detectable prior to aneuploidy, p53 abnormalities, increased tetraploidy, 
and HGD. More than 85% of Barrett’s cells have been shown to possess at least one form of 
p16 mutation, and in fact, the number of p16 abnormalities present increases with increasing 
length of Barrett’s segment. This has led to the hypothesis that Barrett’s starts out as a single 
clone that spreads out as subclones develop with greater numbers of genetic abnormalities. 
 
Figure  2-2 illustrates the metaplasia–dysplasia–adenocarcinoma sequence. It appears there 
are multiple genetic variants of cancer which arise through a series of differing mutations 
along the pathway of carcinogenesis. Some of the most well described early genetic and 
epigenetic changes, which appear to be necessary for cancer development, are indicated. A 
more thorough review of the molecular biology of Barrett’s oesophagus is not within the 
scope of this thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2-2. The metaplasia–dysplasia–adenocarcinoma sequence. Histological stages of 
progression are initiated by genetic, epigenetic and environmental factors which drive 
cell cycle and cell adhesion sequelae. LOH: loss of heterozygosity. APC: adenomatous 
polyposis coli gene. Figure adapted from Almond et. al..[26] 
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2.2.5 Barrett’s Neoplasia 
 
Dysplasia is defined as “an unequivocal neoplastic alteration of epithelium which has the 
potential to progress to invasive malignancy but remains confined within the basement 
membrane of the epithelium within which it arose.”[90; 91] Dysplasia is classified as 
either low grade (LGD), or high grade (HGD), based on its histological appearances. HGD 
has a higher malignant potential than LGD and malignant transformation classically occurs 
through a stepwise progression of pathology as described above. The diagnosis, classification 
and clinical significance of dysplasia and early adenocarcinoma will be discussed further 
below. 
 
2.3 Histological Diagnosis and Classification 
 
When diagnosing dysplasia and adenocarcinoma it is essential to first understand and 
recognise normal oesophageal histology. 
 
Figure  2-3 depicts the layers of the normal oesophagus. Most of these layers can be seen in 
the biopsy specimen in Figure  2-4 which has been stained with Haematoxylin and Eosin. 
 
 
Figure  2-3. Depiction of layers of the oesophageal wall.[92] 
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Figure  2-4. Oesophageal wall (H&E).[92] 
The innermost layer of the oesophagus is a thick protective stratified squamous epithelium 
(not keratinised). This is supported on a basement membrane and overlies the lamina propria 
which contains scattered lymphoid aggregations, lymphatics, nerves and blood vessels. It also 
contains some mucous glands named ‘cardiac glands’ because of their resemblance to the 
cardiac glands of the stomach. Deep to the lamina propria is the muscularis mucosae, 
containing mucosal smooth muscle. These layers together form the mucosa. At the 
oesophagogastric junction the mucosa changes abruptly to a tightly packed glandular 
secretary mucosa. 
 
The mucosa sits on a submucosa which is a relatively loose layer of areolar connective tissue 
which enables some sideways movement of the mucosa on the muscularis propria (as occurs 
as the oesophagus distends during passage of a food bolus). The submucosa is highly 
vascular and also contains lymphatics and parasympathetic ganglion cells (Meissner's 
submucosal plexus). In addition, it contains some small mucous glands (predominantly in its 
lower third) which aid lubrication of the mucosa. 
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The muscularis propria is a thick muscular layer consisting of distinctly separate inner 
circular muscle and outer longitudinal muscle. The muscle of the upper third of the 
oesophagus is skeletal, the middle third consists of both smooth and skeletal muscle, and the 
lower third consists of only smooth muscle. The circular and longitudinal muscular layers are 
separated by loose connective tissue containing Auerbach's myenteric plexus. 
 
The outermost layer of the oesophagus is a connective tissue advantitia which merges with 
connective tissue surrounding adjacent structures such as the trachea. Below the diaphragm 
the oesophagus is surrounded by serosa. 
 
2.3.1 Histological Appearances of Barrett’s Oesophagus 
 
As previously discussed, Barrett’s oesophagus is a metaplastic change from normal stratified 
squamous epithelium to a single-layered columnar epithelium. The presence of Goblet cells is 
necessary to demonstrate intestinalised metaplasia (IM) (Figure  2-5). 
 
 
 
Figure  2-5. Histology of Barrett’s oesophagus.[93] Goblet cells are clearly visible 
confirming the diagnosis of IM. 
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‘Gold-standard’ biopsy regimens only demonstrate histological confirmation of IM in 35-
45% of patients who have endoscopic appearances of Barrett’s oesophagus.[105] IM is more 
readily identified in longer Barrett’s segments: 80% if >3cm, but only 30% if <3cm.[12; 106; 
107] In addition, repeat biopsies in patients with shorter Barrett’s segments may increase the 
likelihood of histologically identifiable IM by around 20%.[97] These findings explain the 
refusal of the BSG to include IM in the definition of Barrett’s oesophagus but also indicate 
the difficulties in making a diagnosis based on microscopic appearances alone. 
Intestinalised metaplasia may also be found at the gastric cardia or fundus and biopsies from 
these sites can therefore be histologically indistinguishable from oesophageal IM. The 
distinction relies entirely on correct endoscopic recognition of the site from which the biopsy 
was taken. 
 
Occasionally oesophageal biopsies can be histologically diagnostic for Barrett’s oesophagus 
where a native oesophageal gland or a duct from these glands can be seen in close 
juxtaposition to metaplastic mucosa.[26] This is however an uncommon finding due to the 
superficial nature of most biopsies. 
 
2.3.2 Histological Grading of Dysplasia / Cancer 
 
Dysplasia is an atypical change in the nuclei and cytoplasm of the cells of the epithelium. In 
normal Barrett’s tissue the pattern of cellular growth is very even and the nuclei are of a 
consistent size and shape (Figure  2-5). 
 
Differentiating normal Barrett’s mucosa from low-grade dysplasia can be difficult, 
particularly in the presence of inflammation and/or hyperplasia (see below). In these 
circumstances pathologists may report the specimen as ‘indefinite for dysplasia’.  
 
Low-grade dysplasia is characterised by atypical cellular changes in association with normal 
architectural appearances of the glands and the epithelium. In LGD, some (but less than 50%) 
of the nuclei are large, often with prominent nucleoli. Some cells may be seen to be dividing 
– indicating an increased mitotic rate. In HGD most cells display atypical changes and the 
architecture of the glands has been disrupted. Most cells have prominent nuclei containing 
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large nucleoli and reduced cytoplasm. In addition, many may be seen to be dividing. There is 
also typically a reduced number of goblet cells (Figure  2-6). 
 
 
 
Figure  2-6. Barrett’s oesophagus with high-grade dysplasia. [93] The epithelium is no 
longer arranged in neat, ordered rows and the glands have become distorted. The 
nuclear to cytoplasmic ratio has increased. However, there is no invasion through the 
basement membrane and this is therefore not cancer. Some inflammatory cells are seen 
within the lamina propria as are normal stromal cells. 
 
HGD may be occasionally reported as ‘carcinoma in situ’. By definition this describes cells 
that appear cancerous but are confined to the basement membrane and have therefore not 
invaded the lamina propria. This term has now been abandoned. 
  
In malignant disease the atypical cells have breached the basement membrane and invaded 
into the lamina propria or beyond (Figure 2-7). 
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Figure  2-7. Barrett’s associated cancer. This is a biopsy of the lamina propria from a 
patient with Barrett’s oesophagus. Cancer cells are evident scattered throughout the 
lamina propria having invaded through the basement membrane.[93] 
 
The identification and grading of dysplasia within an area of Barrett’s oesophagus is 
notoriously difficult. Agreement between pathologists has often been shown to be poor to 
moderate (K=0.2-0.6) and only minimally improved by education.[85] Histological 
assessment however remains the gold-standard technique for distinguishing between grades 
of dysplasia, and also permits assessment of the integrity of the basement membrane. It is 
hoped that development of novel technology (such as Raman spectroscopy) may act as an aid 
to histological diagnosis in the future, and help to minimise subjectivity. The implications of 
inter-observer disagreement in grading dysplasia are discussed further in later chapters. 
 
2.3.3 Histological Diagnosis and Staging of Oesophageal Cancer 
 
Achieving an accurate histological diagnosis is an essential step in assigning treatment 
strategies for early Barrett’s malignancies. Importantly though, histopathologists can also 
have difficulty differentiating between HGD and early invasive (T1) carcinoma based on 
point biopsy appearances alone. In recent years endoscopic resection (ER) has become 
recognised as not only a potentially curative therapy, but also a vital diagnostic technique. 
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This role has expanded as pathologists have realised the clinical relevance of accurate 
assessment and grading of early (T1) tumours. 
The current BSG guidelines from 2005 do not recognise the diagnostic role of EMR. 
However, new guidelines are currently being formulated which will stress the need for 
accurate assessment of the presence and depth of invasive cancer and will recommend 
confirmation using ER. 
 
2.3.4 Histological T-staging of Oesophageal Carcinoma and Clinical 
Significance 
 
A complete description of pathological TNM staging of oesophageal cancer is included in 
Appendix I. 
 
Recent studies have demonstrated the importance of accurate staging of early (T1) tumours 
(Figures 2-8 and 2-9). Intramucosal cancers (T1a lesions confined to the mucosa) have a very 
low incidence of lymphatic invasion (<5%) whereas, invasion into the submucosa is 
associated with lymphatic spread in 20-45% of cases. New evidence has suggested that the 
distinction between T1sm1 and T1sm2 (i.e. between the upper 1/3 and lower 2/3 of the 
submucosa) may be particularly significant as the risk of lymphatic spread appears to 
significantly increase in T1sm2 tumours. This data is important as surgical oesophagectomy 
and lymphadenectomy provide the only chance of cure for patients with lymphatic spread, 
whereas endoscopic therapy is potentially curative in those without lymphatic invasion. 
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Figure  2-8. The T-stage classification of T1 oesophageal adenocarcinoma is illustrated. 
Figure from Gut, 2007. [3] 
 
 
 
 
 
Figure  2-9. Illustration of T-staging in normal (squamous) oesophageal mucosa. Figure 
reproduced from Pech et. al.. Gut, 2007. [3] 
 
m1 
m2 
m3 
sm1 
sm3 
sm2 
sm2 
sm3 
sm1 
m3 
m2 
m1 
 18 
2.3.5 Buried Glands 
 
In some cases following ablative therapy for Barrett’s oesophagus, a normal squamous 
epithelium may re-grow over a portion of Barrett’s tissue (Figure 2-10). Endoscopically this 
appears normal, but these buried Barrett’s glands can retain malignant potential.[99] This 
potential for buried Barrett’s has implications for post-endotherapy surveillance. 
 
     A: 
 
 
 
 
 
 
 
 
 
    B: 
 
 
 
 
 
 
 
 
 
 
Figure  2-10. A: Oesophageal biopsy following previous photodyanamic therapy (PDT). 
Neosquamous epithelium is situated on top of residual buried Barrett’s glands, which 
may retain some malignant potential. Note that goblet cells are clearly visible. B: Buried 
high grade dysplasia and intramucosal adenocarcinoma in a Barrett’s patient who had 
previously received PDT. Images reproduced from Odze et. al..[99] 
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2.4 Risk of cancer and mortality in Barrett’s oesophagus 
 
The presence of Barrett’s metaplasia is accepted as a significant risk factor for the 
development of adenocarcinoma. However, the overall risk of progression to adenocarcinoma 
and the risk of disease specific mortality is low. 
 
A large number of studies have estimated the risk of adenocarcinoma arising from Barrett’s 
oesophagus, with very variable results.[100-110] Many of the early studies were likely 
subject to publication bias, with results only being published if they demonstrated a high 
incidence of cancer, leading to an overestimate of risk.[111] A meta-analysis from 2012 by 
Desai et. al. which investigated the incidence of adenocarcinoma in non-dysplastic Barrett’s 
included 57 studies and a total of 58 547 patients-years of follow-up.[112] The pooled annual 
incidence of adenocarcinoma was 0.33% (95% CI 0.28% to 0.38%) and a subgroup analysis 
showed an even lower rate of 0.19% in patients with short segment Barrett’s (<3 cm) on 
index endoscopy. However, as is the case with meta-analyses, this report was limited by 
selection bias affecting each of the included studies. 
 
Recently two large population based cohort studies reported significantly lower annual rates 
of progression to adenocarcinoma (0.12-0.13% per year) than previously reported.[100; 101] 
(Both of these studies were published just prior to publication of the meta-analysis reported 
by Desai et. al., but neither were included in this analysis).  
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Reference Patients Mean follow-up 
(years) 
Total 
follow-up 
(patient 
years) 
Annual risk of 
progression to 
cancer 
Bhat et. al.. (2011) 8,522 
3,179
*
 
3917
^ 
7.0 
- 
- 
59,784 
23,417
*
 
28,323
^ 
0.13% 
0.04%
*
 
0.23%
^ 
Hvid-Jensen et. al.. 
(2011) 
11,028 5.2 (median) 67,105 0.12% 
 
Table  2-1. Two large recent studies have reported the incidence of oesophageal 
adenocarcinoma in Barrett’s oesophagus. Unless stated figures represent the annual 
risk of malignant progression from non-dysplastic intestinal metaplasia. Figures from 
Bhat et. al.. Are divided into *patients where IM was absent following index biopsy, and 
^patients who had IM identified on index biopsy. (The presence or absence of IM was 
unknown for 1426 patients). Table reproduced from Almond et. al..[26] 
It is important to note that these figures exclude carcinomas of the gastric cardia and do not 
reflect progression to HGD. In addition, the two studies used slightly different mechanisms 
for identifying patients with Barrett’s oesophagus. 
 
Hvid-Jensen et. al.. conducted a population-based case control study including 11,028 
patients who were followed for a median of 5.2 years. Patients with Barrett’s oesophagus 
were shown to have an annual risk of malignant progression of just 0.12%, and a relative risk 
of 11.3 for developing adenocarcinoma compared to the general population. Only 7.6% of the 
total oesophageal adenocarcinomas diagnosed nationwide over the study period had a 
previous diagnosis of Barrett’s oesophagus. However, this study used the Danish National 
Pathology Registry without corroboration with endoscopic findings to identify patients with a 
previous diagnosis of IM. It is therefore possible that patients with cardiac IM rather than 
oesophageal IM were included leading to a potential under-estimate of the risk of disease 
progression. 
 
Bhat et. al. included patients with CLO at endoscopy who had Barrett’s metaplasia 
corroborated histologically. However, the validated Prague system for recording the Barrett’s 
segment was not used and it was unclear whether there may have been an overestimate of 
CLO due to the presence of hiatal hernia. 
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Interestingly, the data reported by Bhat et. al. demonstrated an increased risk of neoplastic 
progression in patients who had a histological diagnosis of IM at index endoscopy, compared 
to those with CLO without confirmed IM. This finding supports evidence from smaller 
studies demonstrating a higher risk of disease progression in patients with confirmed IM.[7; 
113; 114] 
 
It is also important to note that previous studies have suggested a significant geographical 
variation in the incidence of carcinoma arising in Barrett’s oesophagus in Western countries. 
Previously rates of malignant progression in the UK have been shown to be almost double 
those in the US.[115] For this reason variations in population demographics are important to 
consider when interpreting population based studies such as the Danish study by Hvid et. al. 
discussed above. For example, compared to Denmark, rates of obesity, a risk factor for 
disease progression, are significantly higher in the UK. Likewise, a greater proportion of 
males, who are also at a higher risk of malignant progression, develop Barrett’s oesophagus 
in the UK. 
 
It is essential to appreciate that whilst patients with Barrett’s oesophagus have an increased 
relative risk of developing adenocarcinoma, the majority will die from other causes. A study 
from the UK has demonstrated an increase in overall mortality and oesophageal cancer 
mortality in Barrett’s patients compared with an age- and sex-matched population without 
Barrett’s. Interestingly, there were more cancer deaths from other cancers (18%) than from 
oesophageal cancer (10%) and by far the greatest cause of mortality was cardiorespiratory 
disease (49%).[116] 
 
2.5 Natural History of Dysplasia in Barrett’s Oesophagus 
 
The true natural history of dysplastic Barrett’s oesophagus has been difficult to ascertain. 
Studies have suffered from inadequate power, insufficient follow-up durations, sampling 
errors at endoscopy and considerable diagnostic variability due to histological subjectivity. 
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2.5.1 Low-grade dysplasia 
 
Reported rates of regression / progression from LGD vary considerably reflecting the 
difficulties discussed above. 
 
A recent prospective cohort study of 713 Barrett’s patients, including 111 with LGD, 
reported that LGD was a significant risk factor for progression to HGD or adenocarcinoma 
compared to non-dysplastic disease (RR 9.7; 95% CI 4.4-21.5).[117] Similarly, Hvid-Jensen 
et. al.. reported that the relative risk of oesophageal cancer among those who had LGD at 
baseline endoscopy was 4.8 (95% CI 2.6-8.8). The annual risk of progression to HGD or 
cancer was found to be 1.27% for those with LGD at baseline. Bhat et. al. reported a hazard 
ratio of 5.67% (95% CI 3.77 to 8.33) for patients with LGD compared to no dysplasia.[100] 
However, a recent study by Wani et. al.. which followed up 210 patients with Barrett’s 
oesophagus with or without LGD for a mean of 6.2 years found no associations between 
presence of prevalent, incident or persistent LGD, or the extent of LGD, with progression 
rates.[26; 100] 
 
Bergman et. al. recently reported considerable over-diagnosis of LGD in non-specialist 
hospitals and concluded that the true significance of the diagnosis has probably been 
underestimated by most reported series.[118] 1198 Barrett’s patients underwent surveillance 
at six non-specialist hospitals identifying 147 (12.5%) patients with LGD. However, 
following a review of the histology by two external expert pathologists only 8 (0.7%) patients 
were deemed to have a diagnosis of LGD and the majority of samples were reclassified as 
non-dysplastic Barrett’s oesophagus. In this study 42% of patients with LGD diagnosed by 
consensus expert pathologists demonstrated progression to either carcinoma or HGD, and 
2.2% regressed to non-dysplastic Barrett’s oesophagus, over a mean follow-up period of 51 
months.[118] 
 
In summary, although the true natural history of LGD has been difficult to ascertain it 
appears clear that the majority of patients with LGD diagnosed without consensus pathology 
reporting will either remain stable or regress to non-dysplastic disease or squamous mucosa. 
The majority of evidence from large recent trials reports that the presence of LGD at baseline 
endoscopy increases the relative risk of malignant progression (RR 4.8-9.7). However, it is 
possible that widespread misclassification of non-dysplastic Barrett’s oesophagus or 
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oesophagitis as LGD may have led to a widespread under-recognition of the true risk of 
LGD.[26] 
 
 
2.5.2 High-grade dysplasia 
 
The natural history of HGD is also unclear although this diagnosis is known to confer a 
significant risk of progression to adenocarcinoma. Reid et. al. reported that 59% (45/76) 
patients with HGD who were followed for 5 years developed adenocarcinoma. Another study 
reported that 3 of 24 patients (13%) with focal HGD and 17 of 42 patients (40%) with diffuse 
HGD developed carcinoma after a mean follow-up of 41 and 23 months respectively. 
 
It is important to consider what proportion of HGD patients who undergo oesophagectomy 
have an occult cancer detected in the resected specimen. Reported rates vary widely (0-73%) 
but the average appears to be around 40% (Table 2-2).[9-26] Those with visible, nodular 
HGD, appear to have a significantly greater risk of harbouring coexisting cancer.[119; 120] 
This emphasizes the importance of using strict biopsy protocols in patients with Barrett’s 
oesophagus. 
 
Given that intramucosal cancers (T1a) may be managed by endoscopic therapy, it may be 
more pertinent to ask the prevalence of submucosal invasive cancer at oesophagectomy for 
HGD. Following a retrospective assessment of 41 patients with preoperative HGD and 19 
with preoperative IMC who underwent oesophagectomy, Wang et. al. demonstrated rates of 
invasive cancer of 5% in patients with pre-operative HGD, and 11% in patients with pre-
operative IMC.[24] 
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Reference 
Patients with 
high-grade 
dysplasia 
Invasive cancer at 
postoperative 
histology Percentage 
Altorki et. al. (1991)[23] 8 4 50 
Pera et. al. (1992)[24] 18 9 50 
Streitz et. al. (1993)[25] 9 2 22 
Levine et. al. (1993)[26] 7 0 0 
Peters et. al. (1994)[28] 9 5 56 
Edwards et. al. (1996)[27] 11 8 73 
Rice et. al. (1997)[29] 16 6 38 
Collard et. al. (1997)[30] 12 4 33 
Ferguson and Naunheim (1997)[31] 15 8 53 
Cameron and Carpenter (1997)[32] 19 2 11 
Falk et. al. (1999)[33] 28 10 36 
Headrick et. al. (2002)[34] 54 19 35 
Tseng et. al. (2003)[35] 60 18 30 
Sujendran et. al. (2005)[36] 17 11 65 
Read et. al. (2005)[37] 49 18 37 
Wang VS et. al. (2009)[38] 41 16 (14 IMC; 2 inv. ca.) 39% (34% IMC, 5% 
inv. ca.) 
Nasr and Schoen (2011)[39] 68 12 (4 IMC; 8 inv. ca.) 17.6 (5.9 IMC; 11.7 
inv. ca.) 
Total 441 152 34 
 
Table  2-2. Studies reporting the incidence of adenocarcinoma in resected specimens 
following oesophagectomy for high-grade dysplasia. IMC – intramucosal cancer; inv. 
ca. – invasive cancer (denotes invasion into submucosa or beyond). Reproduced from 
Almond et. al.[26] 
 
2.6 Endoscopic Recognition and Assessment of Barrett’s 
Oesophagus 
 
In the majority of cases, Barrett’s oesophagus is identified incidentally in patients who are 
undergoing an oesophagogastroduodenoscopy (OGD) for investigation of reflux symptoms. 
The National Institute for Health and Clinical Excellence (NICE) now recommends that all 
patients with long-term symptomatic reflux (greater than 5-10 years) should be referred for a 
screening endoscopy to check for Barrett’s oesophagus.[116; 121; 122] 
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Barrett’s oesophagus has a classical appearance on OGD. There is proximal displacement of 
the squamocolumnar junction which in normal circumstances lies at the proximal limit of the 
linear gastric mucosal folds. ‘Salmon pink’ columnar mucosa is seen in the distal oesophagus 
arising from the oesophago-gastric junction (OGJ), often with characteristic ‘tongues’ 
extending proximally. Occasionally there may also be readily identifiable islands of columnar 
mucosa. Following endoscopic recognition, the extent of proximal extension above the OGJ 
should be measured and documented (taking care to accurately identify any sliding hiatus 
hernia which may confuse this measurement). The diagnosis must then be confirmed / 
corroborated histologically by multiple pinch biopsies of the affected segment. When 
biopsies are obtained it is crucial that they originate from the oesophagus and that their site is 
recorded as accurately as possible. 
The ‘Prague C and M criteria’, defined by an International Working Group on Barrett’s 
oesophagus, offers a validated method of classifying Barrett’s based on its endoscopic 
appearance.[123] The extent of circumferential (‘C’) involvement in centimetres from the 
OGJ should be recorded, as should the maximum (‘M’) length of the Barrett’s segment 
(including tongues of Barrett’s but excluding isolated ‘islands’). 
Although the risk of malignant progression is greater in long Barrett’s segments (>8cm), it is 
now recognised that shorter lengths, even below 3cm have malignant potential.[124-127] 
However, short Barrett’s segments can cause considerable diagnostic difficulties - what 
appears endoscopically to be a short segment of metaplasia in the distal oesophagus or an 
irregular z-line may in fact represent intestinal metaplasia of the gastric cardia known as 
cardia intestinal metaplasia (CIM).[7]This can lead to misclassification of CIM as Barrett’s 
oesophagus. For this reason the endoscopist has a crucial role in defining the exact position 
from which biopsies are taken. 
 
It is important that clinicians make a thorough and systematic inspection of the mucosa in 
order to identify any evidence of early macroscopic neoplastic disease. Water or 1% 
acetylcysteine should be used to remove blood, saliva and refluxate from the oesophagus and 
insufflation must be carefully optimized to allow clear visualization of any mucosal 
abnormalities whilst still permitting recognition of the mucosal folds at the OGJ. Clinicians 
should be aware that the majority of early neoplastic lesions arise between 6 o’clock and 12 
o’clock in the endoscopists view.[128] 
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Despite meticulous inspection using white light endoscopy (WLE), recognition of early 
neoplastic lesions is difficult and subjective, even for expert endoscopists. Guidelines 
therefore recommend that quadrantic biopsies are taken every 2cm of Barrett’s oesophagus 
with additional targeted biopsies from any visible areas of mucosal abnormality.[7] 
Currently, the routine use of jumbo biopsy forceps is not recommended. 
 
Rigorous biopsy protocols, which are commonly poorly adhered to outside of specialist 
centres, sample less than 5% of the mucosa and may miss up to 57% of dysplasia.[129][8] 
Several advanced endoscopic imaging techniques have been developed which may aid 
targeted biopsies from high-risk areas, improving diagnostic yield (see section 3.14 on 
advanced endoscopic imaging).[130-134] 
 
 
 
Figure  2-11. Nodular multifocal HGD in Barrett’s oesophagus. Clinicians must have a 
very high level of suspicion for the presence of invasive malignancy. 
 
2.7 Barrett’s Oesophagus Surveillance 
 
Patients with Barrett’s oesophagus are typically kept under endoscopic surveillance to 
monitor for dysplastic and malignant change. The surveillance interval depends 
predominantly on the presence and degree of dysplasia identified, but also to a lesser extent 
on patient age, comorbidity and preference. 
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Several small retrospective studies have demonstrated a survival benefit for patients with 
cancers detected by surveillance endoscopy rather than following symptom 
investigation.[135-139] However, others have failed to support this finding.[140] It is likely 
that these small studies have been subject to both selection bias and length bias and doubt 
therefore remains as to the true benefits of a surveillance-for-all strategy. The on-going 
randomised multicentre Barrett’s Oesophagus Surveillance Study (BOSS) aims to define the 
objective value of endoscopic surveillance and the most appropriate surveillance protocol. 
BOSS randomises patients with at least 1 cm of circumferential or 2cm non-circumferential 
Barrett’s oesophagus to either protocol endoscopic surveillance with protocol biopsy or 
endoscopy at the time of need, the latter group being discharged unless they develop new 
symptoms or alarm symptoms.[26] 
 
Despite the current lack of high level evidence, most clinicians elect to follow up patients 
with Barrett’s oesophagus provided the pros and cons of surveillance have been fully 
discussed with the patient and that they subsequently wish to proceed with surveillance 
endoscopy. Clearly, this approach is not suitable for all-comers, and management should 
therefore be individualised appropriately. For example, long-term follow-up of elderly 
patients who are unfit for intervention is not usually recommended. 
 
Patients should also understand the disadvantages and limitations of surveillance 
programmes. In addition to a physical and psychological burden, it must be remembered and 
communicated to patients at enrolment, that early neoplasia may be missed by surveillance 
due to sampling error and limitations of current endoscopic imaging techniques. Similarly, 
curative intervention will not necessarily be available for all surveillance detected cancers. 
 
Where surveillance is deemed appropriate current BSG guidelines suggest that individuals 
with Barrett’s oesophagus without dysplasia should undergo surveillance endoscopy every 2 
years. The current recommendation for quadrantic biopsies every 2cm of Barrett’s 
oesophagus is based on a mathematical model which assumes the risk of progression to 
adenocarcinoma in Barrett’s oesophagus to be approximately 1% per annum.[26] However, 
the recent evidence suggesting significantly lower rates of malignant progression questions 
the rationale for surveillance of patients with non-dysplastic disease. Outcomes of the BOSS 
trial are awaited, however it is possible that future recommendations for surveillance will 
require additional risk factors such as segment length >3cm, a history of dysplasia, or 
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molecular markers of increased risk. This may enable categorization, or even 
individualization of surveillance protocols reflecting patient and disease factors. Surveillance 
of dysplastic disease will be discussed further below. 
 
2.8 Screening for Barrett’s Oesophagus 
 
There are now successful screening programmes in the United Kingdom for colorectal, breast 
and cervical cancer. Screening programmes aim to identify curable premalignant or early 
malignant disease, however despite the recognition of Barrett’s dysplasia as a risk factor for 
the development of adenocarcinoma, no oesophageal screening test has been developed. 
In light of the recent developments in endotherapy for HGD and intramucosal cancer there is 
a significant clinical need for a screening test to facilitate identification and treatment of early 
oesophageal neoplasia. The proximity of the distal oesophagus lends itself to safe and quick 
assessment with an endoscope. However, widespread population screening using OGD would 
be expensive, impractical, and not without associated morbidity. A more favourable 
technique would be screening of a targeted group of individuals who are regarded to be at a 
higher risk of oesophageal neoplasia than the general population. 
Patients with symptomatic chronic GORD have a 5-15% chance of developing Barrett’s 
oesophagus, with males over fifty having the highest risk of progression to 
adenocarcinoma.[71; 141; 142] This data has prompted a call for selective screening of this 
group. However, the absolute risk of adenocarcinoma in patients with GORD is low, in the 
region of 1 in 1000 per annum[90] and it is also important to note that up to 40% of patients 
who develop adenocarcinoma have no history of symptomatic reflux. In addition, a recent 
study has shown that 44% of patients with Barrett’s oesophagus are asymptomatic for at least 
3 months prior to their diagnosis. A policy of screening based on reflux symptoms alone 
would therefore seem inadequate and endoscopic screening of individuals with chronic reflux 
symptoms to detect either Barrett’s or cancer is therefore not currently recommended in 
either the UK or US.[7; 56] 
Several attempts have been made to develop a scoring system using symptoms and patient 
demographics to predict a diagnosis of Barrett’s oesophagus for screening purposes.[143; 
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144] However, recently interest in these risk prediction strategies has waned due to inability 
to generate sufficient accuracy of diagnostic predictions. 
 
In the future it is hoped that non-invasive screening tests could be developed to detect 
patients with susceptible phenotypes using spectroscopic or molecular techniques. Several 
clinical trials are underway including the Chemoprevention of Premalignant Intestinal 
Neoplasia (ChOPIN) trial, and the Barrett’s Oesophagus Screening Trial (BEST2) trial which 
aim to explore non-invasive methods of screening for Barrett’s oesophagus and molecular 
predictors of malignant progression. ChOPIN aims to detect a panel of predictive serum 
biomarkers, whereas BEST2 aims to investigate the potential of a non-endoscopic 
immunocytological device (Cytosponge).[145; 146] This trial requires patients to swallow a 
small capsule which dissolves into a 3cm sponge within the stomach and is then withdrawn 
through the oesophagus in order to collect cells. The cells are assessed for a range of 
predictive biomarkers including TFF3 positivity (the principle endpoint) as well as ploidy, 
Mcm2, cyclin A, TP53, and methylation. Cost data and the impact of screening on 
psychosocial well-being are also being evaluated. It is hoped that non-invasive screening tests 
such as these could enable safe, accurate and cost-effective population based screening in the 
future.[12] Currently, identifying patients with early neoplasia and determining which of 
those will progress to adenocarcinoma, remains a significant and as yet unsolved challenge. 
 
2.9 Management of Barrett’s Neoplasia 
 
All patients with Barrett’s oesophagus, with or without neoplasia, should be commenced on 
high dose acid suppression therapy unless contraindicated. Subsequent management is largely 
dependent on patient comorbidity, patient preference, and the presence, grade and extent of 
dysplasia (see Appendix II). 
 
2.9.1 Endotherapies 
 
There are two main forms of endoscopic therapy available to treat HGD and intramucosal 
tumours – endoscopic resection and endoscopic ablation. These techniques aim to destroy the 
lining of the oesophagus and promote regenerative re-growth of normal squamous mucosa. In 
 30 
order for this to occur, (as opposed to columnar re-growth) some of the superficial squamous 
lined ducts must survive the process. Techniques for mucosal ablation include photodynamic 
therapy, thermal ablation, radiofrequency ablation and argon plasma coagulation. 
 
Endotherapy is indicated in selected patients with HGD, intramucosal cancer (T1a) and early 
submucosal cancers (T1b). It offers an attractive alternative to radical surgery in terms of 
reduced mortality and morbidity, with excellent short and medium term results, but long-term 
efficacy remains unclear. 
 
Figure  2-12. Treatment Depths. T-stage classification is illustrated. Mucosa (M), 
submucosa (SM), muscularis propria (MP), adventitia (ADV). 
2.9.1.1 Endoscopic Resection 
 
Endoscopic mucosal resection aims to remove the mucosa and submucosa down to the 
muscularis. For this reason the term endoscopic resection (ER) is now preferred. The 
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technique involves raising an area of mucosa using suction or by submucosal injection, and 
then snaring it off in a similar manner to a colonic polyp. It is a useful technique for 
removing focal areas of HGD or early cancer, and as well as being therapeutic it provides 
important diagnostic information. 
 
ER preserves tissue architecture, obtains specimens that are easy to orientate, and enables 
accurate assessment of the depth of invasion (Figure 2-13).[99] A retrospective study of 150 
ER specimens (focal lesions) found that initial diagnoses based on point mucosal biopsies 
were changed in 49% of cases following assessment of ER specimens. A change in 
management plan was demonstrated in 30% of patients.[147] Similarly, Mino-Kenudson et. 
al. recently demonstrated that interobserver reporting agreement between pathologists was 
improved when reporting ER specimens rather than point biopsies, particularly when 
differentiating between intramucosal and submucosal carcinoma, a key distinction when 
planning a treatment strategy.[148] In addition, ER specimens also enable improved 
assessment of other important prognostic factors such as the grade of cellular differentiation 
and the presence of lymphovascular invasion. ER has been shown to be the best technique for 
assessment of visible mucosal abnormalities within Barrett’s oesophagus. 
 
ER is indicated for removal of focal HGD. Piecemeal resection is required for lesions greater 
than 2cm with meticulous care being taken to ensure completeness of excision. 
Complications are uncommon - bleeding (3%) and perforation (0.1-5%) - and most can be 
managed endoscopically.[149] 
 
ER has been shown to achieve remission in 82.5% to 95% of patients with HGD, but may be 
associated with metachronous lesions or disease recurrence in up to 14% of patients within 12 
months, and 21.5% of patients over 5 years.[150-153] Factors associated with recurrence 
include piecemeal resection, long-segment Barrett’s oesophagus (>5 cm), delayed treatment 
of HGD >10 months, multifocal disease and omission of adjuvant ablative therapy.[150] 
Recurrent disease necessitates re-treatment which can be successful and provide long-term 
disease control but which may have higher complication rates. 
 
Several trials have reported circumferential ER for removal of widespread multifocal disease 
however this practice has led to high rates of post-treatment stricture formation (17-26%) and 
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higher rates of perforation (3%) and is therefore not widely recommended.[154; 155] In 
addition, significant recurrence rates have been reported using this strategy. Also, in up to 
25% of cases, complete resection of the Barrett’s segment may be impossible despite multiple 
staged attempts at treatment.[98] 
 
As discussed previously, oesophageal lesions that invade into the lamina propria but are 
confined to it (do not invade the submucosa), T1a lesions, have a 5% chance or less of nodal 
involvement. Recent data have suggested that shallow submucosal invasion T1sm1 also has a 
significantly lower risk of nodal metastases than deeper invasion.[156; 157][158] In early 
cancers with a low risk of lymphatic spread, ER therefore offers a potentially curative, 
minimally invasive, treatment option, which may be particularly appropriate in older patients 
at higher risk of operative morbidity / mortality. Average 3-year survival rates of more than 
80% have been reported for T1a adenocarcinomas treated by ER. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2-13. Endoscopic resection of focal HGD with clear margins (A), and an early 
invasive cancer (B). 
 
 
 
 
A 
B 
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2.9.1.2 Mucosal ablation therapy 
 
Endoscopic ablation techniques aim to destroy the lining of the oesophagus and promote 
regenerative growth of normal squamous mucosa. Techniques for mucosal ablation include 
argon-beam plasma photocoagulation (APC), multipolar electrocautery (MPEC), laser 
therapy and cryotherapy; chemical methods, such as photodynamic therapy (PDT); and radio-
frequency (RFA) ablation. The ablation depths achieved by the respective therapies are 
illustrated in Figure  2-12 and evidence supporting each technique is discussed below. 
 
2.9.1.3 Radiofrequency Ablation 
 
RFA is a relatively new technique which can be used to ablate circumferential (HALO
360
) or 
focal (HALO
90) Barrett’s oesophagus. Circumferential ablation is performed using a balloon 
to apply radiofrequency energy evenly to the lining of the oesophagus. The procedure is 
described below. 
 
The length of the Barrett’s segment is first measured endoscopically. N-acetylcysteine is then 
used to wash saliva and gastric juice from the oesophagus and a guidewire is placed into the 
gastric antrum. The endoscope is removed and a sizing balloon is inserted over the guide wire 
and inflated once in the distal oesophagus. In long segment Barrett’s oesophagus several 
measurements are taken and subsequently, an appropriately sized ablation catheter is selected 
(based on the smallest oesophageal diameter measurement). The catheter is then passed over 
the guide wire and positioned at the proximal extent of the Barrett’s segment. The endoscope 
is re-passed to ensure correct positioning of the catheter and the balloon is then inflated and a 
standardised dose of energy is delivered (which has a power density sufficient to ablate down 
to the muscularis mucosae, 700-1000µm deep). After a short period of treatment (<5s) the 
catheter is passed distally to the next portion of the oesophagus to be treated, trying to 
minimise overlap between zones by endoscopic visualisation. Once the entire Barrett’s 
segment has been ablated the catheter is removed and the endoscope is reinserted in order to 
debride the ablated mucosa. The procedure is then repeated so that the whole Barrett’s 
segment receives two treatments. 
 
 34 
Complications are rare but include significant bleeding (1-2%), stricture formation (6%) and 
perforation (very rare).[159] Repeat OGD is recommended after 2 – 3 months and any 
residual focal Barrett’s oesophagus can then be treated using HALO90 RFA. 
 
A large randomised trial of RFA by Shaheen et. al. demonstrated successful resolution of 
dysplastic Barrett’s oesophagus following treatment with RFA.[159] Complete eradication of 
LGD was seen in 90.5% (ablation group) compared to 22.7% (control group) (P<0.001). 
Complete eradication of HGD occurred in 81.0% (ablation group) versus 19.0% (control 
group) (P<0.001). RFA also decreased the likelihood of disease progression (3.6% vs. 16.3%, 
P=0.03) and cancer (1.2% vs. 9.3%, P=0.045). 
 
Recently encouraging longer term follow-up results have been reported. A randomised trial 
of 127 patients with dysplastic Barrett’s oesophagus demonstrated eradication of dysplasia in 
55 of 56 subjects after 3 years. The rate of oesophageal adenocarcinoma was calculated at 
0.55% per patient-years over the study period.[169] 
 
2.9.1.4 Photodynamic Therapy 
 
Photodynamic therapy (PDT) involves systemic (intravenous) administration of a 
photosensitising agent (porfimer sodium) which is retained selectively by dysplastic cells. 
After 48 hours the patient undergoes an upper endoscopy and a laser is used to excite a 
cytotoxic reaction in dysplastic Barrett’s cells, leading to their destruction. There is now 
strong evidence that PDT can prevent the progression of disease in patients with Barrett’s 
HGD. [170] A five year randomised multicentre trial by Overholt et. al. demonstrated that 
PDT was significantly more effective at eradicating HGD than omeprazole only (odds ratio 
2±0.7). It also significantly lengthened the time taken to progress to malignancy and reduced 
the overall risk of malignant progression by half.[26; 161] 
 
Side-effects of PDT include nausea and chest pain in the first day or two after treatment. In 
the longer term, oesophageal strictures may occur in up to a quarter of patients. Oesophageal 
perforation has also been described (very rarely). In addition, due to the photosensitising 
affect of porfimer sodium, patients are required to minimise light exposure to their skin for up 
to 4-6 weeks after the treatment. 
 35 
 
Several trials in Europe have used 5-ALA as the photosensitising agent in an effort to reduce 
skin sensitivity and oesophageal strictures. However, additional blood pressure and cardiac 
complications have been reported with 5-ALA and further work is therefore required to 
clarify the most effective drug with the least side-effects. 
 
2.9.1.5 Argon Plasma Coagulation 
 
APC is the most widely used form of thermal ablation. A jet of ionized argon (plasma) is 
directed through an endoscopic probe to ablate short segments of Barrett’s oesophagus or 
areas of persistent disease following other ablative treatment. A trial by Pech et. al. 
retrospectively assessed disease recurrence in patients treated by ER with or without 
subsequent APC ablation of the residual Barrett’s segment. Rates of recurrence fell from 
33.3% to 17.6% with the inclusion of APC ablation. Other studies support these results and 
report low complication rates.[26; 162-164] 
 
2.9.1.6 Multipolar Electrocoagulation 
 
MPEC is widely used as a method of endoscopic therapy for acute gastrointestinal 
haemorrhage, however it also has a well recognised role in thermal ablation of Barrett’s 
oesophagus. A RCT comparing MPEC with APC followed 35 patients over a two year 
period. Complete reversal of Barrett’s oesophagus was demonstrated in 75% of patients 
treated by MPEC and 63% treated by APC. One patient treated by MPEC developed an 
oesophageal stricture but no major complications (bleeding / perforation) were reported.[165] 
Another trial of MPEC by Sampliner et. al. showed that 78% (45/58) patients had complete 
reversal of Barrett’s oesophagus following a mean number of 3.5 treatments.[26] 
 
2.9.1.7 Cryotherapy 
 
Cryotherapy has recently been approved for use in the United States in patients with 
dysplastic Barrett’s oesophagus. The technique involves the non-contact delivery of liquid 
nitrogen to Barrett’s epithelium via an endoscopic catheter. A retrospective multicentre study 
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of endoscopic cryotherapy by Shaheen et. al. included sixty patients who underwent a median 
of 3.4 treatments. 97% had complete eradication of HGD, 87% had eradication of all 
dysplasia with persistent non-dysplastic intestinal metaplasia, and 57% had complete 
eradication of all intestinal metaplasia.[166] However, patients were followed for a median 
time of just 10.5 months. Evidence of ‘buried‘ metaplastic cells were found in 2 patients 
(3%). Strictures were described in 3 patients, bleeding (requiring admission) in 1 patient and 
severe chest pain in 2 patients. No perforations have been reported following 
cryotherapy.[26] 
 
2.9.1.8 Lasers 
 
A variety of lasers (KTP, Nd:YAG, CO2, diode) have been used for ablative therapy in 
Barrett’s oesophagus with mixed results. Barham et. al. used KTP laser ablation in 16 
patients with non-dysplastic Barrett’s oesophagus.[167] 11/13 patients were found to have 
persistent Barrett’s despite a mean of three treatments per patient. Biddlestone et. al. 
demonstrated similarly unconvincing results – 11/24 biopsy samples from 10 patients treated 
using KTP showed evidence of residual Barrett’s mucosa.[168] In 2011 Polese et. al. 
published results of long-term follow-up of Barrett’s oesophagus treated by diode laser 
ablation.[169] Twenty patients with IM (including four with LGD) were treated with a mean 
of eight treatments over 2 years. Complete remission was demonstrated in 13 patients (11/12 
with BO ≤ 3 cm and 2/8 with BO >3 cm). Similar results have been obtained previously by 
Weston et. al. using Nd:YAG laser.[170] 
 
Laser therapy (whichever modality is chosen) is safe and may have a role in ablating short 
Barrett’s segments. However, as with APC and MPEC, its most appropriate use may be in 
targeted ablation of small persistent areas of Barrett‘s oesophagus following earlier RFA or 
PDT ablation.[26] 
 
2.9.2 Management of LGD 
 
The detection of LGD should prompt a course of high-dose acid suppression with a PPI 
followed by repeat endoscopy with extensive biopsies at 2-3 months. If LGD persists then 
surveillance endoscopy should be repeated at 6-monthly intervals and the patient should 
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remain on a PPI. If regression to metaplasia without dysplasia occurs on two consecutive 
examinations then the surveillance interval may return to 2-yearly.[7] 
 
Endoscopic treatment of LGD is controversial and is not supported by current UK guidelines 
based on a number-needed-to-treat analysis. However, simple surveillance of LGD is not 
universally supported and there is growing backing for early intervention. 
 
The reported significant over-diagnosis of LGD in routine clinical practice may account for 
low reported rates of disease progression and supports the widely recommended policy of 
close surveillance, without endoscopic therapy. However, an alternative option might be for 
referral of all histology slides showing suspected LGD for specialist consensus reporting, 
with subsequent endoscopic treatment for confirmed cases of LGD. This approach would 
have considerable economic and practical implications and is not currently feasible in the 
UK. 
 
2.9.3 Management of HGD 
 
The detection of HGD has serious implications for the patient and should be considered 
analogous to a malignant lesion. The diagnosis should always be confirmed by a second 
expert pathologist within the setting of a multidisciplinary meeting. The diagnosis of HGD is 
usually an indication to end surveillance and patients should be fully informed of the 
significance of the diagnosis and of the pros and cons of endoscopic and surgical treatment. 
 
Falk et. al. demonstrated that 38% of cancers were missed when taking quadrantic biopsies 
every 2 cm from patients with HGD. Jumbo biopsy forceps made little difference to detection 
rates (67% versus 62%).[19] Similarly, Cameron and Carpenter found 2/19 (10.5%) 
unsuspected adenocarcinomas following quadrantic 2 cm biopsies in patients who 
subsequently underwent oesophagectomy.[171] Reid et. al. compared a quadrantic 2 cm 
biopsy protocol to biopsies taken at 1 cm intervals in 45 patients diagnosed with HGD who 
subsequently developed cancer.[172]  The 2 cm protocol missed 50% of the cancers that were 
detected by the 1 cm protocol in Barrett's segments 2 cm or more without visible lesions. 
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Following referral to specialist centres patients with HGD should therefore be re-biopsied 
with quadrantic biopsies every 1 cm with further targeted biopsies from suspicious areas. 
Where indicated a large number of samples should be taken - up to 84 biopsies from a single 
patient has been reported.[12] However, it is important to consider that Barrett’s 
adenocarcinomas may still be missed in up to 29% of cases.[173] Patients should be carefully 
staged, including use of diagnostic ER, and patients with nodular disease should be 
considered at particular risk of harbouring occult invasive disease.[119; 120] 
 
The choice of intervention in patients with HGD remains a controversial subject. 
Traditionally, individuals who were fit enough were recommended oesophagectomy while 
endoscopic techniques were reserved for those unfit for resection. However, with increasing 
evidence of therapeutic benefit, endoscopic therapy is now generally considered to be first 
line treatment ahead of oesophagectomy in fit patients provided they have been adequately 
staged. 
 
Most units favour a policy of focal lesion resection using ER followed by ablation of the 
entire Barrett’s segment using RFA to destroy the neoplastic field change in adjacent 
metaplasia. ER improves histological assessment and aids detection of occult 
adenocarcinoma[174; 175] but the need for subsequent ablation of the surrounding non-
dysplastic Barrett’s oesophagus is controversial. There are no RCTs addressing this directly, 
however there is some evidence to suggest lower recurrence rates if ER is used in conjunction 
with whole segment ablation.[19; 113] 
 
Patients must be informed of the potential need for lifelong endoscopic surveillance 
(including biopsy) following endotherapy, even in cases of complete response, to ensure the 
absence of long-term recurrence and the identification of buried glandular elements which 
may retain malignant potential. Surveillance after oesophagectomy is not routine as 
recurrence rates are low, although Barrett’s associated adenocarcinoma above the gastric 
conduit has been described. 
 
The choice of ablative modality is also open to debate. RFA and PDT deliver an even 
distribution of treatment over a consistent therapeutic depth and can be readily applied to 
large areas of circumferential disease. Both have been shown to be highly efficacious at 
eradicating dysplastic Barrett’s oesophagus,[159-162; 168; 176-181] however RFA is now 
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widely regarded as the first line therapy due to its relative ease of administration, more 
favourable side-effect profile, and low rates of recurrent dysplasia.[180] 
 
There is RCT evidence supporting the efficacy of both MPEC and APC for treatment of 
dysplastic Barrett’s although, compared to RFA, these techniques are less user-friendly for 
treating large Barrett’s segments and treatment depths are less consistent. In addition, they 
may be more likely to be complicated by strictures and the development of buried glandular 
mucosa beneath neosquamous epithelium.[165] Currently these techniques are favoured for 
‘touch-up’ therapy in patients with small patches of persistent metaplasia following previous 
RFA treatments. A RCT comparing the two thermal techniques, MPEC and APC, found no 
significant advantage with either technique.[165] 
 
The decision between endotherapy and oesophagectomy is controversial and dependent on 
patient comorbidity and the nature of the disease: HGD versus intramucosal cancer; unifocal 
versus multifocal; long versus short segment Barrett’s; presence or absence of 
lymphovascular invasion; and grade of differentiation. Endotherapy can effectively eradicate 
HGD with low rates of disease recurrence in the medium term (long-term data awaited).[159; 
160; 182] In addition, any recurrent disease can usually be managed endoscopically, or if 
necessary surgically, without excess mortality.[98; 183] However, advocates of surgery state 
the risk of occult adenocarcinoma, particularly in nodular disease, and the possible risk of 
under-staging of disease using a non-operative approach. In addition, there is evidence that 
prophylactic oesophagectomy in HGD is associated with a lower risk of operative mortality 
than routine oesophagectomy as patients are typically younger with fewer comorbidities, and 
have not undergone neoadjuvant therapy.[21] There are no randomised trials comparing 
surgery and endotherapy in the management of HGD and these studies should be undertaken 
as a matter of urgency. However, it is certainly clear that endotherapy is a viable treatment 
option for patients with HGD, with close surveillance, early endoscopic treatment of 
recurrence, and progression to oesophagectomy if indicated. The Surveillance Epidemiology 
and End Results database of the US National Cancer Institute found no difference in survival 
between patients with HGD or stage 1 (T1N0M0) tumours treated by endoscopic therapy 
compared to radical surgery.[184; 185] However, most of the current studies directly 
comparing radical surgery and endoscopic therapy have been severely limited by selection 
bias.[156; 184; 185] A recent Cochrane review was unable to recommend either surgery or 
endotherapy as first line treatment in HGD due to the paucity of high level evidence and the 
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multitude of contributing factors, and made strong recommendations for the initiation of well 
designed multi-centre randomised trials.[186][26] 
 
2.9.4 Management of Early Oesophageal Cancer 
 
Patients with confirmed oesophageal adenocarcinoma should undergo complete tumour 
staging to establish the presence or absence of distant or locoregional metastases. Surgery 
should be regarded as the treatment of choice in young patients with multifocal nodular IMC 
provided they are fit enough to tolerate oesophagectomy. Fit patients with T1sm1 disease 
should also be offered surgery as a first-line therapy due to the significant risk of lymph node 
involvement. 
 
Patients with a small focus of IMC should be considered for dual modality endotherapy, with 
surgical resection reserved for salvage. EUS to assess nodal status could be considered in 
these patients, however, it is generally thought to be poor at distinguishing between T1a and 
T1b tumours (33-85% accuracy) and importantly under-diagnosis of T1b is common.[4; 187] 
EUS is therefore not usually undertaken in early (T1) disease. 
 
Older patients and those with significant co-morbidities should be treated by endotherapy 
even in the case of T1b disease as not all will have lymph node involvement, particularly 
those with disease limited to the upper third of the submucosa (T1sm1). 
 
2.10 Summary: Clinical Need for a Novel Diagnostic Tool 
 
For more than a hundred years clinicians have relied on the histological appearance of cells in 
order to establish the diagnosis of most malignant and inflammatory conditions. Although a 
trusted technique, histological assessment of tissue is time consuming, expensive, and 
necessitates tissue biopsy which carries with it the risks of bleeding and visceral perforation. 
Furthermore, as previously discussed, histological diagnosis can be extremely subjective. 
Kerkhof et. al. demonstrated a poor level of interobserver agreement between expert 
histopathologists (K=0.58) in the grading of low-grade (LGD) and high-grade (HGD) 
oesophageal dysplasia.[188] However, this distinction has vital consequences for patient 
management as LGD can be monitored by serial surveillance endoscopy whereas HGD 
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necessitates early endoscopic therapy or even surgery, and carries a significant risk of 
malignant progression. Although histological assessment remains the ‘gold standard’ at 
present, there is a clear need for an objective diagnostic test which relies on biochemical or 
molecular analysis of target tissues rather than an individual’s assessment of cellular 
appearance. 
 
As well as being difficult to classify histologically, dysplasia and IMC can be extremely 
difficult or even impossible to recognise at endoscopy even for skilled endoscopists. 
Progression to dysplasia or IMC in Barrett’s oesophagus is rare and the lack of familiarity of 
most endoscopists with the typical appearances of early neoplasia is a significant limiting 
factor in its detection.[100; 101; 103] Guidelines therefore advise that multiple biopsies are 
taken whenever Barrett’s oesophagus is identified at endoscopy.[7] Most endoscopists take 
four quadrant biopsies every 2 cm of Barrett’s oesophagus, or fewer. 
 
 
 
Figure 2-15. Current clinical practice. Clinicians are advised to take multiple, random 
oesophageal biopsies. This policy samples <5% of the mucosa. 
 
Surveillance biopsy protocols sample less than 5% of the mucosa and may miss up to 57% of 
early neoplastic lesions.[8] In addition, patients with HGD are known to have a 30-40% 
chance of occult adenocarcinoma which may be missed by sampling error in up to 50% of 
patients when using a standard biopsy regimen. Several studies have compared the results of 
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endoscopic biopsy assessment to surgical pathology following oesophagectomy for the 
detection of adenocarcinoma in dysplastic Barrett’s segments. Falk et. al. demonstrated that 
over a third of cancers (38%) were missed when quadrantic biopsies every 2 cm were taken 
from patients with HGD. Jumbo biopsy forceps made little difference to detection rates (67% 
versus 62%).[19] Cameron and Carpenter found 2/19 (10.5%) unsuspected adenocarcinomas 
following quadrantic 2 cm biopsies in patients who subsequently underwent 
oesophagectomy.[171] Similarly, Reid et. al. showed that this biopsy regimen would have 
missed 13/26 (50%) of cancers in their cohort. They also demonstrated that targeted biopsies 
of endoscopically visible suspicious lesions were only able to establish the correct diagnosis 
in 15 out of 45 (33%) patients who were subsequently proven to have cancer.[172] 
 
There is a clear clinical need for advanced imaging tools that could improve endoscopic 
detection of HGD and IMC and enable targeted treatment. 
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CHAPTER 3 
 
3 Literature Review: Raman Spectroscopy 
 
Raman spectroscopy is a technique that measures the interaction between light and tissue in 
order to obtain specific biochemical information. Over recent years scientists have recognised 
that Raman spectroscopy has considerable potential for use in medical diagnostics. The 
technique is quick and non-invasive and is capable of differentiating between normal, pre-
malignant, and cancerous tissue. It is hoped that with further development, Raman probes 
may provide accurate, non-invasive optical diagnosis in ‘real time’, without the need for 
biopsy. 
 
3.1 Raman Scattering – Principles and Basic Science 
 
When light interacts with a molecule it may be absorbed, or scattered, or may pass straight 
through it. For absorption to occur, the energy of the incident light must match the specific 
energy required to excite the molecule from its resting ‘ground state’ to an ‘excited state’. 
Only a particular frequency of light, with the specific energy required, can be absorbed by a 
particular molecule. This principle forms the basis of absorption spectroscopy. 
 
In contrast to absorption, scattering of light does not require the energy of the incident light to 
correspond to the energy gap between the ground and excited states of the molecule. 
Scattering results when the incident light causes polarisation of the electron cloud around the 
molecule as the electrons move into a higher energy state. At this instant the interaction 
between the light and the molecule can be considered a very short-lived ‘complex’ where 
energy is transferred from the light wave instantaneously to the molecule. This changes the 
configuration of the electrons in the molecule but does not necessarily cause nuclear motion. 
Almost immediately the unstable ‘complex’ releases the light as scattered radiation. This 
scattered light characteristically has the same wavelength (i.e. the same energy) as the 
incident light and the process is therefore termed ‘elastic’ scattering. This effect is known as 
Rayleigh scattering and is by far the most intense form of scattering (Figure 3-1). 
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The other form of scattering which can be readily identified is Raman scattering. This is a 
much rarer event and occurs in only 1 in 10
6 – 108 of the photons scattered. Raman scattering 
was first described in 1928 by an Indian physicist of the same name who was later awarded 
the Nobel Prize. [189] 
 
The key differentiating characteristic of Raman scattering is that there is an appreciable and 
measureable change in energy between the incident and the scattered light. This form of 
scattering is therefore termed ‘inelastic’ scattering (Figure 3-1). 
 
Raman scattering occurs when the incident light interacts with a molecule and not only 
causes electron polarisation but also induces nuclear motion. In this process energy is 
effectively passed from the incident light to the molecule to create nuclear vibration. The 
scattered light is therefore of lower energy (lower frequency) than the incident light. The 
energy change between the incident and scattered light, which corresponds to the energy of 
vibration of the molecule, is known as the Raman shift. This is measured in wavenumbers 
and can be plotted against intensity. This plot is termed a Raman spectrum (see section 3.2). 
 
Two types of Raman scattering have been described, dependent on the state of the molecule 
when the interaction with light occurs. Stokes scattering results when light interacts with a 
Figure  3-1. Changes in energy states during elastic (Rayleigh) and inelastic (Raman) 
scattering. 
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molecule in its ground (unexcited state). Nuclear motion is initiated and the scattered light 
has a lower energy than the incident light. However, where the molecule exists in an already 
vibrationally excited state, as is seen at high temperatures, the scattered light is of a higher 
energy than the incident light. This is known as anti-Stokes scattering. 
 
At room temperature, most molecules are at the ground vibrational state and therefore Stokes 
Raman scattering is much more prevalent than anti-Stokes scattering. It is possible to 
calculate the proportion of molecules in a substance that are in the ground and excited states 
using the ratio of intensities of Stokes and anti-Stokes scattering. 
 
3.1.1 Molecular Vibration and Polarisation 
 
Within a molecule there are a defined number of electrons in molecular orbits. A molecule 
also has a defined number of positional or vibrational modes in which these electrons can be 
found in relation to their nuclei. The number of vibrational modes possible for a molecule is 
described by the equation 3N-6, where N is the number of atoms in the molecule. Hence, a 
triatomic molecule such as H2O or CO2 will have three modes of vibration. Importantly, the 
energy required to alter these vibrational modes differs for each molecule. 
 
When a molecule vibrates the change in configuration of the nucleus alters the shape of the 
surrounding electron cloud. This can induce a change of the dipole moment or a change in the 
polarisation of the molecule. For the vibrational change in a molecule to be Raman active 
there must be a change in the polarisation of the molecule. That is to say that in shifting from 
one vibrational state to another, the electron density relative to the position of the nucleus 
must change. However, not all changes in vibrational states can be detected by Raman 
spectroscopy as in some cases the change in vibrational mode represents a change in the 
dipole moment of the molecule and not its polarisation. This change is not detected by Raman 
spectroscopy but could be detected by IR spectroscopy. For this reason IR and Raman 
spectroscopy are often regarded to be complimentary to one another. 
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Figure  3-2. Three modes of vibration are possible for a CO2 molecule: symmetrical 
stretch, a bending mode and an asymmetrical stretch.[190] In triatomic molecules, 
symmetrical stretch causes large polarisation changes and therefore strong Raman 
signals, whereas bending and asymmetric stretch cause a dipole change and little 
polarisation change and therefore a weak Raman signal. 
 
 
Another example of the differences in vibrational modes can be appreciated when the 
properties of a phenyl ring are compared to an OH bond. The phenyl ring has a large electron 
cloud and is highly polarisable giving a strong Raman signal, whereas an OH bond is less 
polarisable (so gives a weak Raman signal), but a dipole change is readily induced causing a 
strong IR signal. 
 
The properties of the OH bond have important consequences for the application of 
spectroscopy to living tissue diagnostics. As a result of the strong IR signal, all water must be 
excluded from tissue samples before using IR spectroscopy to prevent profound distortion of 
the spectra from the marked dipole effect of the OH bonds. This effect is not seen with 
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Raman spectroscopy and so allows this technique to be used to analyse fresh tissue. It is 
usually seen that any molecule of sufficient complexity will exhibit a usable Raman signal. 
 
3.2 The Raman Spectrum 
 
A Raman spectrum is a plot of ‘Raman shift’ measured in wavenumbers (on the x-axis) 
against intensity (on the y-axis) (Figure  3-3). The zero point on the x-axis corresponds to the 
energy of the incident light. Data to the right of this point therefore represents Stokes 
scattering, whereas data to the left represents anti-Stokes scattering. 
 
A Raman spectrum is always relative to the wavelength of the incident light. However, the x-
axis of a Raman spectrum is rarely measured in wavelength as this would vary with the 
incident light chosen for excitation. Instead, wavenumber is used to represent the ‘Raman 
shift’ and facilitate comparison between spectra. 
 
 
Figure  3-3. A Raman spectrum acquired from normal squamous oesophageal mucosa. 
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A larger Raman shift indicates that a greater energy is required to create vibrational motion in 
a given molecule and crucially, the ‘value’ of the Raman shift for a given compound is 
independent of the frequency of the excitational light. However, excitational light frequency 
does directly affect the intensity of the Raman signal. 
 
Raman peaks are spectrally narrow and correspond precisely to the vibration of specific 
bonds within molecules. In addition, the intensity of a peak is proportional to the 
concentration of the specific molecular constituent that gives rise to it. This allows specific 
vibrations to be assigned to certain spectral peaks enabling a precise qualitative and 
quantitative biochemical fingerprint to be obtained.[191] However, in complex molecules 
peak assignment can be difficult and unreliable as the various peaks merge to form bands. It 
is then the shape and distribution of these bands that can be used as a chemically sensitive 
signature of the specimen. 
 
Analysis of pure natural compounds such as glycogen and collagen has enabled scientists to 
assign peaks that are characteristic of these molecules (Figure 3-4 and Table  3-1). For 
example, glycogen molecules have characteristic peaks at 490, 853, 937, 1083 and 1123cm
-1
. 
[192] Although potentially obscured by signal from other molecular constituents, modern 
multivariate analysis techniques can be used to extract these subtle spectral features and 
enable conclusions to be drawn regarding the nature of a tissue specimen. These statistical 
techniques can help realise the potential of Raman spectroscopy to deliver objective, 
quantitative information which can enable precise tissue analysis and clinical diagnosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3-4 . Examples of spectra from a variety of human molecular constituents. 
Characteristic peaks can be seen for each substance at reproducible positions.[192] 
 
Table  3-1 displays a list of common biochemical constituents found in oesophageal tissue 
with their corresponding characteristic Raman peak positions obtained from the 
literature.[191; 193-195] A more comprehensive list is provided for reference in Appendix 
III. 
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Peak position (cm
-1
) Major assignments 
490 
524 
574 
643 
669 
720 
755 
781 
853 
937 
1001 
1083 
1128 
1262 
1313 
1335 
1446 
1575 
1655 
Glycogen  
Disulfide stretch in proteins 
Glycogen 
Tyrosine 
Cysteine 
Nucleic acids 
Tryptophan 
RNA/DNA 
Glycogen 
Glycogen 
Symmetric ring mode of phenylalanine 
Glycogen 
Glycogen 
Amide III 
Collagen I 
DNA 
CH2 bending of proteins and lipids 
DNA (Nuclei acids and heam protein) 
Amide I (Histones) 
 
Table  3-1. List of common biochemical components found in oesophageal tissue with 
their corresponding peak position. Table reproduced from Stone et. al.[191] 
 
3.3 Raman Instrumentation 
 
Raman spectrometers must be enormously sensitive in order to detect Raman signal which is 
of extremely low intensity.[196] They must also be able to exclude all other signal, including 
elastically scattered light, to ensure the Raman signal is not completely obscured. This is 
achieved using a series of filters within the instrument. 
 
The basic components of a modern Raman system are identified in Figure  3-5. 
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Figure  3-5. Standard apparatus within a laboratory Raman spectrometer. 
 
As the position of Raman peaks are relative to the wavelength of incident light, a 
monochromatic (single wavelength) incident laser is used for excitation. When assessing 
biological tissue, incident laser light in the near-infrared (NIR) region is generally the 
preferred source for excitation. At this wavelength there is minimal tissue absorption and the 
risks of thermal or mutagenic effects are therefore avoided. In addition, the effect of 
fluorescence seen with visible and UV light is largely overcome. 
 
A series of mirrors typically guide the laser onto the sample. Scattered light passes back into 
the spectrometer and is filtered to remove elastically scattered light. A lens focuses the light 
onto a slit, which removes any stray light. The light is then split and dispersed by the 
diffraction grating and then reflected onto the charge-coupled device (CCD) (Figure 3-5). 
 
The CCD typically consists of a sectored length of silicon. This enables different frequencies 
of scattered light to be collected separately, and this information can then be relayed to a 
computer in order to construct a spectrum. The shape of the spectrum will depend on the 
number of photons striking each sector of the silicon. 
 
In this thesis a custom-built fibre-optic probe has been coupled to a Renishaw system 100 
spectrometer (Renishaw Plc., Wotton-under-Edge, Gloucestershire, UK) to assess potential 
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for endoscopic RS in the oesophagus. Full details of the probe-spectrometer design are 
included in Chapter 4. 
 
3.4 Application of Raman spectroscopy to medical diagnostics 
 
The ability of Raman spectroscopy to accurately identify pathological changes in tissues has 
been proven using ex vivo tissue specimens from breast, cervix, larynx, bladder, prostate, 
lymph nodes and oesophagus.[31-51] 
 
These studies have demonstrated the huge potential for future clinical and pathological use of 
Raman spectroscopy, particularly in oncological diagnosis. On-going research utilising 
modern fibre-optic technology now aims to develop a Raman probe for use endoscopically or 
laparoscopically to enable rapid tissue diagnosis. In the oesophagus, a Raman probe could 
identify early neoplastic changes which are often invisible using standard endoscopy. With 
further development Raman spectroscopy could remove the subjectivity from histological 
assessment and even eliminate the need for a biopsy altogether (so called ‘optical biopsy’). 
 
Objective endoscopic diagnosis of neoplastic change in the oesophagus would enable 
immediate intervention to take place. HGD in Barrett’s oesophagus could be diagnosed and 
then treated by endoscopic resection (ER) during a single endoscopy session; or similarly 
intra-operatively tumour margins could be assessed to ensure an adequate surgical resection. 
In addition, when re-scoping a patient with biopsy-proven focal HGD or IMC, Raman 
spectroscopy could accurately identify the lesion so that ER (of the correct area) could be 
performed. 
 
The diagnostic potential of Raman spectroscopy is significant. Laboratory results have been 
consistent and encouraging, and the development of fibre-optic Raman probes is another 
significant step towards possible in vivo use. However, the challenge of developing in vivo 
Raman systems is considerable as several important factors must be addressed and overcome: 
[191] 
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- Weak signal strength 
o Raman signals are inherently weak (only 1 in 106 – 108 photons are 
inelastically scattered). 
o Biochemical changes in cells that have become dysplastic are very difficult to 
detect as they may be present in minute concentrations. 
o When used on living tissue, the intensity of the excitatory laser must be 
limited to prevent tissue damage. This limits the ability to generate strong 
scattering signals from the tissue. 
- Signal interference 
o Biological tissues are inhomogeneous in composition and thus highly 
scattering. 
o Tissue fluorescence. 
o Spectral contamination caused by the background Raman and fluorescence 
signals generated in the fibre-optic materials. 
 
Previous work has addressed many of the issues related to signal strength and signal 
interference. One method of circumventing this problem is to utilise highly sophisticated data 
analysis techniques. Previous studies have recognised that simple peak analysis comparing 
the intensities and wavenumbers of individual peaks, fails to provide discrimination between 
pathology. Instead, one must consider diagnostic information to be spread throughout the 
spectrum and complex chemometric approaches such as principal component analysis (PCA) 
and linear discriminant analysis (LDA) have been utilised to tease out biochemical 
differences between tissue types (see Chapter 4). 
 
When aiming to optimise signal strength it must be considered that the intensity of a Raman 
peak is dependent on the polarisability of the molecule being excited, the concentration of 
that molecule in the tissue, and the intensity of the incident laser. In fact, the power of Raman 
scattering is known to increase with the fourth power of the frequency of the excitation 
source. In addition, signal to noise ratio (SNR) is proportional to the square of the intensity of 
the incident light multiplied by the acquisition time. 
 
Therefore, increasing both the incident laser power and the acquisition time would be 
expected to generate a stronger Raman signal. However, in-practice this could cause injury to 
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human tissue and therefore does not offer a realistic solution. Moreover, prolonged 
acquisition times of more than a few seconds would be impractical for in vivo use. 
Using excitatory light in the near-infrared (NIR) wavelength helps to minimise its absorption 
by human tissue and so enables relatively high laser power to be used safely. In addition, NIR 
light can penetrate more deeply into tissue (mm or more) which can be of particular 
advantage when trying to detect internal organs or deep tissues. 
Another problem when using Raman spectroscopy to examine biological tissue is that of 
tissue fluorescence which often obscures the Raman signal. 
 
3.4.1 Fluorescence 
 
Fluorescence is the emission of light by a substance following absorption of light of a 
different wavelength. Although fluorescence is an absorptive process, its result is essentially 
very similar to that of Raman scattering – both transfer a molecule to a higher (or lower) 
energy level, and both lead to the production of photons with different frequencies from those 
used for excitation. The major difference is that Raman scattering occurs with any frequency 
of incident light, whereas for fluorescence to occur, the incident light must have a frequency 
specific to the molecule it is exciting. This means that Raman peaks are completely 
independent of the wavelength of the incident light, whereas fluorescence peaks are 
dependent on it. For this reason a wavelength of incident light can be chosen which aims to 
minimise tissue fluorescence. 
 
In practice, fluorescence poses a major challenge to the application of Raman spectroscopy to 
medical diagnostics. Its effect can however be diminished considerably by using an excitation 
laser in the ‘near-infrared’ (NIR) wavelength which dramatically reduces the number of 
molecules with excited states low enough in energy to give fluorescence. 
 
Further discussion on spectral interference caused by excessive fluorescence signal is 
included in Chapter 5. 
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3.4.2 Summary 
 
The intensity of the Raman signal is related to: 
- the power of the excitatory laser; 
- the square of the polarisability of the molecule being analysed; 
- the fourth power of the frequency used for excitation. 
 
It is clear then that only one molecular property (its polarisability) affects the intensity of the 
Raman signal. By contrast there are two instrumentation parameters, chosen by the 
spectroscopist, which can influence the intensity of scattered output. 
 
It might seem logical to maximise the frequency of the incident light in order to improve 
Raman sensitivity. Use of UV excitation would therefore appear beneficial, particularly as 
this would also help minimise tissue fluorescence. However, UV radiation is absorbed by 
many compounds, and as a result may cause tissue destruction through thermal injury. NIR 
light has been shown to provide the best balance between adequate scattering intensity, 
minimisation of fluorescence, and avoidance of thermal or mutagenic effects on the tissue 
being assessed. Similarly, increasing the power of the incident laser would increase peak 
intensity but may also cause thermal injury to the tissue (depending on the area of tissue 
being irradiated i.e. the power density). Shim et. al. previously demonstrated that a 250mW 
830nm laser focused to a spot size of 500 um produced no detectable rise in temperature 
following an exposure time of 1 minute.[197] 
 
3.5 Raman Spectroscopy in the assessment of oesophageal 
pathology (in vitro) 
 
Several groups have explored the potential of Raman spectroscopy for diagnosis of 
oesophageal pathology in vitro. 
 
In 2003 Kendall et. al. analysed snap-frozen oesophageal biopsy specimens using Raman 
microspectroscopy.[198]Their subset analysis included normal squamous mucosa, Barrett’s 
mucosa and adenocarcinoma, and showed a high level of agreement (k=0.89) between 
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consensus pathological opinion (the gold standard) and Raman measurements. They also 
showed that the level of agreement between Raman spectroscopy and consensus histological 
diagnosis compared favourably to that between an independent pathologist and the consensus 
pathology opinion for the same biopsy specimens (k=0.76). This illustrated the importance of 
gaining a consensus pathology opinion in order to reduce inter-observer variability, a finding 
supported by others.[199, 200] 
 
Kendall et. al. reported the sensitivity and specificity of Raman microscopy for characterising 
eight different pathological subtypes of oesophageal tissue (Table  3-2). Visible differences in 
spectra were not evident and complex multivariate analysis was required to distinguish 
between the pathological groups. Where differences were found between Raman data and the 
‘gold standard’ pathological opinion, Raman microscopy tended to overestimate the degree of 
dysplasia, for example, in several cases Barrett’s metaplasia was predicted by the model to be 
HGD. 
 
 
 Normal 
squamous 
Cardiac-
type 
Fundic-
type 
IM HDG Adeno-
carcinoma 
Squamous 
dysplasia 
SCC 
Sensitivity 94% 100% 96% 77% 88% 73% 100% 100% 
Specificity 99% 100% 98% 99% 92% 99% 99% 100% 
 
Table  3-2. Accuracy of Raman spectroscopic diagnosis of 8 pathological groups in the 
oesophagus. [200] 
 
Shetty et. al. used Raman spectroscopy to characterise some of the early biochemical changes 
that occur in oesophageal mucosal cells as they progress to Barrett’s metaplasia and then to 
dysplasia and cancer.[43] Shetty et. al. found a marked variation in the distribution of a 
collection of biochemical constituents in normal, dysplastic and malignant cells. Biochemical 
constituents studied included sugars, lipids, and amino acids. Raman spectroscopy identified 
increased levels of DNA, actin and oleic acid in dysplastic glandular tissue compared to 
normal Barrett’s or squamous mucosa (Figure  3-6). Conversely, glycogen was particularly 
prominent in normal squamous tissue and reduced in neoplastic tissue. This study further 
supported the potential of Raman spectroscopy for early diagnosis of malignancy, and raised 
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the possibility that Raman spectroscopy could perhaps enable detection of biochemical 
changes in tissue before morphological changes manifest. 
 
 
Figure  3-6. A biochemical distribution plot. Reproduced from Stone et. al. [8] Normal 
squamous (NSq), cardiac metaplasia (CM), fundic metaplasia (FM), intestinal 
metaplasia (IM), low-grade dysplasia (LGD), high-grade dysplasia (HGD), 
adenocarcinoma (adeno). Relative concentrations have been normalised to a total of 
100%. Note there is no LGD as histolpathological agreement was not consistent. 
 
The proven ability of RS to analyse and classify biopsied oesophageal tissue has 
demonstrated potential for the technique to be used to aid histological assessment of tissue 
samples. The ability of RS to objectively characterise tissue based on its biochemical profile 
could help to overcome the inherent subjectivity associated with histopathological 
classification. 
 
High quality Raman microspectrometers can be used to acquire oesophageal Raman maps 
based on distinction of histologically relevant biochemistry within frozen tissue sections. 
Figure 3-7 displays a high quality map of a sectioned biopsy from a patient with Barrett’s 
oesophagus. This pseudocolour PC scores image was acquired in 48 hours using an x and y 
step size of 8.4 µm and an acquisition time of 30s per pixel. 
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Figure  3-7. A high quality Raman map is able to identify 4 distinct areas which have 
been discriminated through differences in their biochemical composition. Each has a 
characteristic spectral fingerprint which can be distinguished using PCA. 
Recently, Hutchings et. al. demonstrated that ‘rapid Raman maps’ of oesophageal tissue can 
be acquired in clinically practicable timescales.[38] Hutchings et. al. used a Renishaw 
StreamLine system (Renishaw Plc., Wotton-under-Edge, Gloucestershire, UK) coupled to a 
microscope to map 12 oesophageal biopsy samples which had been snap frozen and 
sectioned. An 830 nm diode laser was used for excitation which had a power of 70 mW at the 
sample. 
 
Continuous readout of the CCD minimised time between sequential data measurements 
resulting in the acquisition of thousands of spectra in short timescales. Mapping of a 2mm 
oesophageal biopsy in 30-90 minutes (0.5 s acquisition time per 25.3 µm Raman pixels) in 
conjunction with principal component analysis was shown to be sufficient to generate 
spectral maps with clearly identifiable pathological regions.[34] 
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Figure 3-8 illustrates a rapid Raman map of a portion of an oesophageal tissue section. This 
map was acquired in 15 minutes using an x and y step of 26.4 µm and a 1 s acquisition time 
per pixel. 
 
 
 
Figure  3-8. A rapid Raman map (right) acquired from a region of clinical interest (left). 
 
Rapid Raman mapping has the potential to provide prompt objective assessment of biopsied 
tissue samples without the need for tissue fixation or staining (Figure 3-8). This low signal to 
noise mapping lends itself to automation. Furthermore, objective diagnosis can be obtained 
by projecting measured spectral data onto pre-established multivariate algorithms in order to 
obtain a diagnosis based on the biochemical profile of the tissue, thus removing the 
subjectivity of histological reporting. 
 
Work is currently underway to further evaluate the diagnostic potential of rapid Raman 
mapping as an aid to oesophageal histopathology evaluation, particularly with regard to the 
grading of Barrett’s-associated dysplasia. 
 
This ability to map out pathological regions within oesophageal biopsy specimens, which can 
be correlated with histology appearance, provides further evidence of the ability of Raman 
spectroscopy to objectively assess tissue and therefore gives additional support to the 
proposal of developing diagnostic Raman probes for in vivo use in the oesophagus. 
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3.6 Fibre-optic Raman Spectroscopy 
 
In order to develop a clinically applicable in vivo Raman probe for upper gastrointestinal 
endoscopy, there are several specific scientific and practical considerations which must be 
addressed and overcome. These are in addition to those discussed in section 3.4 and relate to 
the nature of the fibre-optic probe. 
 
- The probe must be narrow and long enough to fit down an endoscope channel - 
modern endoscopes have a 2.8 mm diameter instrument port and are 90 cm in length. 
In practical terms this necessitates construction of a probe of at least 2 m in length. 
- The design of the probe tip must not interfere with manipulation of the articulated 
distal end of the endoscope. 
- Signal-to-noise ratio must be maximised, although acquisition times must remain 
clinically applicable. 
- The probe and spectrometer must be coupled to a data processing unit so that short 
acquisition times are translated to meaningful clinical results in near ‘real time’. 
- Data measurement should also be close to ‘real time’ (short acquisition times) to 
enable rapid assessment of large areas of oesophagus and to minimise inaccuracy 
caused by scope movement or oesophageal peristalsis. 
- The probe must be safe for use in vivo – laser wavelength and power must be 
carefully chosen so as to not cause tissue destruction or long-term mutagenic effects. 
- The probe must function effectively in the presence of endoscopic light – laboratory 
Raman spectroscopy requires reduced ambient light to minimise unwanted spectral 
noise. 
- The sampling depth and volume must be optimised to enable diagnosis of epithelial 
disease. Metaplasia and dysplasia are epithelial conditions and therefore the optimum 
depth from which to attain Raman signal is 10-200µm.[43] Sampling from large 
surface areas would provide more rapid assessment of clinical pathology but may 
decrease sensitivity and specificity for focal abnormalities. 
- The probe must work in direct contact with the mucosal surface in order to facilitate 
endoscopic use. 
- The probe must work safely and accurately in the presence of blood, saliva and gastric 
juice. 
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- The probe must be packaged so that it can be reused for multiple endoscopies and 
must be robust enough to withstand sterilisation procedures or must be simple and 
cheap enough to manufacture to enable single use. 
- Measurements must be reproducible on different days, by different endoscopists and 
using different probes and spectrometers; 
- High sensitivity and specificity must be achievable in the clinical setting – levels of 
diagnostic accuracy must be tested and reproduced in vivo. 
 
As Raman scattering is weak and the power of the incident laser must be low (to minimise 
thermal injury), the design of a fibre optic Raman probe must centre on maximising 
collection efficiency whilst minimising intrinsic scattering and fluorescence produced by the 
probe. 
 
One of the most potentially difficult problems to overcome is the propensity of probe fibres 
to generate their own Raman and fluorescence signals.[201; 202] In some cases, the Raman 
signals may be greater than those arising from the tissue being studied. Fibre signal is 
proportional to fibre length and to the intensity of excitatory light. It is generated in the 
delivery fibre due to excitation by the laser light and in the collection fibres by elastically 
scattered light transmitting back along the collection fibre. Notch or edge filters can be used 
to remove elastically scattered light from the collection fibre, and bandpass filters are 
commonly used to remove fibre-optic signal that has been generated in the delivery fibre. 
 
In 1998, Mahadevan-Jansen et. al. published in vivo results using a fibre-optic Raman probe to 
analyse dysplastic change in cervical tissue.[203] Silica-silica fibres were shown to cause less 
signal disruption than sapphire and liquid guide fibres despite their tendency to generate 
significant background signal at low wavenumbers (below 900 cm
-1
). The probe consisted of a 
single excitation fibre and 50 collection fibres and had a total diameter of 12 mm. The 
excitation fibre was positioned at the edge of the probe, and the laser output (at 789 nm) was 
reflected by a gold mirror at an angle to produce a 900 µm diameter excitation spot on the 
tissue surface. A bandpass filter on the distal tip of the excitation fibre blocked fluorescence 
and Raman scattering generated by the fibre, but transmitted the excitation light. Although 
demonstrating that Raman spectra could feasibly be measured in vivo using a fibre-optic, the 
dimensions of this probe and the time taken for spectral acquisition (90 s) meant this design 
was impractical for use in the gastrointestinal tract. 
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The next important challenge was to develop an effective miniature fibre-optic probe that 
employed state-of-the-art probe technology but which was compatible for use with a medical 
endoscope. An endoscope is 90 cm in length and has a 2.8 mm diameter instrument channel 
through which a Raman probe could be delivered. This presents a considerable technical 
challenge; to package a probe with all its constituent parts (filters, collimating lenses, 
illumination and collection channels, and external casing) into a durable device with a diameter 
smaller than 2.8 mm. 
 
In 1999 Shim et. al. reported on utilising an endoscope compatible, fibre-optic Raman probe 
consisting of one central delivery fibre (400 µm diameter) surrounded by seven collection 
fibres each with a 300µm diameter (Visionex, Inc, Sunnyvale, CA, USA, probe).[204] Filters 
were placed over the fibres approximately 2.5 cm from the probe tip and the collection fibres 
were part bevelled so that they predominantly collected signal from a zone in front of the 
delivery fibre and at a specified collection depth, determined by the bevelled angle. This design 
provided a means of controlling the sampling volume whilst optimising collection efficiency. 
 
In 2000, Shim et. al. reported the first in vivo Raman measurement of gastrointestinal tissue 
using the Visionex probe described above (Table 2).[197] In this feasibility study the probe was 
passed through an endoscope into the oesophagus, stomach and colon. Twenty patients 
successfully underwent the endoscopic procedure following routine sedation and no 
complications were reported. The probe was positioned to touch an area of mucosa for 5 
seconds during which time readings were taken. The probed site was then biopsied to allow 
comparison of Raman spectra with histopathology at that site. Subtle differences were reported 
in spectra from normal and diseased areas but the data acquired was not sufficient to 
discriminate between pathological groups. Whilst demonstrating feasibility, Shim et. al. 
concluded that more work was needed to enhance the signal-to-noise ratio (SNR), to minimise 
acquisition times, and to improve data interpretation before reliable results could be generated. 
This study illustrated that endoscopic Raman spectroscopy could be performed safely in human 
patients, but was not large enough to enable comparison with results generated using laboratory 
based Raman spectrometers. 
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Table  3-3. In vivo Raman spectroscopy in the upper GI tract. (Trials are in humans 
unless stated). All probes incorporated miniature in-built optical fibres. 
+
NBI - narrow 
band imaging, 
*
AFI – autofluorescence imaging. 
 
 
Motz et. al. used a novel probe to study dysplasia in rat palate tissue using 100 mW of laser 
light (at 830 nm) for excitation.[197; 205] Multivariate data analysis of Raman spectra 
demonstrated differences in low and high grade dysplasia, but it was concluded that further 
modifications to the probe were necessary to optimise collection depth as a significant spectral 
contribution was collected from tissue that was deeper than 500 µm. More recently a greater 
Year Authors Site Number of 
Patients / 
Spectra 
Measurement 
Parameters 
Probe Design Accuracy / Conclusions 
2000 Shim et. 
al.[197] 
Oesophagus, 
stomach (& 
colon) 
20 patients 
400 spectra 
Diode laser at 785nm 
Acquisition time, 5s 
~500mW of excitation 
power. 
 
Visionex probe, 7 
bevelled collection fibres, 
1 excitation fibre 
Silica fibres 
Shutter to block white light  
Tissue contact 
Collection depth ~500µm 
 
Feasibility demonstrated 
Subtle difference in normal and 
diseased spectra not sufficient to 
discriminate between pathologies. 
More work to enhance SNR, 
minimise acquisition times, 
improve data analysis 
Background signal subtraction 
demonstrated 
2005 Motz et. 
al.[205] 
Rat palate  Diode laser at 830 nm 
Acquisition time, 1s 
Power output, 100mW 
Single central delivery 
fibre, 15 collection fibres. 
Collection depth 
exceeded 500µm 
Improvements in collection optics 
necessary 
2005 Wilson et. 
al.[206] 
Oesophagus 65 
192 spectra 
Diode laser at 785nm  
Acquisition time, 5s 
70mW power output 
Single delivery fibre, 6 
bevelled collection fibres 
Collection depth 800µm 
Sensitivity 86% and specificity 88% 
for dysplasia (compared to non-
dysplastic oesophagus) 
2007 Hattori et. 
al.[207] 
Rat 
oesophagus 
and stomach 
 Ti:sapphire laser at 
785nm  
80mW power output 
Single central delivery 
fibre, 8 collection fibres 
Feasibility demonstrated 
Further improvements in SNR 
necessary 
2010 Huang 
et.al.[209] 
 
Stomach 71 patients 
1102 spectra 
Diode laser at 785nm  
Acquisition time, 0.5s 
1.5 W/cm2 power 
density at probe tip 
 
Single central delivery 
fibre, 32 collection fibres 
(diameter 1.8mm) 
System used in 
conjunction with NBI 
Collection depth 800µm 
Delineation of malignant gastric 
ulcers (from benign gastric tissue): 
Sensitivity, 82.1% 
Specificity, 95.3% 
2011 Huang et. 
al.[210] 
 
Oesophagus 27 patients 
75 spectra 
Diode laser at 785nm  
Acquisition time, 0.5s 
1.5 W/cm2 power 
density at probe tip 
Probe as above. 
Multimodal imaging – 
NBI+ plus AFI* 
Collection depth 800µm 
Delineation of oesophageal cancer 
(from normal oesophageal mucosa): 
Sensitivity, 97.0% 
Specificity, 95.2% 
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emphasis has been placed on targeted illumination of the epithelial lining of the gastrointestinal 
tract. Precancerous dysplasia develops in epithelial cells and, by definition, has not yet invaded 
deeper structures. For optimum diagnostic accuracy, probes must collect signal from the 
epithelial layer and minimise spectral contributions from scattering occurring in deeper tissues. 
 
In 2005, Wilson and co-workers published results of an in vivo trial in the upper 
gastrointestinal tract of humans. They used a probe consisting of a central delivery fibre 
surrounded by six 300 µm diameter bevelled collection fibres that achieved an estimated 
sampling depth of 500 µm.[206] In conjunction with a diode laser (emitting at 785 nm) and a 
modern CCD detector they reported an accuracy of 87% for delineating between normal 
oesophageal tissue and dysplasia. 
 
Huang and co-workers recently described the use of a ball lens at the distal tip of a novel 
Raman probe to focus excitation light onto the epithelium and help collimate scattered light 
into the collection fibres.[210] In 2010, following a number of preliminary in vitro and in vivo 
studies in rats, Huang et. al. published a series of results from in vivo trials of endoscopic 
Raman spectroscopy for the detection of gastric neoplasia in humans. They used a 1.8 mm 
diameter Raman probe consisting of 32 collection fibres surrounding a single central delivery 
fibre. The probe had two stages of optical filters, at its proximal and distal ends, and used 785 
nm excitation. Each spectrum was acquired in 0.5 s. In December 2010 they reported a 
diagnostic sensitivity of 82.1% and a specificity of 95.3% for delineating malignant gastric 
ulcers from benign tissue.[208] In 2011, the same Raman probe system was used in the 
oesophagus demonstrating a sensitivity of 97.0% and a specificity of 95.2% for detecting 
oesophageal cancer.[209]
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Figure  3-9. Progress towards in vivo Raman spectroscopy in the upper gastrointestinal 
tract. 
3.7 Analysis of Raman Spectral Signatures Using Multivariate 
Statistics 
 
Measured Raman spectra represent a combination of tissue autofluorescence, weak tissue 
Raman scattering signals and noise from background signals generated by the probe and 
spectrometer components. Moreover, cells undergoing neoplastic progression demonstrate 
simultaneous biochemical alterations that are subtle and complex. For these reasons visual 
comparison of spectra, or peak ratio calculations, are insufficient to extract the subtle spectral 
differences that correspond to distinct pathological groups. Complex multivariate statistical 
analysis is therefore necessary to enable accurate discrimination of varying spectral 
characteristics across the dataset which can be used to inform pathological classification 
algorithms. 
 
A variety of different multivariate techniques are currently being investigated for use in 
diagnostic spectral classification.[36; 39; 211] The most commonly described algorithm for 
this particular application, termed linear discriminant analysis (LDA), has been widely shown 
to be successful.[31; 32; 38; 47; 206; 211; 212] Prior to the application of LDA, principal 
component analysis (PCA) is performed to reduce the dimensionality of the data. Principal 
component (PC) fed LDA has previously enabled Raman signatures to be ascribed to 8 
distinct pathologies in the oesophagus.[49] This multivariate approach is widely used in 
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spectral analysis and has been chosen as the principal method of spectral characterisation in 
this thesis.[34] 
 
3.7.1 Data Pre-Processing 
 
Prior to multivariate analysis several pre-processing steps are advisable to reduce any 
systematic and random errors in the Raman spectra.[213] Spectral normalisation acts to 
eliminate significant differences in intensity, and mean centring (subtraction of the mean of 
the entire dataset from each individual spectrum) scales the data facilitating subsequent 
spectral comparison. 
 
 
3.7.2 Principal Component Analysis 
 
PCA simplifies the differences between spectra into a number of principal components which 
describe the variance in the sample dataset. This preserves the biochemical information that is 
characteristic of each pathology but does not necessarily split the data in the direction most 
suitable for separating the pathological groups. 
 
Figure  3-10(A) illustrates the principle of PCA when there are only two variables. The dotted 
lines represent the principal components 1 and 2 which are orthogonal to each other. These 
can be re-plotted as shown in Figure  3-10(B). This demonstrates that PC1 accounts for the 
majority of the variation within the data points. 
 
PCA can be considered a rotation of the axes in such a way that PC1 is in the direction of 
maximal variation whilst the angle between the axes is maintained at 90 degrees. The first 
principal component (PC1) accounts for most of the variation in the data set, the second 
(PC2), accounts for the next largest variation and is orthogonal to the first, and so on. 
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Figure  3-10. (A) Illustration of the two principal components, PC1 and PC2, for the two 
variables, X1 and X2. (B) Datapoints have been referred to the principal component 
axes.    Indicates data points,  indicates their projection onto the axes. Figure 
reproduced from Miller and Miller.[213] 
 
PCA is essentially a mathematical method of data reduction. It does not assume that there is 
any particular distribution within the dataset and is an ‘unsupervised’ technique, that is to say 
it incorporates no prior knowledge of the expected groupings. However, in many cases PCA 
alone is insufficient to enable optimum classification of a group of spectra. Additional 
multivariate techniques which incorporate information about the nature of the samples, so 
called ‘supervised’ techniques must then be employed to maximise separation. LDA has been 
widely used for this purpose and its success is well documented.[31; 32; 38; 47; 206; 211; 
212] 
 
3.7.3 Linear Disriminant Analysis 
 
Linear discriminant analysis (LDA) can be employed to aid pathological separation. In 
contrast to PCA, LDA is a supervised technique, which incorporates information about the 
pathological nature of the samples in order to maximise the variation between the groups. 
Linear discriminant functions describe the directions in spectral space that provide maximal 
A
: 
B 
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separation between groups whilst minimising separation within each group.[34] They can be 
used to construct a classification model onto which individual spectral datasets can be 
projected in order to statistically test and validate the model. These statistical mechanisms 
also allow for alterations in the classification of groups within the model so that sensitivity 
for detection of cancer can be maximised to the expense of specificity or vice versa. When 
used in a clinical setting, this could enable a Raman probe to have a programmed high level 
of sensitivity for the detection of cancer or dysplasia (prompting targeted tissue biopsy), in an 
attempt to minimise the prevalence of missed disease. 
 
LDA essentially aims to create a classification model for allocating a new spectrum to a 
particular group. The linear discriminant function represents a line of maximal variation 
between two groups and therefore, depending on where a new datapoint sits in relation to the 
line, enables discrimination between two groups. This holds true for groups that have 
similarly shaped distributions. 
 
LDA can be extended to the situation where there are more than two groups of objects, for 
example when attempting to classify three or more different oesophageal pathologies. The 
ability of LDA to classify correctly is assessed initially by way of a confusion matrix. This 
uses the LD classification model to classify each spectrum and compares this to its true 
classification which in this case was provided by consensus histological assessment of the 
particular biopsy specimen. However, an inherent problem with this method is its tendency to 
be over-optimistic in its ability to correctly classify. This so-called ‘overfitting’ of the 
training data is a consequence of the fact that the spectra being classified form part of the 
dataset which was originally used to derive the classification model.[214] Problems of 
overfitting can be overcome by using separate test and training datasets, however, this 
solution compromises the number of spectra which can be used to train the model. Instead a 
technique known as cross-validation, in particular leave-one-out cross validation, is preferred. 
 
3.7.4 Validation Using Test and Training Datasets 
 
The most rigourous way to test the validity and accuracy of a classification model is to 
project onto it a completely new spectral dataset, known as a ‘test’ dataset. In this case the 
classification model will have been trained using a ‘training’ dataset to define the linear 
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discriminant function(s). The ‘test’ spectra will then be classified based on their spectral 
information and this classification compared to the consensus histological diagnosis in order 
to calculate the level of agreement between the two. This method is ideal for comparing 
between spectra acquired in different timescales or using different Raman systems. Test 
spectra should be scaled and/or have a calibration correction applied and then projected onto 
the trained classification model to assess its ability to classify the pathology of the test 
spectra. Using these techniques enables a statistical assessment how the results of an analysis 
will generalise to an independent dataset. 
 
3.7.5 Leave-one-out Cross Validation 
 
When attempting to calculate probe accuracy the need to split the data into independent 
training and test datasets means that a proportion of the data is excluded from training the 
model. However, clearly the more data that is used to develop the model the more reflective it 
will be of the potential variation within the oesophagus. Therefore, in practice a technique 
termed leave-one-out cross validation is applied. This utilises n-1 of all the spectral data 
collected to ‘train’ the model and then projects on the single spectrum which has been 
excluded as the ‘test’ dataset. This is repeated n times until all the spectra have been 
individually excluded and projected onto the model as a test. Crucially, no sample is ever 
found in both training and test datasets at the same time. 
 
This method of simulating the predictive performance of the algorithm for data not part of the 
training process mimics as closely as possible a real situation. For instance, in a clinical 
setting it would be impossible to include all potential patients in a training dataset. Therefore 
a classification algorithm must be trained from a sub-group of patients but be capable of 
making diagnostic predictions in patients that were not included in the training process. 
 
3.7.6 Diagnostic Outcome Measures 
 
The most commonly used measures to describe the ability of a diagnostic test to correctly 
predict the presence or absence of a medical condition are the sensitivity and specificity. The 
sensitivity of a test is the percentage of individuals with a disease who are correctly classified 
as having the disease. A highly sensitive test would therefore be positive for the majority of 
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individuals who have the disease. The specificity of a test is the percentage of individuals 
without the disease who are correctly classified as not having the disease. A test is therefore 
highly specific if it is positive for only a tiny percentage of those who do not have the 
disease. In the case of assigning a sensitivity and specificity to the Raman system probe the 
spectral prediction has been regarded as a true positive result if both the test and the 
consensus histopathology for a sample were in agreement. 
 
Receiver Operating Characteristic (ROC) curves plot the true positive rate (sensitivity) 
against the false positive rate (1-specificity) (see Chapter 8). The area under an ROC curve 
(AUC) represents another measure of how well the test can distinguish between two 
diagnostic groups: the higher the AUC the greater the overall accuracy of the test. 
 
An alternative measure of agreement besides sensitivity / specificity and AUC is the kappa 
statistic which allows for the fact that that observers will sometimes agree or disagree purely 
by chance (see Chapter 8). In the case of Barrett’s oesophagus, the kappa statistic is often 
used to report the level of subjectivity between histopathological diagnoses. 
 
3.8 Competing Advanced Imaging Techniques 
 
In an attempt to address the need for a reliable endoscopic diagnostic tool to detect early 
Barrett’s neoplasia, a variety of techniques at varying stages of preclinical / clinical 
development have been explored. Although all of these appear to have the potential to 
enhance endoscopic diagnosis, no one single technique has garnered universal favour with 
clinicians. This reflects a variety of limitations including subjectivity, poor sensitivity or 
specificity, excessive cost and demanding training requirements. 
 
This section illustrates the current position with regards to advanced endoscopic diagnosis in 
Barrett’s oesophagus. It is hoped that endoscopic RS may overcome many of the pitfalls 
associated with these alternative techniques. There may also be an indication to combine RS 
with a wide-field imaging modality, a concept which is investigated further in Chapter 7. 
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3.8.1 Wide-Field Detection Techniques 
 
3.8.1.1 High Resolution Endoscopy (HRE) 
 
Modern high resolution endoscopes which generate up to one million pixel images (compared 
to the 300,000 pixel images of traditional scopes) have been shown to have a higher 
sensitivity than standard white light endoscopy (WLE) for the detection of early Barrett’s 
neoplasia provided they are used by expert endoscopists.[132; 215] So not to negate their 
effect these endoscopes should be used in conjunction with high definition television 
monitors to further enhance the projected image quality and prevent loss of resolution when 
larger images are required. 
 
Even in the hands of experts, Kara et. al. showed that targeted biopsy using HRE was only 
capable of detecting 79% of dysplasia, and differentiation between HGD and LGD for the 
purposes of targeted treatment was difficult.[215] HRE should replace standard WLE where 
possible. Although to significantly improve endoscopic diagnosis of dysplasia, HRE may be 
best utilised in conjunction with additional endoscopic imaging technology. 
 
3.8.1.2 Chromoendoscopy 
 
Chromoendoscopy involves exogenous administration of stains to the oesophageal mucosa in 
order to improve tissue characterization during endoscopy. Absorptive stains (such as 
methylene blue) cross epithelial membranes selectively, whereas contrast stains (such as 
indigo carmine) permeate into mucosal crevices highlighting surface topography and mucosal 
irregularities.[216] 
 
Studies utilising chromoendoscopy in Barrett’s oesophagus have had mixed results and have 
highlighted problems such as difficulties in uniformly coating the oesophageal mucosa with 
the stain, and excessive times necessary for stain spraying.[85; 217; 218] The technique has 
not been shown to consistently out-perform HRE in the detection of early neoplastic 
lesions.[133] 
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Chromoendoscopy is relatively widely available and does not require any particular 
equipment except for a spray catheter which is easy to use and cheap to purchase. However, 
chromoendoscopy is often both labour-intensive and operator-dependent and is therefore 
unlikely to become widely utilised. 
 
3.8.1.3 Narrow Band Imaging 
 
Narrow band imaging (NBI) illuminates the mucosa with blue and green light in order to 
enhance the resolution of the mucosal surface by relying on the principal that longer 
wavelengths of light penetrate deeper into tissue than shorter wavelengths. Narrow band blue 
light displays the superficial capillary networks, while green light displays the subepithelial 
vessels, and a combination of the two images produces an extremely high definition image of 
the mucosal surface allowing visualisation of subtle mucosal irregularities and alterations in 
vascular patterns consistent with dysplasia and IMC.[219] 
 
NBI is a widely available technique which avoids the need for staining or intravenous 
contrast agents. It has shown promise in detection of dysplastic lesions when in the hands of 
experienced users.[220; 221] A recent review of NBI with magnification demonstrated high 
accuracy for the diagnosis of HGD in Barrett’s oesophagus based on recognition of irregular 
mucosal pit patterns and/or irregular microvascularisation.[222] However, NBI is time-
consuming and results have been mixed due to high levels of inter-observer variability.[133; 
223] Overall, data on the accuracy of NBI in Barrett’s oesophagus are inconclusive and 
results of multicentre randomised controlled trials are awaited. 
 
 
3.8.1.4 Autofluorescence Imaging 
 
AFI detects fluorescence radiation following excitation of tissue using light of short 
wavelengths. Variation in the type and concentration of fluorophores enables differentiation 
between normal, metaplastic and neoplastic tissue. Several studies have suggested that AFI is 
sensitive for detection of HGD in Barrett’s oesophagus although the technique appears 
limited by low specificity.[224][225; 226] Curvers et. al. demonstrated an increased detection 
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rate of HGD/IMC using AFI compared to WLE alone (53% Vs 90%) but this came at the 
expense of a high false positive rate of 81%.[227] 
 
Further trials are necessary to demonstrate improvements in specificity through combination 
with other imaging techniques such as confocal microscopy. 
 
3.8.1.5 Optical Coherence Tomography 
 
OCT is analogous to ultrasound imaging but can produce higher resolution images as it relies 
on backscattering of near-infrared light (as opposed to radio waves) to generate cross-
sectional images of epithelial and sub-epithelial tissues. 
 
OCT is performed using probes passed through the instrument channel of endoscopes. It does 
not require the use of exogenous contrast and, unlike with ultrasonography, tissue contact is 
not required. 
 
Several studies have assessed the role of OCT in the detection of dysplasia. In a study of 55 
patients with Barrett’s oesophagus, OCT was shown to delineate between HGD and 
adenocarcinoma with a sensitivity of 83% and a specificity of 75%.[228] Another study of 33 
patients demonstrated a diagnostic accuracy of 78% for the identification of dysplastic 
Barrett’s oesophagus, however considerable user discrepancy (56% to 98%) was 
demonstrated.[229] 
 
Further clinical evaluation is required to assess the diagnostic performance of OCT in the 
oesophagus. In the future the technique may have a greater role in the staging of early 
oesophageal tumours rather than in the detection of dysplasia, however the considerable time 
required to acquire and interpret the images may become a significant limiting factor. 
 
3.8.1.6 Labelling of Biomarkers 
 
Visually tagged probe molecules have been engineered which selectively bind to neoplastic 
cells.[230; 231] Lu et. al. identified a cell surface peptide specific to adenocarcinoma which 
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they labelled using a fluorescein-tagged antibody delivered topically. The oesophagus was 
then washed to remove any unbound antibody and a fluorescence endoscope was used to 
visualise neoplastic disease.[232] 
 
Similarly, the Fitzgerald group recently demonstrated that alterations in cell-surface glycans 
during progression to adenocarcinoma could be identified through changes in their lectin 
binding properties.[2] Selective binding of a candidate lectin (wheat germ agglutinin) sprayed 
into an ex vivo oesophagus enabled visualization of high-grade dysplastic lesions, which 
were not detectable by conventional endoscopy. 
 
These highly promising molecular techniques require further work in order to identify novel 
molecular targets to improve sensitivity and specificity before clinical implementation can be 
considered. 
 
3.8.2 Point Measurement Techniques 
 
3.8.2.1 Confocal Microscopy 
 
CM magnifies the mucosa 1000-fold enabling real-time visualisation of cellular structures. 
CM has shown considerable potential in Barrett’s oesophagus with reported accuracy of up to 
97.4% for the detection of dysplasia.[233] However, due to considerable inter-user variation 
these results have not been universally matched.[3] The technique has also been criticised for 
being both time-consuming and expensive as well as requiring considerable training to 
interpret and relying on the use of exogenous contrast to demonstrate the irregular 
neovascularisation that is characteristic of neoplastic tissue. Further trials are required before 
this technique can be recommended for widespread use. 
 
3.8.2.2 Elastic Scattering Spectroscopy (ESS) 
 
ESS uses a fibre-optic probe passed through the instrument port of an endoscope to generate 
morphological information about the nature of the Barrett’s segment. White light is 
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elastically scattered from the mucosa and submucosa with varying signal depending on the 
size and shape of the cell nuclei and the degree of cellular crowding. 
Spectral signal can be acquired in short acquisition times which approach ‘real-time’ 
imaging. 
 
Dysplastic and malignant tissues have been shown to have a characteristic ESS signature 
however, due to signal interference from deeper structures the accuracy of ESS appears 
limited to around 85%.[234] Lovat et. al. measured spectra from 181 tissue sites from 81 
patients which were correlated with consensus histopathology. ESS identified HGD with a 
sensitivity of 92% and a specificity of 60% and was able to differentiate these sites from 
inflammation with a sensitivity and specificity of 79%.[235]This current level of accuracy 
was deemed insufficient to support clinical uptake of ESS unless it can be improved through 
refinement of the technology or the use of a concomitant imaging modality. 
 
Recently Qiu et. al. described a novel endoscopic polarised scanning spectroscopy (EPSS) 
system capable of performing rapid optical scanning of the oesophageal surface in near real-
time.[131] The technique records elastically scattered light and filters signal from deeper 
tissue enabling epithelial interrogation. 5 patients with Barrett’s oesophagus underwent 
EPSS. 95 biopsies were taken for comparison to spectral data which, compared to a 
histological gold standard, demonstrated a sensitivity of 92% and a specificity of 96% (all 
pathologies). Further on-going development of this technology is necessary before sound 
conclusions on its potential for widespread clinical use can be drawn. 
 
3.8.3 Novel Imaging Techniques: Summary 
 
Currently, none of these advanced endoscopic imaging techniques have yet been widely 
adopted into clinical practice. This reflects a variety of limitations including insufficient 
sensitivity or specificity, inter-observer variability, cost and technical difficulties. There is a 
continuing need for a novel imaging technique that could enable objective assessment of 
Barrett’s segments in order to minimise missed disease and aid targeted ER. 
 
The advent and now widespread use of ER has meant that accurate targeting of focal 
HGD/IMC has become essential. A study by Vieth et. al. showed that a complete (R0) 
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resection was achieved in just 26.8 % (87/326) of patients at the first attempt due to 
inadequate endoscopic assessment of lesion margins.[8] This improved to 74.8% (244/326) 
following repeat endoscopy. The study concluded that failure to achieve R0 resections at the 
initial endoscopy would introduce an unnecessary time delay and may increase complication 
rates, and the development of improved endoscopic imaging techniques was strongly 
advocated. 
 
The potential ability to objectively target neoplastic lesions makes endoscopic RS an 
intriguing and exciting possibility and has led to the exploration of this technology within this 
translational research thesis. 
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Imaging modality Concept Reference 
White light endoscopy   
High-resolution endoscopy (HRE) Greater magnification and resolution 
than normal endoscopy allowing more 
detailed visualisation of the mucosa 
May et. al. (2004)[18]
 
Chromoendoscopy Topical application of dyes improves 
visualisation of mucosal surfaces. 
Examples: methylene blue – absorbed 
with different patterns into different 
types of mucosa; indigo carmine – 
accumulates in mucosal fissures 
accentuating surface topography 
Canto et. al. 
(2006)[220] 
Optical endoscopy   
Autofluorescence imaging (AFI) Short-wavelength light causes 
excitation of endogenous biological 
tissues with subsequent release of 
longer wavelength fluorescent light. 
Kara et. al. (2005)[230] 
Narrow-band imaging (NBI) Narrow-bandwidth green and blue light 
(with exclusion of red light) only 
superficially penetrates mucosa, 
improving visualisation of mucosal 
microvasculature and surface 
morphology 
Curvers et. al. 
(2008)[142] 
Confocal microscopy (CM) Real-time magnification of the mucosa 
up to 1000-fold enables visualisation of 
cellular structures. 
Dunbar et. al. 
(2010)[139] 
Elastic scattering spectroscopy 
(ESS) 
Elastic scattering of white light 
generates real-time morphological 
information about the size and shape of 
the cell nuclei and the degree of cellular 
crowding in the mucosa and 
submucosa. 
Qiu et. al. (2010)[140] 
Trimodal imaging 
 
 
 
Molecular imaging 
Incorporates HRE, AFI and NBI in a 
single endoscope with ability to switch 
between modalities during procedure. 
Fluorescently-tagged molecular probes 
bind selectively to metaplastic or 
dysplastic cells. 
Curvers et. al. 
(2008)[20; 240] 
Fitzgerald et. 
al.(2012)[16] 
 
Table  3-4. Advanced endoscopic imaging modalities being investigated for use in 
Barrett’s oesophagus surveillance programmes and for facilitation of targeted 
endoscopic resection. Reproduced from Almond et. al.[26] 
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CHAPTER 4 
4 Methods 
 
4.1 Raman Probe-Spectrometer Interface 
 
The internal optical components of the novel Raman probe are described in detail below. For 
all spectral measurements, unless otherwise stated, the custom-built probe was used in 
conjunction with a monochromatic 830 nm Innovative Photonics Systems (IPS) laser 
(Princeton, New Jersey, US) and a Renishaw system 100 spectrometer (Renishaw Plc., Wotton-
under-Edge, Gloucestershire, UK) which was optimised for NIR signals using a deep depletion 
CCD camera. Figure 4-1 illustrates the probe-spectrometer system. The photograph in Figure 
4-1 displays the internal components of the Renishaw system 100 spectrometer. Laser light 
enters the spectrometer and is filtered and collimated before being reflected onto a dispersion 
grating and projected onto the CCD (see Figure  3-5). 
 
 
 
 
Figure  4-1. The probe-spectrometer interface. Reproduced from Almond et. al.[237] 
The photograph shows the internal components of the Renishaw spectrometer. 
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Since Raman scattering increases with the fourth power of the frequency of the excitation 
source an excitation wavelength was chosen which maximised signal output whilst 
minimising tissue absorption and generation of unwanted fluorescence signal. Excitation 
using 830 nm wavelengths has previously been shown to be safe, and yielded acceptable 
tissue signal during preliminary experiments (Appendix IV). 
 
4.1.1 Probe Design 
 
This Doctorate assesses the potential for in vivo analysis of oesophageal tissue using a novel, 
custom-built, confocal Raman probe which has been designed specifically for compatibility 
with a standard medical endoscope. The Raman probe was designed and built at the Interface 
Analysis Centre, at the University of Bristol. 
 
A full description of an earlier prototype probe has been published previously by Day J et. 
al.[37] The probe has now been modified to incorporate a graded index (GRIN) lens at its 
distal tip so that it may be placed in contact with a tissue sample. The probe has a fibre-optic 
length of 90 cm and is 2.7 mm in diameter enabling passage through the instrument channel 
of a standard medical endoscope. Its internal optical constituents are illustrated in Figure  4-2 
which also illustrates the direction of the excitation laser (red) and collected signal (green). 
 
The laser is transmitted through the excitation fibre, collimated by a GRIN lens, and filtered 
to remove Raman and elastic scattering signals generated within the fibre. The monolith 
reflects the light onto a dichroic filter which reflects only light at the specified excitation 
wavelength onto a focussing GRIN lens. After interaction with the sample, scattered light is 
collimated by the GRIN lens and transmitted back to the dichroic filter which reflects the 
elastically scattered light but allows inelastically scattered wavelengths to pass through to a 
second dichroic filter. The signal is then focussed onto the collection fibre by another GRIN 
lens and transmitted back to the spectrometer. 
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Figure  4-2. Optical components of the custom-built Raman probe. The confocal design 
facilitates an extremely shallow depth of field and ensures the excitation volume 
matches the sampling volume. Image courtesy of Oliver Stevens, Interface Analysis 
Centre, University of Bristol. 
 
The probe is confocal, that is to say, the exit aperture of the excitation fibre is equal to the 
entrance aperture of the collection fibre.[37] It has been designed to focus to 150µm in order 
to sample from the oesophageal epithelium and minimise signal interference from deeper 
tissues. In addition, unlike previous commercial fibre-optic Raman probes it has a short tip so 
that endoscopic manipulation will be possible when taking probe measurements in vivo. It is 
also designed for direct tissue contact in order to facilitate in vivo endoscopic measurements. 
 
4.2 Laser Safety 
 
A strict laser safety policy was adhered to during all spectral measurements. 
 
Prior to independent measurements training was provided on laser safety issues and safe 
handling of the instrument (via a laser safety course and laboratory tutorials). An assessment of 
laser competence was also completed. 
 
A customised set of laser safety ‘local rules’ was developed to enable measurement of Raman 
spectra both within the laser laboratory, and within the endoscopy department at 
Gloucestershire Royal Hospital (Appendix V). Local rules were approved by the 
Gloucestershire NHS Trust laser protection advisor following inspection of the sites. 
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The local rules detailed the nature of the potential hazards when using the laser and the 
mandatory safety precautions including the need for protective eyewear, and for designation of 
a ‘controlled laser area’ with dedicated access. 
 
A risk assessment was also completed prior to work in the laser laboratory and the endoscopy 
department (Appendix VI). 
  
4.3 System Calibration 
 
If Raman probe systems are to be used widely in clinical settings spectral datasets must be 
shown to be consistently reproducible. However, standardisation of spectrometer 
specifications and probe construction is unlikely to prevent minor spectral variation between 
different systems. It is therefore necessary to define a clear method for Raman system 
calibration. 
 
Prior to each set of spectral measurements the system was calibrated using laboratory 
standards. Power output was initially measured and adjusted to 60 mW at the probe tip. The 
intensity of Raman signal is dependent on both excitatory laser power and laser frequency. 
However, excessive escalation of laser power can lead to thermal tissue injury. An excitation 
power of 60mW was chosen as this output is consistent with those in other published 
studies.[194; 197; 204; 206; 238] The novel Raman probe focuses excitation signal onto the 
epithelium (rather than interrogating deeper tissues as in previous studies). Therefore, a careful 
histological assessment for the presence of thermal injury was conducted by two independent 
pathologists following interrogation of tissue samples using 60 mW of 830 nm excitation for 5 
s. 
 
Calibration of the Raman system aimed to ensure that CCD read-out was reproducible so that 
spectral data could be compared from day to day. It also enabled comparison between Raman 
systems. Spectra were measured from silicon, green glass, a neon argon lamp and PTFE 
standards to enable both offset correction and, where necessary, correction of variation of CCD 
efficacy across the entire spectral range. In practice, following silicon measurement an offset 
correction of the main spectral peak at 520.4 cm
-1
 was performed immediately prior to 
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measurement of the other optical standards. The green glass standard was measured routinely 
to enable future correction of CCD readout variation which commonly varies slightly with 
wavelength, particularly in the higher wavenumber range. Green glass has a broad spectral 
signal so can potentially enable system calibration across a large wavenumber range through 
calculation of an energy transfer function correction. Multiplying a raw tissue spectrum by the 
transfer function allows correction and standardisation of the measured tissue spectra for 
spectrometer energy sensitivity over the entire wavelength range (Chapters 5 and 7). 
 
Following silicon correction an air background signal was also measured to ensure visual 
consistency with previous readings and to enable air background subtraction during data 
analysis where indicated. 
 
All calibration and tissue spectra, unless otherwise stated, were acquired after exclusion of 
ambient light. 
 
4.4 Evaluation of Probe Stability 
 
Prior to tissue measurement it was necessary to establish that the Raman probe could be used 
to record accurate and reproducible spectra from a variety of laboratory compounds with 
predictable spectral signatures. Spectra were acquired from PTFE, green glass and a porcine 
tissue phantom. 
 
All spectra were measured by gently apposing the probe onto the surface of the material / 
tissue being interrogated. 
 
The following experiments were undertaken: 
 
- assessment of temporal variation in PTFE spectra. Serial 5s PTFE spectra were 
measured at 3 minute intervals for a total of 30 minutes; 
- assessment of variation caused by switching the laser source on and off; 
- assessment of the effect of disconnecting the laser source; 
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- assessment of variation due to probe re-positioning (including alteration in angle) 
between measurements; 
- assessment of the importance of adequate probe contact; 
- measurement of tissue spectra using a porcine tissue phantom in conjunction with a 
custom built perspex grid; 
- assessment of the effect of saline and water lavage on spectral recordings; 
- comparison of spectral signals acquired using an original prototype probe, and the 
current novel confocal probe.  
 
Further methodological details and results of these initial probe-spectrometer evaluations are 
included in Appendix IV. 
 
4.5 Ex Vivo Tissue Measurements 
 
 
This section describes the methods of spectral collection from ex vivo oesophageal tissue. Ex 
vivo tissue data are presented and discussed in Chapters 5 and 6. 
 
4.5.1 Ethical Approval and Patient Consent 
 
Informed consent was provided by all patients permitting ex vivo spectral analysis of their 
oesophageal tissue. Ethical approval for the study was obtained from the Gloucestershire 
Local Research Ethics Committee, Gloucester, UK (Appendix VII). 
 
All patients who participated in the study received a patient information leaflet (Appendix 
VIII). They were also required to read and complete a customized consent form (Appendix 
IX). 
 
4.5.2 Sample preparation and spectral acquisition 
 
Following surgical oesophagectomy with curative intent in patients with neoplastic disease, 
multiple spectra were measured from fixed points across the mucosal surface of the distal 
oesophagus using a custom built perspex grid to define measurement locations (Figure  4-3). 
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Following surgical resection the specimen was opened longitudinally and the mucosa gently 
washed using water (Sigma-Aldrich 34478) to remove any blood. The grid was then 
positioned to overlie the mucosa and pinned in place at each corner to prevent movement 
during spectral measurements. The probe was passed through specified grid positions and 
gently apposed to the tissue by hand, to mimic the clinical environment. The Perspex grid 
comprised 200 holes, each with a diameter of 3mm arranged in a 10 x 20 rectangular 
orientation. Each of the holes were 1mm apart. The columns and rows of the grid were 
labeled to enable correlation of the grid position with the Raman spectral measurement. 
 
 
 
Figure  4-3. Photograph taken prior to tissue measurements after placement of the 
perspex mapping grid. The distal oesophagus and proximal stomach have been opened 
and the grid has been pinned in place so that it overlies the distal oesophagus and 
gastro-oesophageal junction. 
 
 
Raman spectra were acquired using 1 s, 5 s and / or 0.1 s acquisition times across the 
wavenumber range 400 – 1850 cm-1. Following spectral measurement, a biopsy was taken 
using standard endoscopy forceps at each of the specified grid positions and immediately 
fixed in formalin. All samples were paraffin embedded, microtomed and stained with H&E 
(Haematoxylin & Eosin) prior to expert histological reporting. 
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Where tumours were too bulky to enable use of the grid, biopsies were taken from the 
resected specimen and mounted on calcium fluoride substrates before immediate spectral 
measurement. Between 1 and 5 spectra were measured from different sites across the biopsy 
depending on its size. Following spectral measurement the tissue was immediately fixed in 
formalin. Samples subsequently underwent routine processing prior to expert histological 
analysis. 
 
Endoscopic resection (ER) and endoscopic biopsy samples were used to augment the spectral 
dataset and increase the numbers of Barrett’s and dysplastic samples (Figure 4-4). When 
collecting endoscopic samples the specimens were immediately placed on acetate and snap 
frozen in liquid nitrogen in order to prevent the tissue from drying out prior to spectral 
analysis. Samples were subsequently allowed to defrost at room temperature for 2 minutes 
(point biopsies) or 5 minutes (ERs) and mounted on calcium fluoride substrate with their 
mucosal surface facing upwards before spectral measurement. One spectrum was acquired 
per point biopsy specimen. Up to five spectra were acquired from different locations across 
ER specimens depending on their size. Biopsy samples were subsequently formalin fixed and 
processed as described above. 
 
Figure  4-4. Schematic depicting methods of spectral measurement from bulk tissue and 
biopsies. 
 
Raman spectra 
measured from 
epithelial surface 
ER taken at 
endoscopy and 
snap frozen 
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All tissue sections were independently reported by two expert Consultant GI Pathologists 
based at different hospitals in order to gain consensus diagnoses. Oesophageal neoplasia was 
recorded using the Vienna classification (Table  4-1).[239] 
 
Category Description 
Category 1 Negative for neoplasia/dysplasia 
Category 2 Indefinite for neoplasia/dysplasia 
Category 3 (Non-invasive) low grade dysplasia  
Category 4 (Non-invasive) high-grade neoplasia  
Category 5 
Category 5.1 
Category 5.2 
Invasive neoplasia 
Intramucosal cancer 
Submucosal carcinoma or beyond 
 
Table  4-1. Vienna Classification of gastrointestinal epithelial neoplasia.[239] 
 
Following an initial period of data collection and a preliminary analysis, a power calculation 
was performed to guide future spectral measurements (Appendix X). 
 
4.6 Spectral Reproducibility Testing Using Two Probe Prototypes 
 
This section corresponds to results presented and discussed in Chapter 7. 
Experiments were undertaken to assess whether two Raman probes of the same design could 
perform consistently. 
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4.6.1 Multi-Operator Probe Comparison Using PTFE Standard 
 
PTFE spectra were independently measured by two operators using two identically built 
Raman probe prototypes. Both operators acquired spectra over 5 seconds using each probe on 
three separate occasions. The sequence of measurements (which probe, which operator) was 
randomized. 
 
Between each set of measurements the probe system was fully calibrated. Both probes were 
used in conjunction with the 830 nm IPS laser and the Renishaw system 100 spectrometer 
described previously. 
 
A wavenumber representing the midpoint of each of the 5 prominent PTFE peaks was 
selected. Following baseline correction and baseline correction plus green glass correction, 
the intensity of each peak was measured at each specified wavenumber for all spectra. Two-
way ANOVA (analysis of variance) was used to investigate the relationship between the 
spectral measurements and the two independent variables. 
 
4.6.2 Two Probe Comparison Using Ex Vivo Tissue 
 
Ex vivo tissue spectra were measured using a third probe. This had an earlier prototype 
design with a different GRIN lens at its distal tip which had not yet been modified for tissue 
contact. This probe was used in conjunction with the 830 nm IPS laser and the Renishaw 
system 100 spectrometer. Spectra were recorded in 1 and 5 seconds with the probe positioned 
2-5 mm from the mucosal surface. Tissue collection, processing and histological reporting 
were performed as described previously. The results of these measurements are included in 
Appendix IV. 
 
The second probe described in section 4.7.1 above was damaged prior to tissue 
measurements. No identical probes were available for further reproducibility testing due to 
probe construction difficulties. These are discussed further in Chapter 8. 
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4.7 Transferability between Spectrometers: Two Spectrometer 
Comparison 
 
This section corresponds to results presented and discussed in Chapter 7. 
 
In order to assess the reproducibility and transferability of spectra acquired using different 
spectrometers, a second, portable system, was evaluated (spectrometer 2). Both spectrometers 
were used in conjunction with the novel Raman probe and a consistent 830 nm 
monochromatic laser source. 
 
Optical standards (PTFE, green glass, silicon) and ex vivo tissue were interrogated using the 
probe in conjunction with spectrometer 2. The internal components of spectrometer 2 are 
illustrated in Figure  4-5. 
 
 
 
 
 
 
 
 
 
 
 
Figure  4-5. The components of ‘spectrometer 2’ - a portable spectrometer which was 
custom-built by Renishaw (Renishaw Plc., Wotton-under-Edge, Gloucestershire, UK). 
(Published with permission from Renishaw). 
 
Fibre-optic 
connector 
Notch Filter Cosmicar lens Mirror 
Renishaw CCD 
Diffraction 
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Spectra recorded from the optical standards were used to define a calibration correction to 
enable cross system comparison between measurements acquired on spectrometer 2 and those 
recorded on the Renishaw system 100 spectrometer (spectrometer 1). 
 
Ex vivo tissue spectra were acquired from endoscopic biopsy samples using spectrometer 2 in 
conjunction with the novel probe. Tissue spectra were acquired in 5 s, 1 s and 0.1 s. 
Comparison was made between tissue spectra measured using the two systems. 
 
4.8 Raman probe performance in the presence of endoscopic white 
light and narrow band imaging 
 
This section also corresponds to results presented and discussed in Chapter 7. 
To assess Raman probe performance in the presence of white light endoscopy (WLE) and 
narrow band imaging (NBI) light sources the novel probe was used in conjunction with the 
portable spectrometer described above (spectrometer 2). 
Spectral measurements were undertaken in conjunction with a modern Olympus endoscope in 
the endoscopy department at Gloucestershire Royal Hospital. Full laser safety measures were 
implemented in line with customized local rules following a prior inspection of the 
endoscopy suite by the Gloucestershire NHS Trust laser safety officer (see section 4.5.1). 
 
Ex vivo Raman spectra were measured from oesophageal biopsies collected during 
endoscopy. Spectra were measured from each biopsy to assess spectral interference from 
simultaneous: (i) white light endoscopy; (ii) narrow band imaging; and (iii) following 
exclusion of all ambient light (dark control measurement). Equivalent measurements were 
also made from PTFE as a consistency standard. All spectra were acquired in 5, 1 and 0.1 
seconds. Spectral measurements, tissue processing and histological reporting were performed 
as described previously. 
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4.9 Statistical Methods 
 
The measured Raman spectra represent a combination of tissue autofluorescence, weak tissue 
Raman scattering signals and noise from background signals generated by the probe and 
spectrometer components. Raw spectral data were normalised using standard vector 
normalisation, mean-centred, and interpolated to integer wavenumber spacings between 400 
and 1850 cm
-1
 (see Chapter 3). 
 
The effect of air background subtraction and energy sensitivity correction (using the green 
glass standard) was evaluated. When comparing between different probe-spectrometer 
systems a calibration algorithm was defined in order to optimize cross system spectral 
comparison. In addition, spectra measured using different acquisition times were scaled 
accordingly to enable accurate comparison. 
 
Principal component (PC) fed linear discriminant (LD) classification models were developed 
for both the 5s and 1s oesophageal tissue datasets using Matlab (Mathworks, Inc.). A 
thorough explanation of PCA, LDA and cross validation has been included in Chapter 3. 
 
PCA was employed to simplify the variance within the dataset into PC scores and loads. The 
number of PC loads chosen was optimised to maximise classification performance and 
prevent over-fitting due to noise. LDA was then employed which utilised pathological 
information in order to define functions which enabled spectral classification. 
 
The classification performance of a variety of ‘models’ was validated using leave one 
spectrum out cross-validation (LOSOCV) (Figure  4-6). This involved projecting a single 
spectrum onto a diagnostic classification model which was created using n-1 spectra. The 
process was repeated n times until each spectrum had been projected as a test dataset. 
Following cross validation Raman probe sensitivity and specificity could be calculated. 
 
 
 
 
 
 91 
 
 
Figure  4-6. Schematic of PC-fed LDA followed by leave-one-spectrum-out cross 
validation. The cycle was repeated n times using 1 spectrum in the test dataset and n-1 
spectra in training dataset until all spectra had been included as a test. 
 
A variety of classification models were evaluated in order to assess the capability of the 
probe to distinguish a variety of oesophageal pathologies. In addition, the probe’s ability to 
distinguish early mucosal disease (e.g. LGD and HGD); types of glandular mucosa (IM, CM 
or FM); and buried neoplasia was also assessed. 
 
The effects of longer (5 s) and shorter (0.1 s) spectral acquisition times on classification 
performance were evaluated. Similarly, the impact on diagnostic performance following 
inclusion and exclusion of non-homogenous tissue specimens, and the effect of training the 
classification model using consensus (as opposed to single pathologist) diagnoses, were also 
evaluated. In addition, sub-group analyses were preformed to assess differences in 
classification between spectra measured from snap frozen (biopsies) and fresh (surgical 
resections) tissue. 
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Independent test datasets were projected onto the 1s classification model to assess the ability 
of the algorithms to classify spectra acquired using different systems. This strategy was also 
employed to assess the classification of spectra measured in the presence of WLE and NBI 
light sources. 
 
Testing the classification model using an independent test dataset required calculation of a set 
of PC scores for the test dataset based on the loads calculated following PCA of the training 
dataset, (the loads of the training set were used to calculate a set of scores for the test set). 
The test scores could then be classified using LD functions described following LDA on the 
training dataset, and were then compared to consensus histology data to calculate 
classification performance. 
 
In addition to LOSOCV, the analysis was repeated using leave one patient out cross 
validation (LOPOCV). Repeated k fold cross validation was also employed in order to assign 
error bars to the classification performance.  
 
Examination of PC loadings and identification of those loadings most important to tissue 
diagnosis was conducted to examine the biochemical basis spectral of spectral classification.   
 
4.10 Additional Projects 
 
4.10.1 Correlation of Raman spectral signatures with molecular markers 
of progression in Barrett’s Oesophagus 
 
I was responsible for initiating a proof of principle study aiming to correlate Raman spectral 
signatures with molecular markers of progression in Barrett’s oesophagus. This study was 
undertaken by Ms Marta Losa, an MSc student at Cranfield University whom I co-
supervised. 
 
The study aimed to determine whether laboratory based Raman spectroscopy had the 
potential to identify histologically normal Barrett’s cells which had undergone molecular 
changes making them more susceptible to neoplastic transformation. 
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Following a review of the literature, the patterns of expression of three biomarkers: cyclin A, 
CDX2 and hTERT were studied using immunohistochemistry, and correlated with Raman 
signatures acquired using a Renishaw StreamLine system (Renishaw Plc., Wotton-under-
Edge, Gloucestershire, UK). Data collection was undertaken by Ms Marta Losa, myself, Dr 
Jo Hutchings and Dr Catherine Kendall. Appendix XI summarises the aims, methodology and 
results of this study. 
 
4.10.2 Oesophageal Spectral Cytopathology 
 
During a British Society of Gastroenterology travelling fellowship I initiated a collaboration 
between the Biophotonics Research Unit in Gloucester and the Department of Medical 
Diagnostics, Northeastern University, Boston, US. The intention of the collaboration was to 
investigate the potential for interrogation of oesophageal cells using spectral cytopathology 
(SCP). Successful results could suggest a potential role for SCP in oesophageal cancer 
screening. 
 
A proof of principle study was conducted and further on-going data collection is in progress. 
A report of the methodology, results and conclusions of the proof of principle study is 
included in Appendix XII. 
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CHAPTER 5 
 
 
5 Evaluation of Diagnostic Performance 
 
 
This chapter presents and analyses the ex vivo tissue data measured using the Raman probe 
system. Further discussion of the results from a clinical perspective is included in Chapter 8. 
 
5.1 Summary of Measurements 
A total of 2226 spectra were measured from ex vivo tissue from 62 patients. To enable 
evaluation of diagnostic classification performance a histological diagnosis was obtained at 
the site of each spectral measurement. Table  5-1 illustrates the 1342 spectra for which a 
corresponding consensus histological diagnosis is available. The nature of the tissue samples 
(biopsies / resections) and the acquisition times used for spectral measurements is illustrated. 
Spectra recorded using alternative probe/spectrometer systems have been excluded from this 
table. Data on these will be included in Chapter 7. 
 
 Total 
number of 
patients 
Number of spectra with 
corresponding pathology  
5 s 1 s 0.1 s 
Oesophageal / Gastric resections 27 231 651 121 
Biopsies / EMRs from endoscopy 35 74 147 18 
Total 62 405 798 139 
 
Table  5-1. Summary of spectra measured from tissue where a corresponding consensus 
expert histological diagnosis is available. Spectra recorded using alternative probe / 
spectrometer systems have been excluded. 
Following initial proof of concept experiments, 1 s measurements were generally favoured 
over longer measurements as they are more applicable to potential clinical use in vivo and 
demonstrated potential for diagnostic classification. 
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Table  5-2 summarises the most common histological diagnoses after an independent review 
of all the biopsy samples by two leading upper gastrointestinal pathologists from different 
UK centres. Only those samples which were homogenous for a particular pathology were 
included here unless stated. Non-homogenous samples were classified as ‘mixed pathology’. 
Mixed pathology specimens e.g. mixed LGD and HGD, or mixed Barrett’s and normal 
squamous tissue, were included in the subsequent analyses only where indicated. Samples 
reported as non-homogenous by one pathologist have been recorded as ‘mixed pathology’ in 
order to optimise training of classification models. The impact of using consensus, rather than 
individual pathology reporting, to train the classification model is evaluated and discussed in 
section 5.12. 
 
Pathology Number of Biopsies 
Pathologist 1 Pathologist 2 Consensus 
Normal Squamous 253 256 252 
IM 137 109 100 
Non-dysplastic Barrett’s oesophagus (NDB) 142 144 114 
Stomach with native structures 15 36 12 
Homogenous LGD 26 85 21 
Homogenous HGD +/- IMC 25 49 10 
All dysplasia including mixed LGD / HGD 82 119 68 
All neoplasia (LGD +/- HGD +/- cancer)+ 231 241 184 
All adenocarcinoma+ 150 139 115 
Benign epithelium over adenocarcinoma 49 65 74 
Any benign pathology* 453 424 406 
Connective tissue 6 4 2 
Mixed pathology* 189 125 189 
Squamous neoplasia 3 3 3 
 
 
Table  5-2. Summary of histological diagnoses. *Includes non-homogenous tissue 
samples. Note that non-dysplastic Barrett’s (NDB) oesophagus includes all columnar 
lined oesophagus (CLO) samples: intestinal metaplasia, cardiac metaplasia and fundic 
metaplasia were classified as CLO provided the tissue sample was taken from above the 
mucosal folds. Glandular samples with clear native gastric features were included as 
‘stomach’. This was to avoid confusion caused by misclassification of CLO as stomach 
or vice versa. 
+
Excludes invasive cancer beneath normal epithelium. Other diagnoses, 
where there was no consensus agreement, are not included. 
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5.2 Spectral Exclusion 
 
Fluorescence is the emission of light by a substance following absorption of light of a 
different wavelength. It is well recognised that excessive fluorescence signal can mask subtle 
inelastic signals preventing Raman spectral analysis. 
 
Despite the use of monochromatic NIR excitation and a modern dispersive spectrometer, 
occasional florid fluorescent spectra were recorded (Figure 5-1). In some instances the degree 
of fluorescence signal was significantly higher than that shown in Figure 5-1 leading to 
saturation of the CCD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  5-1. A collection of spectra measured from a single patient using a 5 s acquisition 
time. Note that a single spectrum (light blue) has a significant fluorescence background 
making tissue classification impossible. 
An initial proof of concept study recorded 180 spectra from a single resected oesophagus. 
18% of spectra, from a range of pathologies, displayed considerable fluorescence signal. The 
reason for this was thought to be excessive blood on the surface of the mucosa following 
dissection of the specimen - blood is known to fluoresce due to a variety of endogenous 
fluorophores.[240; 241] Subsequently, mucosal lavage was performed using water, prior to 
spectral measurement from oesophagectomy specimens. 
400 600 800 1000 1200 1400 1600 1800
0
1
2
3
4
5
6
7
8
9
x 10
4
Wavenumber (cm-1)
In
te
n
s
it
y
 (
c
o
u
n
ts
)
 
 97 
 
To assess the effect of mucosal lavage on unwanted fluorescence signal, 100 consecutive 
spectra were evaluated. Only a single spectrum displayed significant fluorescence and this 
was not reproduced following cleaning of the probe tip and repeated measurement at the 
same tissue site. 
 
1.3% of all 1 s spectra from a variety of pathologies displayed significant fluorescence signal 
despite mucosal lavage. These readily identifiable outliers were excluded from the 
subsequent analysis. In a clinical setting these spectra could be automatically highlighted as 
unreliable prompting the endoscopist to perform lavage and to take a repeat measurement. 
 
To enable a true assessment of the diagnostic performance of the probe, measurements from 
tissue sites for which there was no consensus histological diagnosis, and similarly those from 
non-homogenous tissue, were initially excluded from the multivariate models. 
 
5.3 Unprocessed Spectral Data 
 
Figure  5-2(A) illustrates unprocessed tissue spectra measured from a single patient using 5s, 
1s and 0.1s acquisition times. These spectra are also illustrated individually (Figure 5-2B, C 
and D) to permit visual comparison of the signal-to-noise ratio (SNR) obtained using each 
acquisition time. Despite lower SNR, Figure 5-2 illustrates that tissue spectra can be acquired 
using short, clinically applicable, timescales. Further evaluation will demonstrate whether 
these spectra are capable of diagnostic classification and the impact of reducing spectral 
acquisition times. 
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Figure  5-2. (A) Ex vivo tissue spectra measured using 5s, 1s and 0.1s acquisition times. 
These unprocessed spectra are presented individually in (B), (C) and (D) to allow 
comparison of SNR. 
 
A series of 5 s spectra taken from multiple epithelial sites across a single resected oesophagus 
are shown in Figure  5-3. Normal squamous spectra are coloured in blue, cancer in red, and 
Barrett’s in green. This figure illustrates the variation in spectral appearance and intensity that 
was observed following raw spectral measurements. The intensity variation may reflect slight 
angulation of the probe on the tissue, minor fluctuations in laser power output or alterations 
in the amount of pressure used to apply the probe to the tissue. Whilst power output was 
standardised at the start of each set of measurements, no attempt was made to directly control 
the other two variables. This was an intentional decision since clinical application of the 
probe in vivo would not permit precise regulation of probe angulation or pressure. In 
addition, the effects of probe angulation and pressure have previously been investigated and 
shown not to influence spectral classification.[197] 
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Figure  5-3. Unprocessed spectra measured from a single patient. Each spectrum was 
acquired over 5s. Normal squamous spectra are coloured in green, cancer in red and 
Barrett’s in blue. 
Data pre-processing (routinely normalisation and mean centring) served to minimise 
variations in intensity values. Additional statistical calibration measures were also trialled in 
an attempt to minimise background signal and will be discussed in later sections. However, 
the variation in intensity illustrated in Figure 1-3 did not prevent PC-fed LDA from extracting 
the spectral information required for diagnostic spectral classification. 
 
5.4 Diagnostic Classification Models 
 
The large 1 s spectral database has been used for spectral prediction unless stated. The 
diagnostic accuracy achieved with 5 s and 0.1 s acquisition times is also evaluated below. 
 
Consensus pathology results have been used to inform the linear discriminant analysis (LDA) 
unless stated. In addition, the term ‘cancer’ is used in the tables to refer to adenocarcinoma 
rather than squamous cell carcinoma or other rarer cancers. 
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5.4.1 Three Group Models 
 
A 1 s PC-fed LDA classification model was validated using leave-one-spectrum-out cross 
validation (LOSOCV). Spectra measured from three groups (HGD / adenocarcinoma; LGD / 
Barrett’s oesophagus; and normal squamous) were included. LGD was included with non-
dysplastic Barrett’s (NDB) samples, and HGD with adenocarcinoma, as the division between 
the two groups represents the current clinical treatment line - LGD and NDB are typically 
observed whereas HGD and adenocarcinoma are treated with ER, ablation or surgery. 
 
Figure  5-4 illustrates a scatter plot of cross-validated LD scores for each Raman probe 
prediction. The first 15 PCs were included in the classification algorithm. 
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Figure  5-4. One second, three group cross-validated LD scores plot 3 group (20 PCs). 
 
Figure  5-4 clearly illustrates the predictive capability of the model. The numerical data is 
displayed in Table  5-3. A sensitivity of 86% and specificity of 88% were attained for 
distinguishing HGD / cancer (advanced neoplasia) from the other common pathologies. For 
reference, the sensitivity and specificity of this model for correctly predicting advanced 
neoplasia prior to cross validation were 87% and 90%. 
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Table  5-3. A 1 s three group PC-fed LDA classification model which has been tested 
using LOSOCV. Probe sensitivities and specificities have been calculated. 
Table  5-4 displays the results of a cross validated 3 group Raman probe classification model 
for distinguishing NDB; LGD; and HGD/IMC. Distinction between these pathologies during 
endoscopy can be difficult or sometimes impossible but Raman probe sensitivities of 80-85% 
and specificities of 81-99% are demonstrated for all three groups. 
 
The reliability of this classification performance is limited by the relatively small numbers in 
each group. This was due to small numbers of homogenous LGD and HGD samples, with 
additional sample exclusion due to lack of consensus pathology agreement. These limitations 
are discussed further in Chapter 8. 
 
 
 
 
 
 
 
 
Table  5-4. The 3 group PC-fed LDA classification model has been tested using 
LOSOCV. Probe sensitivities and specificities are displayed. 
 
5.4.2 Two Group Models 
 
Separating two pathology groups may be more clinically relevant than 3 or 4 group 
classification. Table 5-5 displays a series of one second, two group classification models. 
 
 
Raman Spectroscopy 
NSq NDB/LGD HGD/cancer 
Pathological 
Assessment 
NSq 215 20 16 
NDB/LGD 9 97 29 
HGD/cancer 2 15 108 
Sensitivity 87% 72% 86% 
Specificity 96% 91% 88% 
 
 
Raman Spectroscopy 
NDB LGD HGD/IMC 
Pathological 
Assessment 
NDB 97 15 2 
LGD 4 17 0 
HGD/IMC 2 0 10 
Sensitivity 85% 81% 80% 
Specificity 81% 88% 90% 
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Table  5-5. The cross validated results of a series of 2 group classification models are 
displayed. All spectra used for training and testing these models were acquired in 1 s. 
+
In this analysis all benign tissues including e.g. connective tissue have been separated 
from dysplastic and cancerous samples. Non-homogenous benign and neoplastic 
samples (e.g. NSq and NDB, or LGD with cancer) have been included provided they do 
not contain both benign and neoplastic elements. Where there is not an exact consensus 
diagnosis but is agreement of benign versus neoplastic, the data has also been included. 
NDB includes all columnar lined oesophagus (CLO) samples: IM, CM and FM were 
classified as CLO provided the tissue sample was taken from above the mucosal folds. 
Model Cross-validation 
Confusion 
matrix 
Sensitivity Specificity 
NSq Vs. 
HGD/Ca 
230 21 92% 93% 
19 119 93% 92% 
NSq Vs. 
Ca 
228 23 91% 94% 
7 108 94% 91% 
NSq Vs 
NDB 
218 33 87% 89% 
12 102 89% 87% 
NSq Vs. 
IM 
223 28 89% 82% 
17 79 82% 89% 
NDB Vs. 
Ca 
104 11 90% 80% 
20 81 80% 90% 
LGD+NDB Vs. 
HGD+Ca 
111 24 82% 88% 
15 110 88% 82% 
LGD Vs. 
HGD/IMC 
21 0 100% 100% 
0 10 100% 100% 
LGD Vs. 
HGD+Ca 
19 2 90% 100% 
0 93 100% 90% 
LGD Vs. 
HGD/IMC 
21 0 100% 100% 
0 10 100% 100% 
NDB Vs. 
LGD 
99 15 87% 76% 
5 16 76% 87% 
NDB Vs. 
Stomach 
110 4 96% 92% 
1 11 92% 96% 
IM Vs. 
CB/FB 
87 9 91% 80% 
1 4 80% 91% 
NSq Vs. 
Buried Ca 
225 26 90% 78% 
17 57 78% 90% 
NDB Vs. 
Buried Ca 
90 24 79% 81% 
60 14 81% 79% 
NSq Vs. 
HGD/ca inc buried 
227 24 90% 90% 
21 180 90% 90% 
NDB Vs. 
HGD/ca inc buried 
88 26 77% 83% 
34 167 83% 77% 
Benign+ Vs. 
Neoplastic 
304 102 75% 82% 
33 151 82% 75% 
Benign+ Vs. 
Neoplastic inc buried 
303 103 75% 77% 
59 202 77% 75% 
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Normal squamous epithelium can usually be differentiated from Barrett’s oesophagus at 
endoscopy. However, HGD and early cancer may be macroscopically indistinguishable from 
LGD and NDB. Therefore, a two-group classification model including NDB/LGD and 
HGD/cancer is of particular clinical significance (Figure  5-5A). For comparison the results of 
a normal squamous versus HGD/cancer algorithm is also illustrated (Figure  5-5B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  5-5. Two group histograms demonstrating the classification performance of (A) 
the two group model: HGD / cancer versus NDB; and (B) normal squamous oesophagus 
versus HGD / cancer. 
 
 
Cross validated results yielded a sensitivity of 82% and a specificity of 88% for separating 
advanced neoplasia from LGD and NDB (Table 5). This division represents the current 
clinical treatment line. The positive predictive value for detecting a neoplastic lesion was 
95% in this model. These data demonstrate significant potential for fibre-optic RS to be used 
to aid therapeutic decision making. 
 
In addition, advanced neoplasia could be distinguished from normal squamous oesophagus 
with a sensitivity of 92% and a specificity of 93% (Table 5). The ability to distinguish these 
pathologies may be of particular use in patients with dysphagia who are found to have an 
oesophageal stricture. In some cases it can be difficult to distinguish benign from malignant 
strictures and biopsies can be inconclusive or misleading due to sampling error. Taking 
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several rapid Raman measurements in vivo could act to re-assure clinicians or prompt more 
extensive biopsying. 
 
These analyses demonstrate that fibre-optic Raman measurements of fresh unprocessed tissue 
can accurately delineate between a series of pathologies in the oesophagus. Encouragingly, 
these results have been achieved with the novel probe system using just 1 s spectral 
acquisition times suggesting real potential for rapid, non-invasive, objective, in vivo 
diagnosis during endoscopy. 
 
5.4.3 Detection of Epithelial Disease 
 
Normal squamous mucosa, Barrett’s oesophagus and invasive cancer can usually be readily 
identified using standard white light endoscopy. For RS to have a role as an in vivo 
diagnostic aid it is essential that it demonstrates the potential for recognition of superficial 
pre-malignant epithelial changes (and early intramucosal cancer (IMC) – T1a lesions). 
Laboratory spectrometers have been shown to detect Raman signals from the epithelium of 
oesophageal biopsy samples in vitro, enabling accurate classification of pre-malignant disease 
(see Chapter 3). However, to date, prototype probe designs have failed to address the need for 
specific interrogation of the epithelial surface in the oesophagus.[197; 205-209] Recently 
published data reported in vivo detection of cancer in the stomach and oesophagus with high 
degrees of diagnostic accuracy but made no mention of the capacity for diagnosis of early 
(HGD / IMC) disease.[209; 212; 242] 
 
By definition dysplasia is an epithelial condition which has the potential to become an 
invasive malignancy but has not yet breached the epithelial basement membrane. It is 
essential to assess the ability of the Raman probe to detect and differentiate between grades 
of dysplasia and IMC since these lesions are treatable endoscopically. 
 
Despite an array of advanced imaging modalities, differentiating LGD and HGD 
endoscopically is often impossible. Where possible, expert clinicians favour an approach of 
treating HGD with focal endoscopic resection (ER) prior to whole segment ablation.[243] By 
contrast LGD is kept under close surveillance. ER of extensive areas is associated with 
increased risks of bleeding, perforation and stricture formation. Therefore, there is a clear 
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clinical need for an objective diagnostic tool, such as an in vivo RS probe, which could aid 
lesion targeting. As well as confirming which areas should be removed, it could help with 
defining margins and thus potentially improve R0 resection rates. 
 
A two group classification model including LGD and HGD/IMC has been evaluated. This 
demonstrates that the RS probe system is capable of distinguishing HGD/IMC from LGD 
with a sensitivity and specificity of 100% following LOSOCV. This particular model 
contains relatively small numbers of spectra due to the low numbers of consensus 
homogenous LGD and HGD/IMC tissue samples (Table 5-5 and Figure  5-6). However, these 
results are still extremely promising and demonstrate a clear ability to detect signal from the 
epithelium of the oesophagus. It should also be considered that these cross validated results 
are objective, and based on spectra which were acquired in just 1 s. 
 
-60 -40 -20 0 20 40 60 80
0
5
10
15
20
25
30
35
40
LD function
N
u
m
b
e
r 
o
f 
S
p
e
c
tr
a
 
Figure  5-6. LD scores histogram illustrating the performance of a 2 group model at 
distinguishing LGD from HGD and adenocarcinoma. 
Interestingly there is a growing body of evidence that supports early treatment of LGD 
provided an accurate diagnosis can be established. The premise for this is the well 
documented over-diagnosis of LGD by non-specialist pathologists which has tended to lead 
to underestimates of the risk of progression of LGD in many published series.[118] 1 s 
Raman probe measurements are capable of discriminating LGD from NDB with a sensitivity 
of 76% and specificity of 87% (Table 5-5). This potential to provide an objective diagnosis of 
LGD could possibly enable early targeted endoscopic treatment of these lesions. In addition, 
it may help prevent significant over-diagnosis and reduce unnecessary surveillance 
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endoscopy. However, it must be noted that the diagnostic ability to distinguish these two 
pathologies appears lower than for other tissue types. This may reflect the fact that only 
extremely subtle biochemical changes occur during the progression from Barrett’s to LGD. 
Alternatively, since histological discrimination between Barrett’s and LGD is particularly 
fraught with inter-observer disagreement it is possible that there has been some histological 
misclassification leading to incorrect training of the classification model. 
 
Raman probe measurements were also able to discriminate intestinal metaplasia (IM) from 
cardiac metaplasia (CM) and fundic metaplasia (FM) with a sensitivity and specificity of 
91% and 80% respectively. IM, which is characterised histologically by goblet cells, has a 
greater malignant potential than CM or FM, and in the United States is considered necessary 
to confirm a diagnosis of Barrett’s oesophagus. 
 
The analyses presented in this section demonstrate that the custom-built Raman probe is 
capable of detecting early epithelial changes which occur prior to the development of 
invasive malignancy. This could potentially help reduce the incidence of missed dysplastic 
disease and also facilitate early targeted therapy for these patients. In addition, it raises the 
intriguing prospect for potentially detecting subtle spectral differences in non-dysplastic 
Barrett’s tissue which may be associated with an increased risk of disease progression.  
 
Barrett’s is a multiclonal condition consisting of multiple phenotypes. Certain clones are at a 
greater risk of progression than others due to early molecular changes which increase the risk 
of disease progression but do not lead to morphological change. The ability to detect detailed 
biochemical information from the oesophageal epithelium raises the possibility that RS could 
be used to detect particular ‘high risk’ Barrett’s phenotypes. This could trigger a policy of 
closer surveillance in these patients. The prospect for the detection of high risk metaplasia 
needs to be investigated further through in vitro Raman analysis with correlation with 
molecular markers. 
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5.4.4 Distinction of Barrett’s Oesophagus from Gastric Mucosa 
 
 
Table  5-5 illustrates the ability of the Raman probe to distinguish between Barrett’s 
oesophagus and gastric mucosa. The diagnosis of Barrett’s oesophagus is dependent on a 
biopsy being taken from the oesophagus, as opposed to the cardia (the upper stomach), as the 
histological appearances of the two can be identical. Therefore, attempting to distinguish 
Barrett’s oesophagus from gastric mucosa is reliant on all biopsies being correctly labelled as 
either ‘oesophageal’ or ‘gastric’. Distinction between these groups can be very difficult at 
endoscopy, particularly in patients with hiatus hernias, and therefore considerable cross-over 
between these groups in the classification model was expected. 
 
To overcome this problem the analysis presented in Table 5-5 compares glandular samples 
recorded as oesophageal, with stomach samples which contained native gastric features (so 
were definitely of gastric origin). A sensitivity of 96% and specificity of 92% were 
demonstrated for correctly identifying Barrett’s oesophagus. However, it is important to 
acknowledge that these figures were based on relatively small numbers of spectra with 
consensus histology (see Table 5-5), and therefore may represent slightly over-optimistic 
classification performance. 
 
An ability to distinguish gastric from Barrett’s mucosa could be of particular use to clinicians 
in patients with an irregular z line who may be labelled with a diagnosis of Barrett’s 
oesophagus. Over-diagnosis of Barrett’s oesophagus can have significant psychological and 
economic implications (particularly in the US) and may necessitate unnecessary long-term 
endoscopic surveillance. On the other hand, a missed short tongue of Barrett’s may have the 
potential to give rise to an adenocarcinoma. 
 
5.4.5 Non-Homogenous Tissue 
 
Only tissue that is homogenous for a particular pathology has been included in the 
classification models presented (unless stated). This was to ensure optimal training of the 
models so that the true accuracy of disease classification could be evaluated. 
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However, in certain circumstances tissue with mixed pathology has been included as stated. 
For example, samples with HGD overlying invasive cancer were included in the advanced 
neoplasia group. Of particular interest was the potential for the RS probe to detect cancer that 
was buried beneath normal squamous epithelium (Table  5-6). 
 
  Sensitivity Specificity 
Excluding buried 
adenocarcinoma 
LGD / Barrett’s Vs. 
HGD / Adenocarcinoma 
80% 
85% 
85% 
80% 
Including buried 
adenocarcinoma 
LGD / Barrett’s Vs. 
HGD / Adenocarcinoma 
81% 
90% 
90% 
81% 
 
Table  5-6. Performance of a two group classification model (LGD / NDB) and HGD / 
cancer) after the inclusion and exclusion of buried adenocarcinoma. 
The results displayed in Table  5-6 imply that the Raman probe can detect subepithelial, or 
potentially submucosal spread of cancer due to inelastic scattering of laser light transmitted 
beneath the epithelium. This suggests a possible role in intra-operative margin assessment 
during oesophagectomy. Current guidelines recommend that surgeons ensure a 10 cm margin 
proximal to the tumour in addition to a 5 cm distal margin.[185] However, in some cases 
significant margins can be difficult to achieve, and in these circumstances a tool which could 
provide immediate objective margin assessment would prove a significant asset. 
 
Similarly, it is possible that the Raman probe could be used to detect buried metaplasia which 
may occur, and retain malignant potential, following ablative therapies. No samples 
containing buried metaplasia were collected and therefore this could not be evaluated further. 
 
A second possible explanation for the ability to correctly classify buried neoplastic elements 
is that the overlying epithelium is in some way different biochemically to normal epithelium 
despite its consistent histological appearance. Evaluation of this requires further study in 
conjunction with molecular markers (see Chapter 8). 
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5.5 Assessing the Value of Background Subtraction Techniques 
 
This section evaluates the effects of air background subtraction and green glass correction on 
the ability of the algorithms to classify pathology. 
 
Probe spectra contain broad background spectral artefacts which are particularly prominent in 
lower wavelength regions (Figure  5-3). The propensity of probe fibres to generate their own 
Raman and fluorescence signals is a significant factor affecting their ability to detect the 
subtle spectral differences between tissue types.[201; 202] In early probe systems these 
signals were significantly greater than those arising from the tissue making spectral 
classification impossible.[197] 
 
Fibre signal is generated in delivery fibres due to excitation by the laser light, and in the 
collection fibres by elastically scattered light transmitting back along the collection fibre. In-
built optical filters within the probe and spectrometer help minimise these background signals 
(see Chapter 3) and use of 830 nm excitation aids limitation of unwanted tissue fluorescence. 
In addition, since unwanted fibre signal is proportional to fibre length, excess fibre length 
(above the 2 m required for endoscopic use) has been avoided. 
 
However, despite these measures the Raman probe system displays a considerable degree of 
unwanted background signal prompting exploration of computational methods of background 
reduction in an effort to enhance classification performance. 
 
Several methods of background subtraction have been described in the literature although 
none are used routinely due the inherent possibility of introducing systematic or non-
systematic error during the data subtraction process.[244] In addition, although enhancing 
visible identification of biochemical tissue peaks, these techniques frequently fail to improve 
the ability of PCA-LDA algorithms to classify tissue spectra.[245] 
 
Tissue spectra following air background subtraction and green glass correction are illustrated 
in Chapter 6 in order to illustrate some of the biochemical features important for spectral 
classification. 
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5.5.1 Green Glass Correction 
 
Green glass standards can be used to calculate correction (transfer) functions which correct 
for variations in CCD readout across the entire wavenumber range.[191] Figure 5-7 illustrates 
a green glass spectrum measured using a laboratory spectrometer which had been calibrated 
using a lamp standard measured at the National Physical Laboratory; a green glass spectrum 
measured using the Raman probe system immediately prior to recording a set of tissue 
measurements; and the calculated correction function. 
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Figure  5-7. A green glass correction function has been calculated by dividing the green 
glass spectrum measured using the probe system by the green glass standard. 
 
Although the data presented in this chapter were acquired using a single probe-spectrometer 
system, a wavenumber calibration using a green glass correction was applied to raw spectral 
data to account for any variability in CCD readout from day to day and to assess its impact on 
the accuracy of spectral classification. The results of a repeat analysis with and without green 
glass corrected spectra are displayed in Table  5-7 and discussed below. 
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5.5.2 Air Background Subtraction 
 
Following initial system calibration, air background spectra were recorded during each set of 
tissue measurements to ensure visual consistency between spectra. Reproducible air spectra 
between measurements reassured the probe operator that there was no contamination of the 
probe tip, that intensity recordings were consistent, and that no systematic error had been 
introduced. 
 
In some instances multiple air spectra were measured during a single set of measurements. In 
these cases a mean air spectrum has been used for subtraction from all tissue spectra 
measured on that day. 
 
The effect of air background subtraction on diagnostic classification performance is displayed 
in Table  5-7 and discussed below. 
 
5.5.3 Background Subtraction / Correction: Impact on Classification 
Performance 
 
The impact of air background subtraction and green glass correction on the performance of a 
3 group 1 s classification model are displayed in Table 7. 
 
  Sensitivity (%) Specificity (%) 
No correction NSq 
LGD / Barrett’s 
HGD / Adenocarcinoma 
87% 
72% 
86% 
96% 
91% 
88% 
Air background 
subtraction  
NSq 
LGD / Barrett’s 
HGD / Adenocarcinoma 
83% 
62% 
70% 
70% 
98% 
87% 
Green glass 
correction 
NSq 
LGD / Barrett’s 
HGD / Adenocarcinoma 
74% 
81% 
85% 
94% 
88% 
86% 
 
Table  5-7. The effect of air background subtraction and green glass correction on the 
classification performance of a 3 group model tested using LOSOCV. 
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Neither green glass correction nor air background subtraction improved the ability of the 
algorithm to classify pathology. It is clear that the Raman probe system obtained sufficiently 
reproducible spectra to enable tissue classification across the time period of the study without 
significant difficulties due to CCD readout variability. In addition, the capability of PCA-
LDA to extract the important spectral features that enable tissue classification has been 
demonstrated in spite of the significant background signal. 
 
Spectral background subtraction using iterative subtraction of the fifth order polynomial has 
also been described previously[45; 51; 197; 244; 246] However, this was not previously 
shown to improve classification performance and was thought to introduce false variance 
which might in fact diminish classification performance.[247] This mechanism of data 
subtraction is therefore not repeated here. 
 
Despite the ability of multivariate analysis to classify probe spectra with significant 
background signal, engineering developments should still be implemented where possible 
with the aim of further boosting SNR so that more prominent biochemical peaks are 
identified and the accuracy of pathological classification, perhaps in even shorter timescales, 
is maximised. 
 
It appears that PCA-LDA algorithms have the ability to extract the subtle spectral differences 
necessary for pathological separation without the need for prior background subtraction 
processes. It is possible that the techniques of green glass correction and air background 
subtraction are of greater value when attempting to compare and transfer spectral datasets 
acquired using different probes and / or spectrometers. More extensive discussion of the role 
of these background correction strategies is therefore included in Chapter 7. 
 
 
5.6 Evaluation of the 5 s Spectral Dataset 
 
Consensus pathology data is available for 405 spectra which were each acquired in 5 s using 
the standard Raman probe system. Although 5 s measurements would be less amenable to 
clinical implementation, it was interesting to assess the effect on diagnostic classification 
performance. 
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PC-fed LDA was used to generate both a 2 and 3 group classification model which were 
tested using LOSOCV (Figure  5-8). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  5-8. The classification performance of a 3 group (left) and 2 group model (right) 
is illustrated following PC-fed LDA and LOSOCV. 
The corresponding data for each model is shown below in Table  5-8 and Table 5-9. 
. 
 
 
 
 
 
 
 
 
 
 
 
 
Table  5-8. A 5 s three group PC-fed LDA classification model which has been tested 
using LOOCV. Probe sensitivities and specificities have been calculated. 
 
 
 
 
Raman Spectroscopy 
NSq Barrett’s 
/LGD 
HGD/ 
cancer 
Pathological 
Assessment 
Nsq 132 12 10 
Barrett’s/LGD 1 46 2 
HGD/cancer 3 13 72 
Sensitivity 86% 94% 82% 
Specificity 97% 90% 94% 
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Table  5-9. A 5 s two group PC-fed LDA classification model which has been tested using 
LOOCV. Probe sensitivities and specificities have been calculated. 
 
The prediction accuracies achieved were slightly higher for the 5 s models than for the 
corresponding 1 s models as expected. However, the results are perhaps less clinically 
applicable as 5 s measurements from precise areas might be difficult to generate in vivo due 
to patient movement and oesophageal peristalsis. 
 
The fact that increases in acquisition time can enhance classification performance suggests 
that other mechanisms of improving signal uptake could also improve diagnostic accuracies 
(see Chapter 8). 
 
5.7 Evaluation of the 0.1 s spectral dataset 
 
139 spectra, for which consensus pathology is available, were measured from tissue from 9 
patients using just a 0.1 s acquisition time. The aim of this series of measurements was to 
assess the effect of this much shorter acquisition time on the diagnostic performance of the 
model. 
 
Projecting new data onto a predefined model provides the best method of validating 
classification performance. The 0.1 s spectra have therefore been projected onto the 1 s 
classification model as a ‘test’ dataset (Figure  5-9). Table  5-10 illustrates the numbers of 
spectra measured in 0.1 s and how they classify. 
 
 
Raman Spectroscopy 
HGD/cancer  Barrett’s/LGD 
Pathological 
Assessment 
HGD/cancer  166 27 
Barrett’s/LGD 1 48 
Sensitivity 86% 98% 
Specificity 98% 86% 
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Figure  5-9. LD scores plot of the standard 3 group model. 0.1 s spectra (circles) have 
been projected onto the 1 s model (crosses) to see how they classify. 
 
 
 
 
 
 
 
 
Table  5-10. Performance of the 0.1 s spectra after projection onto a 1s 3 group 
classification model. 
 
Clearly, diagnostic accuracy has been diminished considerably by using a 0.1 s spectral 
acquisition time. However, a degree of diagnostic classification has still been possible. This 
raises the significant possibility that future Raman probe analysis could approach ‘real-time’. 
 
 
Raman Spectroscopy 
NSq Barrett’s 
/LGD 
HGD/ 
cancer 
Pathological 
Assessment 
Nsq 17 9 10 
Barrett’s/LGD 3 15 0 
HGD/cancer 9 13 28 
Sensitivity 47% 83% 56% 
Specificity 83% 74% 81% 
 
 
HGD / cancer
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LGD / Barrett's
1s spectra
0.1s spectra
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This would potentially enable clinicians to scan across large areas of mucosa in rapid 
timescales until an abnormality is highlighted. Real-time imaging could be particularly 
advantageous in minimising the incidence of missed dysplasia in long Barrett’s segments. 
 
5.8 Assigning error bars to the classification using repeated cross 
validation 
 
Probe based RS is potentially capable of providing clinicians with specific information to 
help inform treatment decisions. A Raman prediction of HGD would by no means be an 
indication to proceed straight to ER, but could act to support the clinical findings. 
 
However, in clinical practice Raman predictions would best be presented to clinicians as 
probabilities, rather than as definitive diagnoses. For instance, when assessing a suspicious 
area of mucosa in the oesophagus a Raman system could inform a clinician that there is a 
90% likelihood that it represents HGD. 
 
In addition, when assessing the performance of the probe it is useful to have a means of 
assigning error bars to the classification prediction. In a clinical setting this might inform 
clinicians that a suspicious lesion has, for example a 90% +/- 5% likelihood of being HGD. 
 
Repeated cross validation, as described by Lloyd et. al., has therefore been employed in order 
to validate diagnostic accuracy and define error bars.[34,248] Figure  5-10 displays the results 
of a 2 group model (Barrett’s/LGD; HGD/cancer) followed by repeated cross validation. In 
this case cross validation has been performed by randomly selecting a third of the dataset to 
‘leave out’ and project onto the remaining training samples. This process has been repeated 
1000 times using 1000 different random combinations in the test dataset. 
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Figure  5-10. Performance of training and test datasets following 2 group PC-fed LDA 
and repeated (1000 times) cross validation leaving out one third of the dataset. The 
sensitivity and specificity for separating HGD/cancer from LGD/Barrett’s are 
illustrated. 
 
Figure  5-10 demonstrates that this two group model is able to separate HGD/cancer from 
LGD/Barrett’s with a sensitivity of 82% (68% - 93%) and a specificity of 88% (75%-98%). 
 
5.9 Leave One Patient Out Cross Validation 
 
In this analysis the results of the 1 s three group model (normal squamous; NDB/LGD; 
HGD/adenocarcinoma) have been cross validated using leave one patient out cross validation 
(LOPOCV). This method of cross validation was employed as it infers how the model might 
perform for an entirely new patient attending for an endoscopy. Leave one spectrum out cross 
validation (LOSOCV), which has been used previously, assesses the performance of the 
model in classifying individual test spectra which have been ‘left out’. However, using 
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LOSOCV includes in the ‘training’ dataset spectra measured from the same patient as the 
‘test’ spectrum. 
 
By contrast LOPOCV uses all the spectra measured from an individual patient as the ‘test’ 
dataset whilst all other spectra form the ‘training’ set. This overcomes the theoretical concern 
that using LOSOCV projects spectra onto to a model that has been trained by other spectra 
from that patient. 
  Sensitivity Specificity 
LOSOCV NSq 
LGD / Barrett’s 
HGD / Adenocarcinoma 
87% 
72% 
86% 
96% 
91% 
88% 
LOPOCV  NSq 
LGD / Barrett’s 
HGD / Adenocarcinoma 
94% 
77% 
86% 
78% 
66% 
60% 
 
Table  5-11. The standard 3 group model has been tested using leave one spectrum out 
cross validation (LOSOCV) and leave one patient out cross validation (LOPOCV). 
Although accurate sensitivities have been demonstrated following LOPOCV, this is at the 
expense of a significant drop in specificity. The reasons for this probably reflect the fact that 
the patients did not all have an equal mix of pathology. That is to say, there were some 
patients for which no consensus could be achieved except for the normal squamous samples, 
and others where the samples were predominantly Barrett’s, with little or no other 
pathologies (this was particularly true for endoscopy, rather than oesophagectomy, patients).  
 
In addition, in this analysis it is possible that if just a small number of homogenous spectra 
were measured from a particular patient and all misclassified, perhaps due to a systematic 
error on that day (e.g. probe lens contamination), the 0% sensitivity and specificity calculated 
for that patients’ spectra would significantly reduce the overall performance following 
LOPOCV. 
 
In order to improve the statistical validity of LOPOCV, and thus make this analysis more 
representative of the classification of spectra from new patients, the analysis would ideally 
include a larger sample of patients with an equal distribution of pathologies from the three 
groups. This would also provide a better description of the variance within the patient 
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population so that future analyses are able to discriminate between patient spectral 
differences and biochemical spectral differences. 
 
5.10 Principal Component Optimisation 
 
PCA simplifies the variance within the dataset into a variable number of principal 
components (typically 15) which describe the major sources of independent variation 
between the spectra. PCA has been performed on the entire dataset without prior knowledge 
of which spectra were measured from which patient or from which pathology. As described 
previously the first principal component (PC1) reflects the direction of greatest variance 
between all spectra in the dataset. PC2 is in the direction of the largest residual variance and 
so on. 
 
The PCs therefore contain information which is vital for spectral classification (Figure  6-5). 
In theory, the more PCs that are generated the better the description of the variation within 
the dataset. However, later PCs often only represent spectral noise and may therefore be of no 
benefit when attempting to classify a spectrum (Figure  5-12). 
 
PC6:           PC20: 
400 600 800 1000 1200 1400 1600 1800
-0.08
-0.06
-0.04
-0.02
0
0.02
0.04
0.06
0.08
Wavenumber (cm-1)
P
C
 l
o
a
d
in
g
 (
a
. 
u
.)
8
5
2
1
4
4
9
1
3
4
0
1
0
0
4
1
6
5
5
9
3
4
9
3
4
 
Figure  5-11. Comparison of (a) PC6 and (b) PC20. It is clear that significant 
biochemical information is contained within PC6 whereas PC20 appears to contain 
mostly noise and is unlikely to aid spectral classification. 
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In the example illustrated in Figure  5-12, PC-fed LDA was used to assess the probe’s 
accuracy at delineating normal squamous tissue from adenocarcinoma. The influence of each 
of the principal components in achieving accurate diagnostic classification was assessed by 
repeating the LDA using increasing numbers of PCs. A combination of sensitivity and 
specificity over 85% was achieved only when utilising 11 PCs or more, and the optimum 
number of PCs was found to be between 11 and 16 with inclusion of later PCs adding no 
additional benefit to the classification performance. In this example, inclusion of higher 
numbers of PCs in fact led to a drop in performance due to over-fitting of noise. 
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Figure  5-12. Influence of number of PCs on sensitivity / specificity performance. 
 
5.11 Influence of Technique of Tissue Collection 
 
A limitation of the reliability of the main 1 s dataset is that spectra were acquired using two 
different methods: both from fresh tissue (following oesophagectomy) and from tissue which 
had been snap frozen (following endoscopic biopsy or ER). This section evaluates any 
classification differences pertaining to variations in how the raw data were acquired. 
 
Table  5-12 illustrates the proportion of spectra which were measured direct from a resected 
oesophagus compared to those from endoscopic biopsy or ER specimens for three common 
pathology groups. 
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Pathology Group Snap frozen Fresh (%) 
Normal Squamous 26/251 (10%) 225/251 (90%) 
Barrett’s / LGD 55/135 (41%) 80/135 (59%) 
HGD / Cancer 10/128 (8%) 118/128 (92%) 
Total 91/514 (18%) 423/514 (82%) 
 
Table  5-12. Proportions of spectra measured from fresh and snap frozen tissue from 
each of the main pathology categories. 
 
To assess the impact of including both snap frozen biopsy samples and fresh surgically 
resected samples in the same dataset, an LD scores plot displaying spectral predictions for 3 
pathology groups has been re-plotted to identify the nature of the tissue samples (Figure 
 5-13). 
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Figure  5-13. standard 3 group LD scores prediction scatter plot identifying samples 
which have been measured from fresh (stars) and from fresh frozen (circles) tissue 
samples.  
In addition, 3 group PC-LDA with LOSOCV has been repeated for both a ‘fresh only’ dataset 
after exclusion of the frozen samples, and for a ‘snap frozen only’ dataset (Table  5-13). 
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  Sensitivity (%) Specificity (%) 
Both fresh and frozen 
samples 
NSq 
LGD / Barrett’s 
HGD / Adenocarcinoma 
87% 
72% 
86% 
96% 
91% 
88% 
Fresh, surgically 
resected samples only 
NSq 
LGD / Barrett’s 
HGD / Adenocarcinoma 
80% 
71% 
83% 
96% 
86% 
90% 
Snap frozen 
endoscopic samples 
only 
NSq 
LGD / Barrett’s 
HGD / Adenocarcinoma 
96% 
96% 
96% 
98% 
98% 
97% 
 
Table  5-13. Three group classification performance inclusion and exclusion of fresh and 
snap frozen samples. 
Spectra acquired from snap frozen biopsy samples appear to classify with greater accuracy 
than those measured directly from fresh tissue. However, this classification performance is 
likely to be influenced by the small number of samples in the frozen biopsy group. 
 
It is encouraging that the process of snap freezing and thawing does not appear to alter the 
biochemistry of the tissue so as to prevent spectral classification. However, there is no clear 
reason why snap frozen samples would be expected to classify more accurately than fresh 
samples. A possible explanation is that the majority of snap frozen samples were measured 
from point biopsies which have the potential to dry out rapidly. Despite thawing only small 
batches of tissue samples prior to spectral analysis, it is possible that drying of some of the 
tinier biopsy samples may have concentrated the biochemicals responsible for inelastic 
Raman scattering. 
 
Another possible explanation is due to the fact that all spectra from fresh Barrett’s samples 
were measured from patients who had undergone oesophagectomy for either HGD or 
adenocarcinoma. It is therefore possible that the non-dysplastic Barrett’s (NDB) from these 
patients had a different spectral signal to NDB from patients who did not have neoplasia 
elsewhere in their Barrett’s segment. This raises the possibility that RS could be capable of 
detecting early molecular changes which increase the risk of neoplastic progression but which 
precede morphological changes. This could be useful in helping to predict those patients with 
NDB who are at a higher risk of malignant progression (see Chapter 8). 
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5.12 Influence of Consensus Histopathology 
 
In order to reliably assess the performance of Raman spectroscopy as a diagnostic tool it was 
essential to establish the correct histological diagnosis for use as the ‘gold standard’. A 
reliable tissue diagnosis would enable highly accurate training of the classification model, 
whereas an incorrect histological diagnosis could confuse the model and potentially cause 
significant misclassification. 
 
Histological diagnosis of dysplastic Barrett’s is known to suffer from considerable inter-
reporter variation.[85; 188; 199; 200] In addition, diagnostic accuracy has been shown to be 
improved considerably when slides are reported by specialist gastrointestinal pathologists as 
opposed to non-specialists. 
 
To ensure the most rigourous possible gold standard, all the tissue samples included in the 
analyses were independently reported by two internationally acknowledged expert 
gastrointestinal pathologists from separate centres within the UK. Only tissue with a 
consensus diagnosis was used as the ‘gold standard’ to train and test the diagnostic 
performance of the probe. 
 
Cross validated three group and two group analyses were repeated using the pathology results 
reported by each of the independent pathologists. This enabled an evaluation of the effect of 
using consensus diagnoses as the gold standard. 
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  Sensitivity Specificity 
T
h
re
e 
g
ro
u
p
 m
o
d
el
 Pathologist 1 NSq 
LGD / Barrett’s 
HGD / Adenocarcinoma 
84% 
68% 
76% 
96% 
86% 
85% 
Pathologist 2 NSq 
LGD / Barrett’s 
HGD / Adenocarcinoma 
84% 
72% 
70% 
95% 
86% 
85% 
Consensus NSq 
LGD / Barrett’s 
HGD / Adenocarcinoma 
87% 
72% 
86% 
96% 
91% 
88% 
T
w
o
 g
ro
u
p
 
m
o
d
el
 
Pathologist 1 LGD Vs. 
HGD/IMC 
81% 
71% 
71% 
81% 
Pathologist 2 LGD Vs. 
HGD/IMC 
99% 
81% 
81% 
99% 
Consensus LGD Vs. 
HGD/IMC 
100% 
100% 
100% 
100% 
 
Table  5-14. Performance of a two and three group model using pathology data reported 
by each expert pathologist and by a consensus of the two. 
 
The results presented in Table 5-14 demonstrate that classification performance was 
improved by using consensus pathology diagnoses to train the classification models. It must 
be borne in mind when interpreting the results presented in this thesis, that the classification 
performance reflects the proportion of samples that are classified in accordance with the 
consensus pathology diagnosis. That is to say, the consensus pathology results, used as the 
gold standard, are assumed to be 100% correct. It is possible therefore that performance could 
have been further improved by inclusion of an additional one or more pathologists, in order to 
further optimise the gold standard diagnosis. If this was the case it could suggest that Raman 
probe measurements are in fact capable of out-performing consensus pathology when it 
comes to establishing an accurate diagnosis. 
 
It must also be considered however, that current clinical management decisions are frequently 
based on the diagnosis of just a single pathologist, who may not be a gastrointestinal 
specialist. 
 
An interesting additional analysis could compare the diagnoses of a third independent 
pathologist with the consensus diagnosis provided by the first two pathologists. This would 
enable direct comparison between Raman predictions and the diagnostic performance of the 
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third pathologist. However, this analysis would require re-reporting of 673 biopsy samples 
for a third time. 
 
5.13 Oesophageal Mapping 
 
 
A Raman probe may have a role as a mapping tool during surveillance endoscopy. Currently, 
clinicians are recommended to take quadrantic biopsies every 2 cm of oesophageal mucosa 
during Barrett’s surveillance. However, this biopsy protocol can increase endoscopy times 
considerably; samples less than 5% of the oesophageal mucosa; produces a considerable 
workload for pathologists; and can miss dysplasia in up to 57% of patients.[8] An alternative 
strategy could utilise a Raman probe to map across the Barrett’s segment to identify 
neoplastic areas and prompt targeted tissue biopsies. The short acquisition times required to 
collect reliable spectra make Raman mapping a feasible option, even at first presentation of 
Barrett’s oesophagus. The ability to map out a Barrett’s segment would also be beneficial in 
patients referred with known HGD without macroscopic abnormality. This would enable the 
lesion(s) to be identified, and targeted ER to be performed. 
 
To investigate the potential for mapping of Barrett’s segments, spectra measured from 
resected oesophagi in conjunction with the perspex grid were projected, as a test dataset, onto 
the Raman classification model and then displayed as a map. Each Raman probe prediction 
map is displayed adjacent to a corresponding consensus histology map that illustrates the 
gold standard diagnosis at each tissue site. 
 
Figure  5-14 (top left) illustrates maps corresponding to 20 (2 by 10) Raman measurements 
and 20 tissue biopsies. The single tissue site diagnosed as neoplastic by consensus pathology 
was also identified as malignant by the Raman probe. A second site was also predicted as 
neoplastic by the probe – this may represent a false positive prediction. Alternatively, it is 
possible that the probe detected submucosal involvement which was not sampled by tissue 
biopsy. It is also possible that the probe detected biochemical features of residual cancer in 
that area which had been present prior to neoadjuvant chemotherapy, but were no longer 
apparent histologically. 
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Figure  5-14. The pathology of the distal oesophagus has been mapped out (red – HGD / 
adenocarcinoma; green – NSq; grey – no consensus pathology agreement.) Four pairs of 
oesophageal maps are illustrated. The left map of each pair corresponds to Raman 
predictions at each grid position. The right image represents the consensus 
histopathological diagnosis at each grid position (gold standard). 
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When considering the potential for use of a Raman probe during endoscopic surveillance it 
must be remembered that probe spectra represent a point measurement from a specific tissue 
site. This is analogous to biopsying, and therefore probe-based surveillance may be liable to 
sampling error in the same way as standard biopsy protocols. Figure  5-14 does not illustrate 
the gaps between each interrogated area of tissue which could potentially harbour neoplastic 
disease. Although it may be feasible to take many more Raman measurements than biopsies, 
this advantage may be offset by the smaller area of interrogation (<1 mm
2
) when using the 
probe. 
 
However, the advantage of the probe during surveillance endoscopy may be in its ability to 
target biopsies to specific areas thus potentially drastically reducing the numbers of tissue 
samples for processing and reporting, and minimising the chance of significant post-
procedural bleeding. The potential for use of the Raman probe during endoscopic 
surveillance is discussed further in Chapter 8. 
 
5.14 Summary 
 
The data presented in this chapter have demonstrated clear potential for the use of probe 
based Raman spectroscopy in the oesophagus. Following 1 s, 830 nm, spectral interrogation 
of 798 tissue sites a novel custom built Raman probe has demonstrated a sensitivity of 86% 
and a specificity of 88% for detecting advanced glandular neoplasia. Even higher diagnostic 
accuracies were achieved following sole analysis of endoscopic biopsy samples. All the data 
presented have been cross validated using independent test datasets, leave one spectrum out 
cross validation (LOSOCV) or leave one patient out cross validation (LOPOCV). 
 
The ability of the probe system to detect mucosal changes has been demonstrated. This 
suggests potential for detection and targeted early excision of premalignant dysplastic lesions, 
analogous to the current treatment of cervical intraepithelial neoplasia. This would aim to 
prevent progression to invasive malignancy. 
 
In addition, promising results have been obtained from a 0.1 s spectral dataset, raising the 
possibility for future ‘real-time’ imaging and detailed oesophageal mapping. The ability to 
map (or potentially scan across) the oesophagus in short timescales could aid rapid biopsy 
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targeting during Barrett’s surveillance to minimise missed dysplasia. In addition, it could be 
used to rapidly and accurately locate areas of HGD / IMC in patients with known disease 
prior to targeted endoscopic resection. 
 
No improvements in spectral classification performance were seen following air background 
subtraction or green glass correction. This infers that PC-fed LDA was capable of extracting 
the majority of the subtle spectral information required for classification despite the 
considerable probe background signal. 
 
The biochemical basis of spectral classification will be discussed further in Chapter 6. In 
addition, the results presented here will be discussed again in Chapter 8, in the context of 
additional data presented in Chapters 6 and 7. 
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CHAPTER 6 
 
6 Chapter 6: Understanding the Basis of Spectral 
Classification 
 
It is important to evaluate and understand the basis of spectral classification so that probe 
design, spectral acquisition, and/or algorithm specifications can be optimised to maximise 
diagnostic performance. In this chapter established peak position tables have been used to 
correlate particular biochemicals with their corresponding spectral features. 
 
6.1 Mean Tissue Spectra 
 
1 s tissue spectra for normal squamous mucosa, Barrett’s oesophagus, and HGD / 
adenocarcinoma are illustrated in Figure 6-1. Spectra have been offset for clarity and spectral 
peaks have been tentatively assigned following a review of the literature.[193-195] 
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Figure  6-1. Mean 1 s tissue spectra for 3 pathologies. Spectra have been offset for clarity 
and spectral peaks have been tentatively assigned. ‘Neoplasia’ includes spectra from 
both HGD and adenocarcinoma. 
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Figure  3-3, included previously, shows a Raman spectrum for normal squamous oesophageal 
tissue measured on a laboratory based spectrometer. This demonstrates peak assignments and 
is referred to here to illustrate the variation in spectral quality between conventional systems 
and the probe based system. Probe spectra have a significantly lower signal to noise ratio 
(SNR) making visual classification of spectra impossible and necessitating the multivariate 
analysis presented in Chapter 5. 
 
6.2 Difference Spectra 
 
Difference spectra can be plotted to aid identification of the major differences between 
spectra from different pathology classes (Figure  6-2). This can potentially elucidate the peaks 
that are important for diagnostic classification. 
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Figure  6-2. Difference spectra for non-dysplastic Barrett’s (NDB) and adenocarcinoma 
spectra (top); adenocarcinoma and normal squamous (NSq) spectra (middle); and NDB 
and NSq spectra (bottom). 
 
4
9
0
 
1
4
4
6
 
1
6
5
5
 
9
3
7
 
 132 
Figure  6-2 demonstrates that variation in the amount of fluorescent background signal 
accounts for the major visible spectral differences between normal squamous, Barrett’s 
oesophagus and adenocarcinoma. This reflects the fact that background signal varies 
considerably from measurement to measurement (see Figure  5-3). Few biochemical peaks are 
reliably visible in Figure  6-2, particularly when comparing Barrett’s and adenocarcinoma 
spectra. However, we cannot conclude from this that differences in fluorescence signal 
account for the ability to classify pathologies as we have previously noted no visually 
identifiable pattern in background appearance with respect to pathology (Figure  5-3). The 
significance of the biochemical peaks identified in Figure 5-3, and mechanisms to elucidate 
further spectral differences between pathologies are discussed extensively below. 
 
6.3 Background Subtraction Algorithms 
 
A variety of background correction and / or subtraction techniques can be employed to aid 
identification of the spectral features which may be important for classification. Mean air 
background subtracted and green glass corrected spectra for three pathology groups are 
illustrated in Figure  6-3. Comparison with Figure 6-1 demonstrates that these techniques have 
helped to emphasise tissue peaks. However, simple visual comparison of these spectra is still 
not sufficient to enable reliable diagnostic classification, which is why multivariate PC-fed 
LDA has been employed. 
 
Both air background subtraction and green glass correction algorithms have been shown to 
fail to improve diagnostic classification performance when employed in multivariate PC-fed 
LDA models. 
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Figure  6-3. Mean 1 s spectra from three pathology classes following air background 
subtraction (left) and green glass correction (right). The prominent peaks have been 
labeled. 
 
Peaks at 1655, 1446, 1262 and 1001 cm
-1
 are entirely consistent with previously reported 
oesophageal tissue measurements.[49; 206; 209; 212; 237] These peaks can be assigned to 
vibrational modes associated with amide I, CH2
 
bending, amide III and phenyl ring structures 
respectively.[206]. 
 
6.4 Elucidation of Subtle Biochemical Features Using Multivariate 
Analysis 
  
Previous work by Shetty et. al. used ordinary least squares analysis to fit the spectra of a 
variety of biochemical constituents to the mean spectra of each pathology. Changes in the 
distributions of these specific biochemical constituents were correlated with neoplastic 
progression. Concentrations of DNA, oleic acid (a fatty acid), collagen I and actin appeared 
increased in neoplastic tissue, whereas the concentration of glycogen appeared to have 
diminished.[43; 209; 212]  
 
Shetty et. al. showed that the DNA peaks at 720 and 755 and 781 cm
-1
, and the histone peak 
at 1655 cm
-1
 (a protein which packages DNA into nucleosomes), were more prominent in 
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neoplastic tissue (Figure  6-4A).[43] Conversely, glycogen peaks at 490, 853, 937 and 1335 
cm
-1
 were less evident in oesophageal neoplasia (Figure  6-4B). 
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Figure  6-4. Raman spectra from (A) histone; and (B) glycogen acquired on a laboratory 
based system using 10 s acquisition time.[247] 
 
This work has since been supported by Bergholt et. al..[209; 212]They measured reference 
Raman spectra from 35 different biomolecules associated with oesophageal tissue (including 
actin, albumin, pepsin, pepsinogen, RNA, DNA, myosin, hemoglobin, collagen I, collagen II, 
collagen V, mucin, flavins, elastin, phosphatidylcholine, cholesterol, glucose, glycogen, 
triolein, histones, and beta-carotene). Their subsequent analysis indicated that five 
biochemicals: actin, histones, collagen I, nucleic acids, and triolein (a lipid) were the most 
significant Raman-active biochemicals for characterising and discriminating normal 
squamous and cancerous oesophageal tissue. Raman peaks at 1335 and 1575 cm
-1
 were 
highly associated with increased DNA content, and increased intensity of the 1655 cm
-1
 
amide I (C = O) band reflected a higher content of α-helical proteins (e.g. histones) in 
neoplastic tissue. A small decrease in collagen I concentrations in cancerous oesophageal 
tissue was also documented. This is in keeping with reports that invasion into underlying 
stromal tissue leads to a reduction of collagen content.[242; 249; 250] 
 
Previous studies have also demonstrated relative increases in Raman signals from a variety of 
proteins (e.g. at positions 1003, 1265, and 1655 cm
-1
) which are thought to represent 
increased mitotic activity in neoplasia. [212; 242; 249-251] Similarly, studies on gastric 
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tissue have demonstrated reduction in Raman signals related to lipids (at 1078, 1302, 1440, 
and especially at 1745 cm
−1
) in advanced gastric neoplasia.[242]  In addition, prominent 
Raman bands at 1575–1618 cm−1 have been highly associated with the process of 
angiogenesis that occurs during neoplastic progression.[242; 249; 250] 
 
Plotting of PC loadings (Figure  6-5) and linear discriminant functions (LDF) (Figure 6-6) has 
been used to illustrate biochemical peaks that are important for spectral classification. 
Appendix XIII displays all 20 PC loadings computed for the standard three group 
classification model (NSq; NBD/LGD; HGD/cancer). 
 
Evaluation of the PC loadings can enable distinction of those peaks seemingly most 
important for spectral classification based on their relative intensity at positions known to 
correlate with biochemical differences between tissue types. 
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PC6:               PC7: 
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Figure  6-5. A selection of PC loadings are illustrated following PCA of the 1 s spectral 
dataset measured from normal squamous; LGD/NDB; and HGD/cancer tissue. Peak 
labels have been tentatively assigned to prominent features within the loadings. 
 
 
The PC loadings plots presented in Figure  6-5 highlight peaks which are entirely consistent 
with the published literature. Prominent features, clearly important for spectral classification, 
are seen at 490, 1003, 1335, 1446 and 1655 cm
-1
. 
 
PC1 and to a lesser extent PC2, display a considerable degree of background fluorescence 
signal. This reflects the fact that variation in fluorescence signal across the dataset is 
significant, as was illustrated previously by the raw spectra presented in Figure  5-3 and the 
difference spectra in Figure  6-2. 
 
The largest difference between the spectra is in fact the fluorescence signal variation which 
therefore represents the dominant feature in PC1. The ability to classify tissue spectra 
following the exclusion of these early PCs, is discussed further below. However, it appears 
that classification performance may not only depend on variations in Raman peaks, but also 
to some extent on differences in fluorescence signal. 
 
Encouragingly the linear discriminant functions (LDF) for the same three group model 
plotted in Figure 6-6 define group separation based on recognisable biochemical differences 
between pathologies. In addition, in these plots there does not appear to be a significant 
fluorescence contribution. It is likely that the Raman bands at 487, 863, 933 and 1128 cm
-1
 in 
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the LDF1 plot represent a higher glycogen concentration in the squamous epithelium and 
contribute significantly to the ability to separate between normal and metaplastic / neoplastic 
tissue. 
 
The LDF2 plot (Figure  6-6B) illustrates prominent Raman bands at positions 498, 686 and 
1571 cm
-1
. These features can be tentatively assigned to nucleic acid bases which 
predominate in neoplastic tissue and correspond to increased DNA and RNA 
concentrations.[43] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  6-6. Linear discriminant function plots 1 (A) and 2 (B). Prominent peaks have 
been  tentatively assigned. 
 
Peak assignment of the PC loadings and LDF plots demonstrates that differences in 
biochemical composition detected by RS are important for spectral classification. 
 
Visible distinction between unprocessed probe spectra measured from different pathologies is 
not possible. Similarly, visual identification of many of the biochemical peaks important for 
diagnostic classification is impossible from unprocessed spectra. However, data presented in 
Chapter 5 demonstrated that PC-fed LDA was capable of extracting the subtle spectral 
differences which can enable tissue classification. In this section the specific peaks which 
have enabled spectral classification have been identified. 
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6.5 Exclusion of Early Principal Components 
6.5.1 Assessment of Classification Performance 
 
Review of the PC loadings for the 3 group model (NSq; LGD/NDB; HGD/cancer) clearly 
demonstrates prominent peaks in several of the PCs at sites known to correlate with 
significant biochemical differences between squamous, Barrett’s and neoplastic tissue (Figure 
 6-5 and Appendix XIII). However, the early PC loadings (particularly PC1) which represent 
the dominant difference between the spectra, appear to predominantly reflect differences in 
fluorescence signal, without apparently containing important biochemical information. 
 
Although background fluorescence signal varies considerably between measurements (Figure 
 5-3) it is unclear what contribution this variation has on the ability to discriminate between 
pathologies. To investigate this further PC-fed LDA was repeated for this 3 group model after 
exclusion of PC1 and PC2. In addition, the classification performance achieved using just 
PC1 and PC2 was also evaluated. The predicted diagnostic accuracies achieved are displayed 
in Table  6-1. 
 
  Sensitivity (%) Specificity (%) 
PC1-15 fed into LDA NSq 
LGD / Barrett’s 
HGD / Adenocarcinoma 
87% 
72% 
86% 
96% 
91% 
88% 
Exclusion of PC1 NSq 
LGD / Barrett’s 
HGD / Adenocarcinoma 
82% 
71% 
82% 
94% 
87% 
91% 
Exclusion of PC1 and 
PC2 
NSq 
LGD / Barrett’s 
HGD / Adenocarcinoma 
84% 
63% 
77% 
90% 
87% 
91% 
Only PC1 and PC2 fed 
into LDA 
NSq 
LGD / Barrett’s 
HGD / Adenocarcinoma 
44% 
67% 
33% 
71% 
74% 
76% 
 
Table  6-1. Three group classification performance is illustrated following exclusion or 
inclusion of early PCs from the analysis. 
 
Table  6-1 illustrates that exclusion of PC1 and 2 has a small effect on classification 
performance. This may result from loss of a degree of biochemical information which is 
hidden by the fluorescence signal. However, alternatively, it may reflect loss of fluorescence 
information which is itself playing a small role in spectral classification. 
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When just PC1 and 2 have been fed into LDA the model loses its ability to classify 
pathology. This demonstrates that the variation in fluorescence background signal alone is 
insufficient to enable any degree of reliable spectral classification. 
 
6.5.2 Reconstruction of the Dataset Following Exclusion of PC1 
 
Following exclusion of PC1 the normalised spectral data can be re-constructed by 
multiplying the remaining PC loadings by the PC scores. In this instance this effectively acts 
as an alternative technique of background subtraction and enables LD functions to be plotted 
without the contribution of PC1. 
 
Normalised data prior to further analysis is shown in Figure  6-7(A). Normalised data is also 
illustrated in Figure  6-7(B) this time following re-construction of the dataset after exclusion 
of PC1. 
A:           B: 
 
 
 
 
 
 
 
 
 
Figure  6-7. (A) Normalised raw spectral data. (B) Normalised data which has been 
reconstructed after exclusion of PC1. 
 
Figure  6-7(B) demonstrates that exclusion of PC1 reduces the intensity variation within the 
spectral dataset. The visible peaks are still present and are in fact more pronounced following 
PC1 exclusion. 
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Figure  6-8 illustrates newly defined LDF plots following three group LDA performed on the 
reconstructed dataset. Encouragingly, many of the biochemical features present in Figure  6-6 
are visible in Figure  6-8 providing strong evidence that they contribute significantly to 
diagnostic classification. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  6-8. LDF plots following exclusion of PC1. 
 
6.6 Evaluation of which Principal Components Contribute to 
Spectral Classification 
 
Inspection of the PC loadings can be useful for defining biochemical peaks which account for 
spectral classification. However, this approach can be refined further by identifying which of 
the PC loadings contributes the greatest to spectral classification. 
 
LDA generates an LD load value for each of the PCs which describes the relative 
contribution of each PC to spectral classification. Figure  6-9 shows a 3 group (NSq; 
NDB/LGD; HGD/cancer) LD scores plot following PC-fed LDA. LD load 1 accounts for the 
separation between normal squamous and Barrett’s/neoplastic spectra, whereas LD load 2 
accounts for separation between NDB/LGD and HGD/cancer spectra. Inspection of the LD 
loads plots reveals that PC8 and PC9 are particularly significant in separating normal 
squamous and Barrett’s/neoplastic spectra, and PC11 and PC6 contribute most to the 
separation of NDB/LGD and HGD/cancer spectra. 
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Figure  6-9. A three group classification predictions scatter plot (left); and LD loads 
showing the individual contribution of different PCs to spectral classification. 
 
Examining the most significant PC loadings reveals several specific spectral features which 
are important for diagnostic classification. Figure  6-10 shows a plot of PC8 and PC9. 
Prominent peaks are again seen at 490, 933, 1086-1110 and 1128 cm
-1
, all of which are 
consistent with a higher glycogen concentration in normal squamous epithelium compared to 
both Barrett’s and neoplastic tissue. Reference to peak assignment tables (see Appendix III) 
allows other prominent peaks at 638, 731, 782, 885, 1021, 1095, 1334 and 1621 cm
-1
 to be 
tentatively assigned to nucleic acids and protein structures, including histone, which imply 
alterations in RNA and DNA concentrations between normal squamous and metaplastic / 
neoplastic tissues. 
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PC8:       PC9: 
 
 
 
 
 
 
 
 
Figure  6-10. PC 8 and PC 9 loadings following PCA on spectra measured from three 
pathology groups. 
 
The plot of the LD2 load in Figure  6-9 demonstrates that PCs 11 and 6 contribute particularly 
significantly to the differentiation of advanced neoplasia from LGD and NDB. Plotting of 
these PC loads (Figure  6-11) also reveals prominent glycogen peaks at 492, 574 and 937. 
Peaks at 771, 782, 1018, 1360 and 1511 can be tentatively assigned to nucleic acids which 
again reflect changes in DNA and RNA concentrations between metaplastic and malignant 
tissues. 
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Figure  6-11. PC 6 and PC 11 loadings following PCA on spectra measured from three 
pathology groups. 
 
Whilst the PCs illustrated here account for some of the ability to classify spectra, it must be 
remembered that a significant amount of important information is described by the other PCs. 
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There are therefore many other biochemical peaks, in addition to those highlighted here, 
which could contribute to spectral classification. Further work should continue to elucidate 
these significant classifying features, although this will best be studied through in vitro 
measurements using long acquisition times and high quality spectrometers with high SNRs. 
 
It is important to note that PC1 and PC2 appear to contribute very little to spectral 
classification (Figure  6-9). This supports the earlier analysis demonstrating little change in 
performance after exclusion of these PCs. Since PC1, and to a lesser extent PC2, consists 
almost entirely of background fluorescence signal this analysis reinforces the fact that the 
chief contributor to spectral classification is biochemical features detected by Raman 
spectroscopy rather than a difference in fluorescence background in the three tissue groups. 
 
It is also noteworthy that some particularly prominent peaks are seen at the lowest 
wavenumber positions in PCs 9 and 6. It is unclear whether these represent biochemical 
features or significant fluorescence signal. However, the latter is a possibility as there is clear 
visual variation in unprocessed spectral data in this range (Figure  5-2). To assess the 
contribution to spectral classification of features in the low wavenumber range the dataset 
was truncated, and classification performance was re-evaluated. 
 
6.7 Spectral Truncation 
 
The effect of spectral truncation was evaluated to assess the impact of exclusion of spectral 
regions which display significant background signal and minimal biochemical information. In 
the lower wavelength range there is a particularly high background contribution and spectral 
plots show that variation is marked in this region (Figure  5-2). Previous studies have 
demonstrated that exclusion of this low wavelength range may improve spectral 
classification.[45; 203] 
 
Spectra were therefore truncated below 600 cm
-1
 and the classification performance was re-
evaluated (Table 16). 
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  Sensitivity Specificity 
Whole spectral range 
included (400-1850) 
NSq 
LGD / Barrett’s 
HGD / Adenocarcinoma 
87% 
72% 
84% 
96% 
91% 
88% 
Truncated spectral 
range (600-1850) 
NSq 
LGD / Barrett’s 
HGD / Adenocarcinoma 
83% 
76% 
84% 
96% 
88% 
89% 
 
Table  6-2. Classification performance of the 1 s three group classification model is 
illustrated following truncation of the lower wavenumber range. 
 
Table 16 shows that truncation of the lower wavenumber range made little difference to the 
ability of the model to classify. This infers that there is sufficient biochemical information 
retained in the remaining spectral range to permit classification and that the significant 
background in the early wavenumber range may act to mask some of the influence of 
glycogen peak variation (at 490 nm) on spectral classification. 
 
6.8 Biochemical Transition from Barrett’s to Adenocarcinoma 
 
There is a well described histological sequence of progression from normal squamous 
mucosa, to Barrett’s oesophagus, LGD, HGD and then adenocarcinoma. Many of the 
molecular changes, particularly those early in this sequence have been elucidated and are now 
well described. However, the biochemical changes that occur during each stage of the 
progression to adenocarcinoma are as yet less well described. 
 
The above sections have identified and discussed many of the Raman peaks thought to be 
most significant for pathological classification. Encouragingly, these are consistent with 
previous published reports and reflect particular changes in glycogen, nucleic acids, oleic 
acid, collagen I, actin and histone peaks which are known to vary during progression to 
malignancy. 
 
Probe based spectra have a considerably lower SNR than can be recorded using laboratory 
spectrometers. In addition, the spectra presented in this thesis have been acquired in short, 
clinically applicable timescales. These factors make a more detailed evaluation of 
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biochemical features difficult. However, an attempt has been made to demonstrate a 
biochemical progression between Barrett’s and adenocarcinoma (Figure  6-12). 
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Figure  6-12. An LD scores histogram showing spectral predictions following PC-fed 
LDA for a two group model (NDB/LGD and HGD/cancer). Spectra from each 
individual pathology have been plotted separately in order to visually illustrate where 
and how they classify. LGD and HGD/IMC spectra have been plotted inversely on the y 
axis for visual clarity. 
 
The data presented in Chapter 5 indicated that, for a variety of reasons, there was some 
misclassification in the NDB/LGD Vs. advanced neoplasia model. However, the majority of 
spectra can clearly be seen to classify correctly (Figure  6-12). Assuming a linear progression 
of biochemical changes from NDB to invasive adenocarcinoma, those spectra tending to 
misclassify could reasonably be expected to be the dysplastic group. Examination of Figure 
 6-12 shows that this appears to be the case for the HGD/IMC samples which predominantly 
occupy a central position in the histogram. However, one would expect the LGD spectra to 
also cluster predominantly in the middle of the plot, just to the left of the HGD/IMC spectra. 
This is not convincingly the case. 
 
Despite not being able to clearly demonstrate biochemical progression here, the data certainly 
provokes interest and demonstrates potential for further investigation. 
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6.9 Summary 
 
Understanding the basis of spectral classification is important in order to facilitate measures 
to improve diagnostic performance. The data presented in this chapter demonstrate that 
classification is predominantly due to biochemical differences between tissue types detected 
by Raman spectroscopy. Several characteristic biochemical differences along the pathway of 
progression to cancer have previously been reported including changes in glycogen, histone, 
DNA and RNA concentrations. In this chapter these spectral features were all shown to be 
important for spectral classification. 
 
The biochemical changes detected during neoplastic progression are entirely consistent with 
increasing nuclear activity (e.g. a hyperchromatic state) and angiogenesis in neoplastic tissue. 
These are well described characteristic features of tissue carcinogenesis and the ability of 
Raman spectroscopy to detect these features is of considerable value for tissue diagnosis and 
characterisation. 
 
In addition, the fact that these biochemical features are consistent with the literature 
reconfirms the potential suitability and versatility of Raman spectroscopy as an endoscopic 
technique for early detection and diagnosis of dysplasia and cancer based on spectral features 
derived from proteins, DNA, and lipids. 
 
A greater appreciation of the spectral features which account for diagnostic classification 
could potentially facilitate a more targeted approach to spectral measurement. For example, 
measurement of significantly truncated spectra from a limited wavenumber range of interest 
could enable significant reductions in spectral acquisition times whilst maintaining 
classification performance. Alternatively, multiple repeat measurements could be made from 
a focussed wavenumber range in the time it takes to acquire a single set of measurements 
from the relatively broad spectral range recorded at present. This could increase SNR and 
may yield improvements in diagnostic performance. Knowledge of particular biochemical 
characteristics between tissue types could also potentially influence probe design, or perhaps 
more likely, impact on the design of statistical algorithms used for classification. 
 
It is possible that differences in the fluorescence signal generated by different tissue types 
have also contributed to the ability to classify tissue. However, detailed analyses including an 
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evaluation of which principal components contribute to spectral classification, and spectral 
truncation analyses, have demonstrated that any contribution from fluorescence signal 
appears small. It is also important to consider that the priority aim of the custom-built fibre-
optic probe evaluated in this thesis is to correctly classify oesophageal tissue in vivo. 
Ultimately, it is this ability to accurately classify that is important, not the need for 
classification to be based solely on Raman spectral signatures. 
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CHAPTER 7 
 
7 Consistency, Reproducibility and Transferability 
 
 
Prior to clinical use of endoscopic RS, spectrometer specifications and probe construction 
must be standardised in order minimise variation in spectral acquisition. It is likely that 
attaining identically reproducible measurements using different, although standardised, 
equipment will be extremely challenging. Therefore it will be essential to ensure that 
mechanisms exist to correct for inevitable multi-system, multi-site and multi-operator 
variability enabling transferable classification models to be generated. Clinical application 
will necessitate the use of a pre-defined automated classification algorithm based on known 
spectral fingerprints correlating with specific tissue types in order to attain instantaneous 
diagnoses. However this requires that spectral signals measured across all Raman systems 
can be precisely calibrated. 
 
In this chapter the consistency of spectral acquisition over an eighteen month period of data 
collection is evaluated. In addition, the performance of two probes consisting of identical 
optical components is compared. Both these probes are evaluated in conjunction with the 
same Renishaw system 100 spectrometer. A further set of measurements is also presented 
which were acquired using a single probe in conjunction with two different spectrometers. 
Mechanisms for data comparison are explored following a variety of calibration techniques 
and subsequently the ability to correctly classify pathology with the different systems is 
evaluated. 
 
The potential for use of RS in conjunction with narrow band imaging (NBI) is also evaluated. 
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7.1 Spectral Consistency across the duration of the study period 
 
7.1.1 Temporal Consistency of Air Background and PTFE Measurements 
 
It is also essential to demonstrate that spectra can be measured consistently over time. A 
random selection of mean air background spectra measured on eight different days across an 
eighteen month period, using the standard probe-spectrometer system are illustrated in Figure 
 7-1. 
 
  
 
 
 
 
 
 
 
 
 
Figure  7-1. Mean 1 s air spectra measured on randomly selected days demonstrating 
spectral consistency over time. Air 4 was measured in November 2010; Air 66 was 
measured in April 2012. 
 
PCA was performed on the air background spectra measured in November 2010 (Air 4). Figure 7-2 
illustrates the variance within this dataset and plots 95% and 99% confidence intervals. Projection of 
individual air spectra measured on other days (randomly selected) demonstrates the levels of 
consistency achieved. 
 
Projection of new spectra onto this plot allows a simple assessment of spectral consistency 
and reproducibility. Prior to clinical usage, this method could be applied to ensure accurate 
instrument calibration and exclude extraneous contamination of the probe tip. 
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Figure  7-2. Visual illustration of variation in air background spectra compared to day 1 
(Air 4). 95% and 99% confidence intervals are illustrated. 
Methods analogous to this could be used to clearly define instrument tolerability. For 
example, let’s assume a tolerance level based on a 95% confidence interval (CI) of a 
predefined set of calibration air measurements. In this case, a pre-endoscopy ‘test’ air 
background measurement falling within the 95% CI boundary would be considered 
acceptable. This would indicate that the probe-spectrometer system is functioning, using 
acceptable laser power, and without significant spectral contamination. However, a pre-
endoscopy ‘test’ measurement falling outside of the pre-defined tolerance level would prompt 
cleaning of the probe tip, a check of laser power output, and/or replacement of the probe. 
 
In order to define levels of equipment tolerability in this way it must be clear what levels of 
spectral consistency are required for tissue classification. This will necessitate measuring 
sufficient spectra from sufficient patients and with sufficient probes in order to account for 
spectral variation due to either pathology, patient, or probe-spectrometer factors. 
 
Alternatively, it may be possible to define levels of tolerability mathematically by 
introducing random background to the spectral data and assessing the limits of where spectral 
classification becomes impossible. Automated generation of equipment tolerance levels is 
discussed further in later sections. 
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Figure  7-3 illustrates that PTFE spectra have also remained relatively consistent throughout 
the period of data collection despite minor variations in intensity signals as seen with the 
unprocessed tissue data presented in Chapter 5. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  7-3. Eight randomly selected 5 s PTFE spectra. 
The need for reliable and reproducible spectral acquisition will be discussed and evaluated in 
greater detail in later sections. However, the plots presented above have demonstrated 
consistent spectral measurements over the eighteen month period of data collection.  
 
7.2 Influence of the Date of Measurement on the Spectral 
Classification 
 
As discussed in Chapter 6, it is important to appreciate the factors that account for spectral 
variation within the groups. Figure  7-4 illustrates an LD scores plot for the standard three 
group classification model. To investigate any variation in tissue spectra measured on 
different days, three sets of spectra measured on three different days, have been highlighted 
in colour. This plot visually demonstrates that there is no particular clustering of these 
spectra. 
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Figure  7-4. An LD scores scatter plot illustrating spectral predictions for a three group 
(NSq; NDB/LGD; HGD/cancer) classification model. Three randomly selected sets of 
spectra, measured on different days, have been highlighted. 
This illustration does not solely give a visual impression of consistency of spectra measured 
on a particular day. It also reflects any spectral differences pertaining to specific patient 
factors since each set of spectra was acquired from tissue from a different patient. 
Confounding due to snap freezing of a portion of the dataset has been removed here by only 
including fresh tissue spectra measured from resected oesophagi. 
 
This visual illustration demonstrates that the date of measurement, and unique patient factors 
for these three patients, appear to have little impact on the ability of the probe system to 
record spectral data. 
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7.2.1 Summary 
 
This section has demonstrated that despite minor fluctuations in intensity which occur from 
measurement to measurement, spectral data has remained consistent over an 18 month period. 
In addition, results presented in Chapter 5 have demonstrated highly accurate classification 
performance for tissue spectra measured across this time period. 
 
It is not clear at this stage whether Raman probes will be disposable, with the intention of 
single use, or whether they will be amenable to multi-use with sterilisation between patients. 
In the latter case they will be required to operate consistently over an extended period of time 
in a similar way to standard medical endoscopes. The data presented here has demonstrated 
that significant systematic error was not introduced over the course of the study period 
suggesting potential for reliable multi-use systems. However, it is important to note that the 
ability of the probe to withstand multiple sterilisation procedures remains to be evaluated. 
 
7.3 Probe Comparison 
 
If Raman probes are to be used as clinical diagnostic tools, probe construction must be 
standardised and consistent so that spectral measurements can be accurately reproduced. In 
this section data recorded using two identically constructed Raman probes is compared and 
evaluated. 
 
7.3.1 Two Operator, Two Probe Comparison using a PTFE Standard 
 
7.3.1.1 Unprocessed Spectra 
 
Initial measurements aimed to demonstrate that two Raman probes of the same design could 
measure consistent PTFE spectra when used by two operators. 
 
Figure  7-5 shows mean PTFE spectra measured using each probe. Probe 2 has a prominent 
background feature between ~900 and 1100 nm which enables easy visual differentiation 
between the spectra. The source of this additional background signal is unclear although it 
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may be due to subtle variations in one or more of the probe components or a minute 
difference in the alignment of the optical components within the probe. 
 
 
 
 
 
 
 
 
Figure  7-5. Mean PTFE spectra measured in 5 s using probe 1 and probe 2. 
Figure  7-6 illustrates mean PTFE spectra measured by each operator using both probes. 
Visually these appear consistent except for a small variation in the background signal. This 
difference is accounted for by an obvious spectral outlier (see Figure  7-7 below). 
 
 
 
 
 
 
 
 
Figure  7-6. Mean PTFE spectra taken by each operator. 
 
Figure  7-7 shows unprocessed PTFE spectra measured by two independent operators using 
the two probes in conjunction with the same laser source and spectrometer. 
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Figure  7-7. PTFE spectra measured by both operators with each probe. 
 
One spectrum which was measured by operator 1 using probe 2 is a clear visual outlier. This 
spectrum, which has been highlighted, has a considerable additional background signal. The 
measurement was repeated following cleaning of the probe and was found to persist. It is 
unclear what caused the increased background signal detected in this spectrum, the most 
likely explanation being debris on the on the surface of the probe lens. 
 
This spectrum was included in the subsequent analysis. However, it could be reasonably 
argued that visible outliers – those unprocessed spectra which can be easily identified – could 
be removed prior to statistical analysis. A more precise approach is to use pre-defined levels 
of performance tolerance to identify outlying measurements. This approach lends itself to 
automation and could be used to prompt repeat measurements where the initial spectra fail to 
meet the tolerance criteria. 
 
7.3.1.2 Statistical Evaluation of Spectral Consistency 
 
Two-way analysis of variance (ANOVA) was used to investigate the relationship between the 
measured spectra and the two independent variables - the operator and the probe. The 
analysis aimed to establish whether there was any true variation between the groups. 
400 600 800 1000 1200 1400 1600 1800
0
0.5
1
1.5
2
2.5
3
x 10
4
Wavenumber (cm-1)
In
te
n
s
it
y
 (
c
o
u
n
ts
)
Outlier 
 156 
 
A wavenumber representing the midpoint of each of the 5 prominent PTFE peaks was 
selected. Prior to pre-processing (Table 1), and following air background correction plus 
green glass correction (Table 2), the intensity of each peak was measured at each specified 
wavenumber. 
 
The tables illustrate the results of 2-way ANOVA calculations which demonstrate that, with 
one exception, there were no statistical differences between the PTFE peaks measured by the 
2 probes, or by the 2 operators, or by any combination of a particular operator with a 
particular probe (interaction column). (A p value of less than 0.05 indicates that there was a 
statistically significant difference in peak height at a specific peak due to the effects of a 
particular independent variable (or combination). In this instance, the null hypothesis that 
there is no difference in peak height irrespective of the probe or operator, is false). 
 
The single statistically significant peak height difference is highlighted in bold. It is unclear 
why the interaction of a particular operator with a particular probe at this individual peak was 
shown to be significant, although it is possible that inaccuracies were introduced during the 
data pre-processing (air background subtraction and green glass correction). 
 
 
 
 
 
 
 
Table  7-1. The probability that there is no difference in PTFE peak heights when 
measured by the two probes, or the two operators, or by any combination of the two 
(interaction column), is illustrated following 2-way ANOVA. 
 
 
Wavenumber 
(cm
-1
) 
Interaction 
(p value) 
Probe 
(p value) 
Operator 
(p value) 
731 0.9444 0.0716 0.2908 
981 0.7797 0.067 0.178 
1214 0.9041 0.0685 0.3518 
1297 0.9273 0.0727 0.2762 
1378 0.997 0.0736 0.3645 
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Table  7-2. Prior to two-way ANOVA, air background subtraction and green glass 
correction were applied to the raw data. The probability that there is no difference in 
PTFE peak heights when measured by the two probes, or the two operators, or by any 
combination of the two (interaction column), is illustrated. The single statistically 
significant result is highlighted in bold. 
It must be stressed that these analyses have evaluated the spectra at just five wavenumber 
positions. Variations in background signal at other positions have not been taken into 
account. Whilst these results demonstrate that reliable data can be measured using two 
optically identical probes without significant inter-user variation, further analysis of tissue 
spectra across the whole wavenumber range is important to evaluate the feasibility of 
generating transferable diagnostic algorithms (see below). 
 
7.4 Transferability between Spectrometers 
7.4.1 Optimising a Calibration Correction 
 
Spectra have been measured using a custom built portable spectrometer (see Chapter 4), in 
addition to the standard Renishaw system 100 spectrometer used routinely for previous 
measurements. This section investigates the potential for cross system comparison of spectra 
measured using the two spectrometers after a variety of statistical calibration algorithms have 
been applied. 
 
Background subtraction and calibration strategies have been discussed in detail previously. 
Neither air background subtraction nor green glass correction improved the performance of 
the diagnostic classification models presented in Chapter 5. However, these techniques may 
Wavenumber 
(cm
-1
) 
Interaction 
(p value) 
Probe 
(p value) 
Operator 
(p value) 
731 0.0992 0.8481 0.1472 
981 0.0289 0.1624 0.116 
1214 0.1027 0.7859 0.3001 
1297 0.1349 0.6781 0.1744 
1378 0.0722 0.8798 0.2665 
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have a greater importance when attempting to project new data, measured with a different 
system, onto a universal classification model. 
 
Calibration aims to ensure reproducible CCD read-out so that consistent spectral data can be 
recorded from day to day. Calibration standards were measured, as previously described, to 
facilitate both offset correction and correction of variation of CCD efficacy across the entire 
spectral range. Both silicon and PTFE spectra were used to assess any shift in wavenumber 
due to their well defined and reproducible peaks. Figure  7-8 illustrates air background and 
silica spectra measured using a single Raman probe in conjunction using two different 
spectrometers. ‘Spectrometer 1’ was the Renishaw System 100 spectrometer used for all the 
ex vivo tissue measurements presented in Chapter 5. ‘Spectrometer 2’ was the custom-built 
portable spectrometer. 
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Figure  7-8 A, B&C: 5 s air background spectra; and D, a 1 s silica spectrum. All have 
been measured with the custom built probe in conjunction with one of the two 
spectrometers as indicated. 
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The shape of the background signal acquired with the two spectrometers was visually 
comparable although an additional feature was noted between 1200-1300cm
-1 
when using 
spectrometer 2. However, the intensity acquired using spectrometer 2 was significantly lower 
than with the Renishaw System 100 spectrometer (spectrometer 1) meaning a lower SNR was 
achievable. The intensity difference is clearly illustrated in Figure  7-8 C&D which show air 
and silica spectra measured on the two systems. 
 
The software with spectrometer 2 did not permit a silicon offset correction to be applied as 
was performed routinely for calibration of spectrometer 1. It can be seen from Figure  7-8 D 
that the silica peaks are therefore at slightly different wavenumbers. In order to correct this 
difference an offset correction was applied to the spectrometer 2 data in Matlab. 
 
Figure  7-9 illustrates normalised 5 s PTFE spectra acquired using each spectrometer. A 
silicon offset correction has been applied to the spectrometer 2 measurement as described. 
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Figure  7-9. Normalised 5 s PTFE spectra measured using the two systems. A silicon 
offset correction has been applied to the spectrum measured on Spectrometer 2. 
 
Inspection of Figure  7-9 demonstrates that there is a persistent peak offset in the higher 
wavenumber range. Therefore a linear data stretch was applied to the spectrum measured on 
Spectrometer 2 based on the expected peak positions of the 4 prominent PTFE peaks. Again 
the normalised data was compared (Figure  7-10). 
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Figure  7-10. Normalised 5 s PTFE spectra measured using the two systems. A linear 
data stretch has been applied to the data measured using Spectrometer 2. 
 
In an attempt to further improve spectral comparability a green glass correction was applied 
to both PTFE spectra (Figure  7-11). Green glass correction aimed to eliminate variations in 
instrument sensitivity across the spectral range. CCD readout typically varies slightly with 
wavelength, classically tending to fall-off at higher wavelengths. This is due to several 
factors including a gradual reduction in efficiency of the detector across the spectral range; 
and also to a lesser extent variation in CCD pixel sensitivity.[191] 
 
Figure  7-11A shows a reference green glass spectrum measured at the National Physical 
Laboratory which was used as a calibration standard. Green glass measurements acquired 
using the two spectrometers were then used to calculate energy transfer function corrections 
by dividing the reference green glass spectrum by the two measured spectra. Unprocessed 
PTFE spectra measured on each system were then multiplied by the corresponding transfer 
function to calculate green glass corrected spectra (Figure  7-11B). 
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Figure  7-11 (A) Green glass spectra measured on the two experimental systems, and at 
the National Physical Laboratory; and (B) 5 s PTFE spectra measured on each system. 
A silicon offset correction, normalisation and green glass correction has been applied to 
the spectrum acquired on Spectrometer 1. A linear data stretch, normalisation and 
green glass correction has been applied to the spectrum acquired on Spectrometer 2. 
 
Figure  7-11B shows that the use of green glass correction as an additional calibration strategy 
has failed to improve spectral comparability between the two systems (in comparison to that 
seen in Figure  7-10). 
 
Background subtraction was also employed in an attempt to remove some of the spectral 
disparity, particularly in the upper wavenumber range. Corresponding air background data 
were subtracted from each PTFE spectrum and the spectra were then normalised and linearly 
stretched as before. This series of calibration corrections was shown to further improve 
spectral comparability (Figure  7-12). A combination of air background subtraction and green 
glass correction provided no additional improvement in spectral comparability. 
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Figure  7-12. Air background spectra have been subtracted from the two PTFE spectra 
presented. Subsequently the spectra have been normalised and a linear data stretch has 
been applied. 
 
In this model it appears that the most visually consistent spectra can be achieved through a 
process of normalisation, linear data stretching and air background subtraction (Figure  7-12). 
By defining this process for spectral calibration between the two systems it was hoped that 
tissue spectra, measured using Spectrometer 2, could be classified using the multivariate 
model generated from data acquired on Spectrometer 1. 
 
7.4.2 Diagnostic Classification Performance 
 
In clinical practice the intention would be to record spectra using identically built probe-
spectrometer systems with clearly pre-defined levels of engineering tolerability. However, 
since multiple identical probe systems are not currently available for reproducibility testing, 
the process of cross system spectral calibration has been explored here. Section 7.5.1 above 
optimised measures for cross system comparison. In this section, as a theoretical exercise, a 
sample of ex vivo tissue spectra from 3 patients were acquired using Spectrometer 2. 
 
The Raman probe was used in conjunction with Spectrometer 2 to measure 1 s spectra from 
12 homogenous tissue samples for which a consensus histological diagnosis is available. In 
order to assess the transferability of these data, a cross system calibration was employed and 
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each spectrum was then projected, as a test dataset, onto the 1 s classification model acquired 
using Spectrometer 1. 
 
The unprocessed ex vivo tissue spectra recorded by Spectrometer 2 are displayed in Figure 
 7-13. 
 
 
 
 
 
 
 
 
 
Figure  7-13. Unprocessed 1 s ex vivo tissue spectra measured using the Raman probe in 
conjunction with Spectrometer 2. 
 
Prior to projection of Spectrometer 2 tissue data onto the model, the pre-defined cross system 
calibration correction was employed: a background correction was performed (Figure  7-14) 
followed by normalisation and a linear data stretch. 
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Figure  7-14. One second tissue spectra measured using Spectrometer 2 following air 
background subtraction. 
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Following air background subtraction some of the spectra were of very low (or negative) 
intensity suggesting possible poor contact with the tissue, and/or fluctuations in laser power 
output at the probe tip between the time of measurement of the air spectrum and the tissue 
spectra. This finding may also be explained by contamination of the lens leading to reduction 
in both excitation power and signal collection. All data without significant signal after air 
background subtraction were excluded from the subsequent proof of principle analysis. 
 
The pre-established correction algorithm was applied to the tissue spectra measured using 
Spectrometer 2. PCA was then performed on this corrected dataset to generate a set of PC 
scores which were projected as a test dataset onto the standard 3 group (normal squamous; 
NDB/LGD; HGD/cancer) classification model generated from data acquired with 
Spectrometer 1. 
 
The model defined using data acquired with Spectrometer 1 was not able to classify spectra 
measured using Spectrometer 2, despite the calibration correction. The reasons for this likely 
reflect the fact that Raman scattering generates only very weak signals. Persisting differences 
between sets of measurements made on the two different systems, despite the calibration 
correction, were still much more significant than the subtle biochemical spectral differences 
between tissue types, causing misclassification. The calibration correction process may also 
have been hindered by the process of background subtraction which may have introduced 
significant systematic error. 
 
It must be considered that this was a theoretical exercise since in practice systems would be 
standardised prior to spectral measurements. However, the ability to correct significant 
spectral differences even utilising different spectrometers and achieve visually comparable 
spectra is encouraging. This suggests that minor spectral variations between identically built 
probes used in conjunction with identically built spectrometers could be overcome using a 
carefully optimised correction algorithm. When multiple identically built probes are 
available, further testing will be required in order to evaluate cross-system classification more 
fully. 
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7.5 Evaluation of the Potential for Compatibility with Narrow Band 
Imaging 
 
In a clinical setting Raman measurements must be able to be recorded under the direct vision 
of the endoscopist. However, the ex vivo spectra displayed in this thesis have all been 
measured after extrusion of ambient light sources. 
 
Interference of weak Raman signals by ambient light is known to be a significant problem. 
However, this issue can be relatively easily overcome in the laboratory by switching off 
lights and shielding windows and computer screens. Similarly, measurements undertaken in 
published studies of in vivo RS in the upper GI tract have been acquired after switching off 
the endoscopy light source for up to 10 s at a time.[35; 197; 206] 
 
However, for probe-based RS to be seen as a realistic potential tool for in vivo endoscopic 
diagnosis, spectra must be able to be accurately acquired in conjunction with real-time white 
light endoscopy and/or additional wide field imaging techniques. This will enable safe 
measurements to be recorded from very specific areas of clinical interest. 
 
When working to develop a clinically applicable endoscopic Raman probe it is therefore 
important to consider and evaluate the effects of endoscopic white light imaging and 
alternative endoscopic light sources on spectral classification performance. 
 
Modern Olympus endoscopes are capable of both real-time white light (WLE) and narrow 
band imaging (NBI). NBI illuminates the mucosa of the oesophagus with blue and green light 
utilizing the principle that longer wavelengths penetrate deeper into tissue than shorter 
wavelengths. The effect is to enhance the resolution of the mucosal surface potentially 
helping to differentiate dysplasia and early cancer from benign Barrett’s oesophagus.[219] 
 
NBI has been shown to increase the diagnosis of dysplasia in the hands of experienced 
users.[221; 223] However, considerable inter-user variation and high false positive rates are 
widely reported.[133; 223] 
 
The great potential of RS is its ability to provide objective tissue classification with high 
positive predictive values enabling early targeted therapy (see Chapter 5). RS could therefore 
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ideally complement a wide field imaging technique such as NBI which suffers from 
subjectivity and poor specificity.[250] A dual modality (RS-NBI) imaging system could 
potentially limit the high false positive rate associated with NBI and provide objective 
diagnostic assessment to reduce inter-user variation. 
 
This section aims to assess the potential for endoscopic multi-modality imaging using RS, 
NBI and WLE. 
 
Ex vivo Raman spectra were measured in the endoscopy department at Gloucestershire Royal 
Hospital from 14 fresh oesophageal biopsies collected from 3 patients. Spectra measured 
from one of the biopsies was excluded from the analysis due to excessive fluorescence (see 
Chapter 5). In this case the excessive fluorescence signal was probably due to considerable 
contamination of the tissue specimen with blood caused by bleeding at the time of the biopsy. 
 
Tissue spectra were measured using the Raman probe and the custom built portable 
spectrometer in conjunction with WLE, and NBI, and following exclusion of ambient light 
(control measurement). Figure  7-15 illustrates air background spectra measured under each of 
the lighting conditions. 
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Figure  7-15. Air background spectra measured in conjunction with WLE and NBI, and 
following exclusion of ambient light (control). 
 
RS measurements in the presence of NBI were visibly consistent with the ‘dark’ control 
prompting further investigation. A slight difference in background signal was noted in the 
presence of WLE, most notably in the wavenumber region 1460-1600 cm
-1
. 
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Subsequently PTFE and tissue spectra were acquired (Figure 7-16A&B). Visually consistent 
spectra were demonstrated in the presence of both WLE and NBI, the only prominent area of 
disparity was again identified in the wavenumber range 1460-1600 cm
-1
 for both PTFE and 
tissue measurements (Figure  7-17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  7-16. Five second PTFE spectra (A); and mean tissue spectra from 13 
oesophageal biopsies (B); measured in conjunction with WLE and NBI, and following 
exclusion of ambient light (control). 
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Figure  7-17. Variation in tissue spectra acquired in the presence of endoscopic light and 
NBI compared to those acquired after exclusion of all ambient light. Confidence 
intervals for the ‘dark’ control are illustrated. The figure on the right represents a 
truncated dataset (400:1465); the figure on the left includes the whole spectral range.  
 
7.6 Prediction of Ability to Classify Pathology In Conjunction with 
NBI Based on Truncated Dataset Analysis 
 
Data presented in Chapter 5 has demonstrated the ability of the Raman probe system to 
accurately classify normal squamous epithelium, Barrett’s oesophagus, dysplasia and cancer 
following analysis of 798 ex vivo oesophageal samples from 62 patients. As described 
previously spectra were acquired in 1 second across the wavenumber range 400-1850 cm
-1
, 
and PC-fed LDA algorithms tested using leave one spectrum out cross-validation (LOSOCV) 
yielded a sensitivity and specificity of 86% and 88% respectively for the diagnosis of 
HGD/cancer. 
 
Spectral measurement in conjunction with NBI and WLE has demonstrated spectral disparity 
in the upper wavenumber range (Figure  7-15 and 7-16). Wavenumbers above 1465 cm-1 were 
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therefore excluded from the 1 s dataset presented in Chapter 5, and multivariate analysis 
(including LOSOCV) was repeated. Identical classification performance was demonstrated 
pre and post data truncation (Table  7-3) illustrating the ability of the model to correctly 
classify spectra across a narrowed spectral range. 
 
  Sensitivity Specificity 
Whole spectral 
range included 
(400-1850) 
NSq 
LGD / Barrett’s 
HGD / Adenocarcinoma 
87% 
72% 
86% 
96% 
91% 
88% 
Truncated spectral 
range (400-1465) 
NSq 
LGD / Barrett’s 
HGD / Adenocarcinoma 
86% 
73% 
86% 
95% 
91% 
86% 
 
Table  7-3. Comparison of diagnostic classification performance when including the full 
spectral range (400-1850 cm
-1
); and truncated spectra (400-1465cm
-1
). 
 
These findings demonstrate that spectra acquired in the presence of both WLE and NBI are 
free from significant visual interference across the spectral range 400-1465 cm
-1
. In addition, 
classification performance across this truncated spectral range has been shown to be feasible 
and accurate. These data clearly prompt the need for further investigation but raise an 
exciting possibility for the potential for multimodality imaging using WLE, NBI and RS. 
 
7.7 Is Classification Possible Based on Spectral interference from 
white light endoscopy or NBI? 
 
PC-fed LDA with LOSOCV was performed to further explore the influence of white light, 
and narrow band imaging on spectral acquisition. A three group analysis was performed 
(dark; WLE; NBI) which demonstrated poor classification performance (Table  7-4). The PC 
loadings are included in Appendix XIV. The obvious visual difference between the three 
groups of spectra is identified by PC2. Later spectra appear to represent noise, and 
encouragingly, none display convincing Raman peaks suggesting that both white light and 
NBI have little impact on the Raman signal. 
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The classification performance was shown to decrease further, to a point at which it could be 
stated that no classification was possible, following truncation of the dataset (400:1465) 
(Table  7-4). 
 
  Sensitivity Specificity 
Whole spectral 
range included 
(400-1850) 
Dark 
Endoscopic light 
NBI 
85% 
62% 
54% 
73% 
92% 
85% 
Truncated spectral 
range (400-1465) 
Dark 
Endoscopic light 
NBI 
62% 
46% 
54% 
73% 
85% 
73% 
 
Table  7-4. Classification of spectra acquired in the dark, and in the presence of 
endoscopic white light and NBI. 
 
7.8 Summary  
 
Prior to a large scale clinical trial of endoscopic Raman spectroscopy convincing data must 
demonstrate multi-operator, multi-centre and multi-system reliability. The repeatability and 
transferability of spectral measurements acquired with different Raman systems is essential 
since clinical application will necessitate the use of pre-defined automated classification 
algorithms. 
 
Standardisation of spectrometer specifications and probe construction is unlikely to prevent 
minor spectral variation between different systems. It is therefore necessary to define a clear 
method for Raman system calibration. This will require careful optimisation of calibration 
parameters, including clear tolerance levels so that spectral signals measured across all 
Raman systems can be precisely calibrated. 
 
Although more extensive work is required, the two probe – two operator comparison 
described here demonstrated encouraging results. In addition, we have demonstrated 
spectrally consistent data acquired in the presence of NBI and WLE confirming potential for 
future multi-modality oesophageal imaging. 
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CHAPTER 8 
 
8 Summative Discussion and Conclusions 
 
The translational research presented in this thesis aims to assess the potential for in vivo 
endoscopic application of RS in the oesophagus. In light of the data reported in Chapters 5 – 
7 it is essential to discuss exactly how oesophageal RS could enhance a clinician’s armoury 
and how this might potentially impact on patient care. The need for further engineering 
refinements and future clinical testing is also discussed, and scientific and clinical 
conclusions are drawn. 
 
8.1 Clinical Perspective 
 
For years clinicians have relied on the histological appearance of cells in order to confirm the 
diagnosis of most malignant and inflammatory conditions. Although a trusted technique, 
histological assessment of tissue is subjective, time consuming and expensive. Furthermore, 
histological diagnosis necessitates tissue biopsy with subsequent processing and reporting, 
and therefore does not enable immediate diagnosis and targeted treatment. 
 
In the oesophagus the need for improved diagnosis of early neoplasia is particularly 
compelling. Oesophageal adenocarcinoma has increased by 500% over the past 40 years 
while its prognosis has remained relatively constant with current 5 year survival rates of just 
8-15%.[28-30] 
 
Early detection of neoplastic disease, ideally at a premalignant stage, is essential to 
improving cancer outcomes.[28] Successful screening programmes in the colon 
(adenomatous polyps) and the cervix (cervical intraepithelial neoplasia) have facilitated early 
intervention and have been shown to prevent malignant progression. However, it is clear that 
population based, or even targeted endoscopic screening for oesophageal cancer, or its 
precursor, dysplasia, is inappropriate. Conversely, surveillance of patients with Barrett’s 
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oesophagus is currently recommended due to an increased risk of adenocarcinoma in these 
patients.[7; 28] 
 
Several recent large studies have demonstrated a lower than previously reported rate of 
progression from non-dysplastic Barrett’s oesophagus to adenocarcinoma.[100; 101; 103; 
112] In addition, they have confirmed that only a small percentage (7.3%) of patients 
diagnosed with adenocarcinoma have a prior diagnosis of Barrett’s oesophagus.[101] These 
important studies have demonstrated that identifying and surveying patients with Barrett’s 
oesophagus is alone insufficient as a strategy to detect and prevent oesophageal 
adenocarcinoma. In addition, they have fuelled the need for other non-endoscopic screening 
techniques to identify high risk groups, such as assessment of genome wide association data 
following blood sampling, or alternatively, molecular or spectral cytology following non-
endoscopic oesophageal cell sampling.[145; 146; 252-254] 
 
The true value of surveying all patients with Barrett’s oesophagus is highly debatable given 
this recent evidence, and the results of the Barrett’s oesophagus surveillance study (BOSS) 
are therefore eagerly anticipated. However, it is clear that a cohort of patients with Barrett’s 
oesophagus do have a significant risk of progression to adenocarcinoma and one of the 
fundamental goals of translational research in Barrett’s oesophagus must be to distinguish the 
small number of patients who will progress to adenocarcinoma from the majority who will 
not. Currently, there are no validated markers for prognostic evaluation of Barrett’s 
oesophagus that are ready for widespread clinical use other than the presence or absence of 
dysplasia, particularly HGD, as determined by histopathological assessment. However, other 
factors such as the length of the Barrett’s segment are known to correlate with an increased 
risk of progression. Until more sophisticated techniques are available, it is possible that future 
surveillance will be recommended only for those patients with a Barrett’s segment >3cm, 
those with a history of dysplasia, or those with a family history of adenocarcinoma. 
 
It is abundantly evident however that there must be accurate means of assessing and treating 
those patients who are deemed at higher risk of malignant progression. This treatment must 
be possible at an early, ideally premalignant, stage. 
 
Surgery is one potential treatment option in patients with early disease. However, in-hospital 
mortality following oesophagectomy remains around 5% and many older patients, or those 
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with significant co-morbidities, are not surgical candidates. Endoscopic therapy now offers 
an alternative approach with lower morbidity and mortality. 
 
Whole segment therapy using 360 RFA is an option for higher risk patients, particularly those 
with confirmed, macroscopically invisible HGD. RFA is an extremely promising treatment 
modality particularly for patients with flat lesions although it is not indicated for those with 
early invasive cancers (T1a or b). In addition, large-scale long-term data (longer than three 
years) are not yet available. 
 
Where focal HGD and / or T1a lesions are visible endoscopically clinicians can perform 
single or multiple ER to achieve complete excision followed by whole segment ablation 
using RFA, to destroy any malignant field change. Although this combined ER and ablation 
strategy has not been tested in a RCT, it is the policy adopted by the significant majority of 
experts in the field.[243] 
  
For this treatment strategy to be effective it is crucial that endoscopists are able to target areas 
of neoplasia for endoscopic resection and that they have a sensitive, and ideally objective, 
mechanism of defining the margin of the lesion. In addition, to prevent over-treatment, 
clinicians must be able to confirm a neoplastic lesion with a high degree of specificity. 
Despite a variety of endoscopic adjuncts, many of which are widely available including NBI 
and chromoendoscopy, the detection of dysplastic lesions in the oesophagus is often difficult 
and unreliable precluding successful targeted ER. In a study of 742 ERs from 326 patients 
with Barrett’s neoplasia, an R0 resection was attained in only 26.8% of patients following 
initial therapy.[8] Subsequent repeated ER achieved R0 resections in 74.5%, but only after 
several months delay between treatments. The study concluded that if ER is to be used as a 
viable therapeutic strategy in T1a lesions improved mechanisms of lesion detection and 
margin definition must be developed. 
 
The difficulty with identifying areas of dysplasia is seen readily in our own practice at 
Gloucestershire Royal Hospital (GRH). Patients undergoing biennial surveillance endoscopy 
at District General Hospitals are often referred to GRH for specialist assessment and 
intervention. These patients typically have had dysplasia or malignancy confirmed following 
a series of random biopsies. However, on re-endoscopy at GRH it is often difficult to reliably 
identify and remove all areas of neoplasia. 
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In this thesis a custom-built Raman probe has been trialed for use as a potential endoscopic 
tool to improve identification of neoplastic lesions. The Raman probe has demonstrated the 
ability to discriminate between advanced neoplasia (HGD / adenocarcinoma) and LGD / non-
dysplastic Barrett's oesophagus with a sensitivity of 88% and specificity of 82% following ex 
vivo tissue measurements (Table  8-1). Adenocarcinoma could also be discriminated from 
normal squamous oesophagus with a sensitivity of 94% and a specificity of 91% 
demonstrating potential for use in discriminating benign and malignant oesophageal 
strictures. 
 
These levels of diagnostic accuracy were achieved using just 1 s Raman measurements and 
performance was increased further still using 5 s measurements. Reduction to 0.1 s 
acquisition times impaired probe performance significantly, however a degree of 
classification was still possible prompting optimism that further improvements in probe 
design and CCD quality could enable near ‘real-time’ imaging in the future. 
 
 
 
  Sensitivity Specificity 
 
Three group model 
(Spectra acquired in 1 s) 
NSq 
LGD / Barrett’s 
HGD / Adenocarcinoma 
87% 
72% 
86% 
96% 
91% 
88% 
 
 
 
 
Two group models 
(Spectra acquired in 1 s) 
 
NDB / LGD 
HGD / Adenocarcinoma 
82% 
88% 
88% 
82% 
IM 
Non-IM CLO (CB/FB) 
91% 
80% 
80% 
91% 
NSq 
Buried cancer 
90% 
78% 
78% 
90% 
LGD Vs. 
HGD/IMC 
100% 
100% 
100% 
100% 
HGD / Adenocarcinoma 
All benign pathologies* 
82% 
80% 
80% 
82% 
Adenocarcinoma 
NSq 
94% 
91% 
91% 
94% 
Two group models 
(Spectra acquired in 5 s) 
NDB / LGD 
HGD / Adenocarcinoma 
98% 
86% 
86% 
98% 
 
Table  8-1. The diagnostic performance of the Raman probe is indicated. *Includes all 
benign pathologies including gastric tissue, fatty or muscular connective tissue, 
Barrett’s oesophagus, and normal squamous tissue. 
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The probe was shown to be capable of correctly classifying superficial pre-malignant disease 
in addition to demonstrating the ability to detect invasive cancer beneath a histologically 
benign squamous or glandular epithelium. Similarly, the potential to distinguish IM, from 
non-IM CLO was demonstrated (although the numbers of spectra included in this model were 
small). 
 
These data have confirmed that fibre-optic RS can accurately and objectively classify 
mucosal oesophageal pathology ex vivo and have clearly demonstrated potential for in vivo 
diagnosis. Moreover, this ability to classify between pathologies is based on detection of 
identifiable biochemical differences between normal and benign oesophageal tissue which are 
supported by the published literature. 
 
The data presented have been rigorously analysed in order to try to derive a true reflection of 
diagnostic performance and avoid reporting over-optimistic classification. Leave one 
spectrum out cross validation (LOSOCV) has been employed to ensure that each spectrum in 
turn is left out from training the model before being projected onto the model in order to 
validate diagnostic accuracy. 
 
Background subtraction and correction algorithms were not shown to enhance diagnostic 
classification. This agrees with the conclusions of other published reports and may be a 
consequence of the introduction of small systematic errors acquired during measurement of 
the tissue standards.[197; 245] 
 
The ability to record consistent reproducible spectra over 18 months has been demonstrated. 
In addition, two probes, operated by two independent users, have demonstrated spectral 
consistency, and mechanisms for calibration of small spectral differences have been explored. 
Prior to clinical implementation there will also be a need to clearly define levels of 
engineering tolerance. Engineering tolerance is the permissible limit of variation in a 
manufactured object that does not compromise its performance. Production of multiple 
Raman probes and customised spectrometers will inevitably introduce some inherent 
variation in spectral quality. Tolerance limits must be carefully defined so that measurements 
falling outside of these limits are rejected as unreliable. The levels of tolerance defined will 
depend on the levels of performance required. 
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A clinical trial including large numbers of probes and large numbers of patients, with a full 
range of pathologies, will enable tolerance levels to be clearly defined. Alternatively, it may 
be possible to pre-define tolerance levels following mathematical modelling of the existing 
dataset in combination with additional probe testing once further probes have been 
constructed. 
 
In this Doctorate, multi-probe analysis of ex vivo tissue was not possible due to a lack of 
identically built functioning probes. During the course of the work several problems arose 
with reproducibility of probe construction meaning that probe replicas were unable to 
measure reliable signal. This was thought to be due to movement of optical components 
within the probe sleeve and therefore rigid metallic sleeves have been carefully developed in 
the hope of improving manufacturing reproducibility. Further probe calibration and 
reproducibility studies will be needed once multiple probes are available to ensure acceptable 
probe accuracy and to define engineering tolerances. 
 
The ability of RS to establish an objective diagnosis based on precisely measurable 
biochemical differences between tissue types is a significant advantage of this technology 
over other competing modalities. Current advanced imaging techniques such as confocal 
microscopy and narrow band imaging lack this objectivity. Moreover as previously 
discussed, even histological evaluation may be prone to diagnostic uncertainty - interobserver 
agreement between pathologists is well recognised to vary widely, particularly for 
distinguishing HGD from LGD (k=0.2-0.6).[85; 188] This is a particularly important clinical 
distinction as currently patients with HGD are offered therapeutic intervention, whereas those 
with LGD are managed by 6-monthly endoscopic surveillance. 
 
It is important to note that when only tissue with a consensus histological diagnosis was 
included as the ‘gold standard’ the performance of the classification models increased. It 
must also be noted, that even the consensus of two expert pathologists may not represent a 
perfect ‘gold standard’ and therefore the results presented in this thesis must be interpreted in 
light of this. 
 
Bergman et. al. recently demonstrated that LGD is over-diagnosed by non-specialist 
pathologists and argued that its true significance might be underestimated by many reported 
series.[118] In their study, 1198 patients underwent Barrett’s surveillance at six non-
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specialist hospitals identifying 147 (12.5%) patients with LGD. However, only 8 (0.7%) 
patients were deemed to have LGD following histological review by two external expert 
gastrointestinal pathologists. The majority of diagnoses were reclassified as non-dysplastic 
Barrett’s oesophagus. During a mean follow-up period of 51 months, 42% of patients with 
LGD diagnosed by consensus expert pathologists demonstrated progression to either 
carcinoma or HGD, and 2.2% regressed to non-dysplastic Barrett’s oesophagus.[118] This 
report demonstrates the importance of accurate classification of dysplasia and supports the 
need for novel objective diagnostic technology such as Raman spectroscopy. The data 
presented in this thesis has demonstrated that the custom-built Raman probe could be capable 
of distinguishing between non-dysplastic disease and LGD; and between LGD and 
HGD/IMC. This clinically relevant information could prevent inappropriate over- or under-
treatment of patients with dysplastic disease. If sufficient diagnostic accuracy can be 
demonstrated there could also be a case for instigating treatment of LGD, provided the 
diagnosis was confirmed by a Raman classification model which had been trained by 
consensus expert GI pathologists. 
 
Similarly, future work could also aim to assess whether susceptible Barrett’s phenotypes 
could be identified using RS. Further advances in diagnostic accuracy may raise the 
intriguing possibility of using RS to predict disease progression in non-dysplastic Barrett’s or 
LGD since it is possible that biochemical predictors of progression may be detectable before 
morphological changes manifest.[31] 
 
8.1.1 Potential for Multimodality Imaging 
 
One of the main limitations of fibre-optic RS in its current form reflects the fact that it is a 
point measurement technique. In order to improve diagnostic yield of early neoplastic lesions 
within Barrett’s segments wide-field imaging techniques are required which enable clinicians 
to view large areas and detect subtle neoplastic changes. Several large field techniques have 
been described, some of which are licensed for clinical use, however most are hindered by 
low levels of sensitivity and specificity. 
 
Recently a promising wide-field technique has been described using visually tagged probe 
molecules which bind selectively to neoplastic cells.[230; 231][232][2] The report by Bird-
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Lieberman from the Fitzgerald group demonstrated that alterations in cell-surface glycans 
during progression to adenocarcinoma could be identified through changes in their lectin 
binding properties. Selective binding of a candidate lectin (wheat germ agglutinin) sprayed 
into a resected oesophagus enabled ex vivo visualization of high-grade dysplastic lesions, 
which were not detectable by conventional endoscopy. 
 
This technique has considerable potential but is still at the very early stages of clinical 
development and its true diagnostic accuracy remains to be evaluated. However, wide-field 
imaging techniques like this one, or others already in clinical use such as NBI, AFI or OCT, 
could potentially be used in conjunction with RS in the future.[209; 210; 249; 255] [256] 
Interpretation of these wide-field techniques tends to be subjective and experience governed. 
However, multimodality tools could enable identification of suspicious areas using the wide-
field modality with further detailed and objective assessment of these regions using RS. 
 
The data presented in Chapter 7 demonstrated potential for combining WLE, NBI and RS. 
NBI filters white light into blue and green wavelengths allowing visualisation of subtle 
mucosal irregularities and alterations in vascular patterns consistent with dysplasia and 
intramucosal cancer.[219] NBI can be used by endoscopists at the push of a button and does 
not require the use of staining or intravenous contrast agents. However, reported rates of 
diagnostic accuracy vary considerably due to high levels of inter-observer 
inconsistency.[133; 223] 
 
The data presented here have shown that spectra could be accurately and reproducibly 
acquired in the presence of NBI. In addition, spectral diagnostic classification was shown to 
be unchanged when compared to the dark control. Huang et. al. recently described a 
multimodal imaging system combining endoscopic Raman spectroscopy with AFI, NBI and 
standard white light endoscopy for use in the oesophagus and stomach.[210] This trimodal 
wide-field imaging system was used to guide point measurements from suspicious areas 
which were taken using the Raman system. However, Huang et. al. did not comment as to the 
added benefit of this trimodal imaging system on diagnostic yield. 
 
The concept of combining highly accurate objective diagnostic tools with wide-field imaging 
techniques is logical and certainly requires further evaluation in vivo. However, when 
conceiving these multi-modality systems we must remember that they are designed for use as 
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clinical tools in conscious patients. They must therefore be affordable, user-friendly, and 
feasible for use during a standard endoscopy session. 
 
8.1.2 Optimising the Classification Model for Purpose 
 
Receiver Operating Characteristic (ROC) curve analysis can allow for alterations in the 
classification of groups within a model so that sensitivity for detection of neoplasia can be 
maximised at the expense of specificity or vice versa. 
ROC curves plot the true positive rate (sensitivity) against the false positive rate (1-
specificity) and therefore each point on an ROC curve represents a sensitivity / specificity 
pairing at a particular decision threshold. The area under an ROC curve (AUC) is a measure 
of how well the test can distinguish between the two diagnostic groups (e.g. benign versus 
neoplastic). AUC values of 0.5 are analogous to a toss of a coin, whereas those of 0.8 are 
generally considered to be ‘acceptable’ and those of 0.9 to be ‘excellent’.[257] 
A test which allows perfect discrimination between two groups has a ROC curve that passes 
through the upper left corner of the plot (100% sensitivity and 100% specificity). Therefore, 
the closer the curve is to the upper left corner the greater AUC and the higher the overall 
accuracy of the test. 
ROC curves for a 2 group (NDB/LGD versus HGD/adenocarcinoma) PC-fed LDA 
classification model validated using LOSOCV are illustrated in Figure  8-1A. The calculated 
sensitivity and specificity for this model (as presented in Chapter 5) are 88% and 82% 
respectively for the detection of advanced neoplasia. The ROC curve for a second 
classification model (HGD / adenocarcinoma versus all other pathologies) is illustrated in 
Figure  8-1B. A sensitivity of 82% and specificity of 80% have previously been reported for 
discrimination of advanced neoplasia in this model. 
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Figure  8-1. ROC curves showing sensitivity / specificity pairings for the discrimination 
of HGD and adenocarcinoma from (A) LGD and non-dysplastic Barrett’s; and from (B) 
all other pathologies. Note that buried neoplasia has been excluded from these models. 
 
A two group model (all benign pathologies versus LGD/HGD/adenocarcinoma) demonstrates 
a sensitivity of 84% and specificity of 77% for detecting glandular neoplasia. The specificity 
has fallen slightly in this model due to difficulties discriminating LGD from non-dysplastic 
Barrett’s. Possible explanations for this have been discussed in Chapter 5. An ROC curve for 
this model is displayed below. 
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Figure  8-2. (A) An LD scores histogram illustrating probe classification of glandular 
neoplasia from all other benign tissue. (B) An ROC curve for the same cross validated 
classification model is also illustrated. Note that glandular neoplasia includes LGD, 
HGD and adenocarcinoma but excludes disease that was buried beneath a normal 
epithelium. 
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If endoscopic RS is intended for use as a surveillance tool ROC curve analysis would need to 
optimise sensitivity (decreasing false negative results) at the expense of a higher false 
positive rate. Although prompting increased numbers of tissue biopsies, this modification 
would serve to reduce the incidence of missed neoplasia. 
 
During endoscopic surveillance there is a clinical need to detect LGD as well as more 
advanced disease. In this instance, a sensitivity of 95% may be considered acceptable but this 
would shift the specificity of the instrument to just 56% (Figure 8-2). However, this could 
potentially enable significantly less biopsies to be taken whilst still ensuring that neoplastic 
areas are identified. This ability for targeted biopsying could reduce histology processing and 
reporting costs significantly. 
 
If a Raman probe system were intended for use during endoscopic therapy in patients with 
known HGD or early cancer the decision line could be shifted to enable a programmed high 
level of specificity in order to minimise false positive results and therefore reduce the risk of 
complications caused by resection of non-dysplastic areas. In this setting the probe would 
need to distinguish HGD and early cancerous lesions (which can be treated endoscopically) 
from LGD and non-dysplastic Barrett’s (which are currently kept under surveillance) (Figure 
 8-1). 
 
An alternative measure of agreement besides sensitivity / specificity and AUC is the kappa 
statistic. The kappa statistic takes into account the fact that observers will sometimes agree or 
disagree by chance. In the case of Barrett’s oesophagus, the kappa statistic is often used to 
report the level of subjectivity between histopathological diagnoses (see Chapters 2 and 3). 
 
The level of agreement between Raman predictions and gold standard (consensus) 
histopathological diagnosis for the two group model (NDB/LGD and HGD/adenocarcinoma) 
was k=0.70. A kappa score of >0.60 is regarded as a ‘substantial agreement’, and a score of 
0.8 is considered ‘almost perfect’ agreement.[258] Further reporting of the tissue biopsies by 
a third independent pathologist could enable comparison of their performance against that of 
the Raman probe, by comparison to the current gold standard. 
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8.1.3 Potential Role During Oesophagectomy or Oesophageal Cancer Staging 
 
A Raman probe system could potentially have a role as a surgical adjunct during 
oesophagectomy. It could enable surgeons to assess resection margins intra-operatively to 
ensure they are clear of microscopic tumour deposits in order to minimise the risk of locally 
recurrent disease. Similarly the probe could even act as an adjunct to oesohagogastric cancer 
staging, through laparoscopic assessment of suspicious peritoneal or lymphatic deposits, or 
potentially endoscopic assessment of the depth of tumour invasion through the oesophagus. 
Previously, the ability of RS to stage transitional cell carcinoma of the bladder based on 
urothelial measurements has been demonstrated[45], and similar potential for tumour depth 
‘T-staging’ may be possible in the oesophagus. However modification to the confocal, short 
focal length design of the probe described in this thesis would be necessary if it were 
intended for use in T-staging. 
 
8.2 Limitations 
 
This thesis has several methodological limitations which must be highlighted. Several of 
these have been discussed at relevant stages throughout this thesis but are presented again 
here for completeness. The limitations relate to the technique of spectral acquisition, the 
nature and design of the probe, the data pre-processing and analysis, and to assumptions 
made between the ex vivo environment and the real clinical environment at endoscopy. 
 
 Fluorescence – The endogenous fluorophores in blood are well known to induce 
fluorescence which may mask weak Raman signals. Although water lavage could be 
performed during endoscopy to remove excess blood, the fluorescence effects may 
interfere with a clinicians’ ability to take multiple targeted biopsies. This will need 
further evaluation in vivo. As fluorescence was very rare ex vivo (following mucosal 
lavage) and these spectra were easily identifiable as visual outliers prior to data 
analysis, the problems caused by fluorescence in this thesis were minimal. 
 Probe background – The custom-built Raman probe has a significant background 
signal due to Raman, fluorescence, and elastic scattering signals being generated 
within the fibre-optic cables. However, the probe has been shown to be sufficiently 
sensitive to detect the important spectral signals which enable tissue classification. 
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Although not all visible above the probe background, PC-fed LDA could extract this 
data for tissue classification. Background subtraction / correction algorithms were not 
shown to improve classification performance. 
 Exclusion of ambient light – All measurements presented and discussed in Chapters 5 
and 6 were acquired following exclusion of all ambient light as visible wavelengths 
can cause spectral disruption. However, both endoscopic white light and NBI have 
been shown to be compatible with Raman measurements (see Chapter 7). 
 Point measurements – This is a recognised limitation of in vivo Raman spectroscopy 
which has been discussed previously. It is hoped that further developments may 
enable real-time imaging which could facilitate assessment of whole Barrett’s 
segments in clinically applicable timescales. 
 Pressure effects – Inadequate contact of the probe with the tissue may have affected 
the spectral signal. However, as explained previously, this was a translational project 
using a clinically applicable tool which was pressed against the tissue by hand, as 
would be the case in vivo. No attempt was taken to experimentally regulate probe 
pressure as this would be impractical in vivo. Initial probe evaluation data 
demonstrated that adequate probe contact was more significant than minor variation 
in probe pressure or angulation. This finding is supported by previous studies.[209; 
247] 
 Small numbers of dysplastic spectra despite spectral analysis of over 700 tissue 
samples – Many biopsies containing possible dysplastic elements were non-
homogenous, or were classified differently by each expert pathologist. These biopsies 
were therefore excluded from most analyses. Despite relatively small numbers of 
homogenous dysplastic samples with a consensus diagnosis, diagnostic classification 
was still possible. 
 Neoadjuvant chemotherapy – The majority of patients were treated with 
chemotherapy prior to surgical resection. This often led to shrinkage and fibrosis of 
the tumour, which may have affected its spectral signal. 
 Previous ablation therapy – Some point biopsies / endoscopic resections were taken 
from patients who had undergone previous ablation therapy. It is unclear what effect, 
if any, this may have had on the Raman signal obtained from this tissue. However, in 
a clinical setting it will be essential that the probe can detect recurrent Barrett’s / 
dysplasia in patients who have undergone previous endoscopic treatment. The ability 
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to detect buried cancer has been demonstrated. However, the ability of the probe to 
detect metaplasia beneath neosquamous epithelium was not possible due to lack of 
tissue samples. 
 Ischaemia – The effects of tissue ischemia have not been fully established. This may 
mean that the results of this thesis cannot be generalised to in vivo results with 
complete accuracy. A large spectral dataset will need to be established following an in 
vivo trial and at that point comparisons with ex vivo data can be made. 
 Assessment has not specifically evaluated the ability of the probe to identify 
macroscopically invisible areas of HGD / cancer. In order for RS to be a clinically 
applicable tool, it will need to be shown to improve recognition of the lesions which 
are undetectable using white light endoscopy and therefore demonstrate the ability to 
change patient management. This should be considered when designing future in vivo 
clinical trials in order to demonstrate diagnostic benefits. 
 All spectra were acquired from a biased population as all patients had a history of 
Barrett's oesophagus and / or adenocarcinoma. However, these patients represent the 
target population for this clinical tool. 
 It is possible that errors in PCA may have occurred due to systematic error within the 
dataset, for example systematic drift in the intensity or wavenumber axes. However, 
careful calibration prior to all sets of measurements was used to obviate these effects. 
In addition the data presented showed no evidence of systematic drift and green glass 
correction failed to improve the classification performance suggesting that major 
systemic error was not a problem. 
 
8.3 Future Work 
 
This research identified several possible avenues for further work. Further optimisation of 
signal to noise ratio (SNR) could potentially enable diagnostic accuracy to approach 100% 
and permit real-time imaging. However, the principal aim for the future, which is heavily 
supported by the data presented here, is translation of the probe into a clinically tested 
endoscopic tool. 
 
Ideas for alternative research proposals related to oesophageal RS are briefly highlighted 
below (section 8.3.2). 
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8.3.1 Translation to an In Vivo Tool 
 
The work presented here demonstrates that the novel fibre-optic probe can accurately classify 
oesophageal tissue in clinically applicable timescales. In addition, spectra can feasibly be 
measured under direct vision using WLE and/or NBI. The data also demonstrates that reliable 
spectra can be acquired using different identically designed probes used by different 
operators, and that probe performance is reproducible over time. 
 
Previous work, initially by Shim et. al. in 2000, demonstrated that in vivo Raman 
measurements were feasible and safe in the oesophagus, although for a number of reasons 
diagnostically useful information was not obtained (see Chapter 2).[197] Further subsequent 
in vivo work by several groups has supported the conclusions that RS is safe and feasible and 
has demonstrated more encouraging diagnostic data, although detection of early lesions using 
other probe systems has proved difficult.[35; 206; 209; 212] 
 
The results presented here, and the experience from previous pilot clinical trials, support the 
need for an in vivo trial using this custom-built Raman probe system. However, prior to 
commencing such a trial there are several practical considerations which need to be 
addressed: 
 
 Probe durability – Probes must be sufficiently durable to tolerate multiple passes 
down an endoscope without it affecting spectral recordings. During the course of this 
research project a probe was damaged during passage through a scope prompting a 
change to the design of the external rigid coating of the distal tip of the probe. It has 
not been possible to undertake a formal probe durability experiment at this stage due 
to the need to prevent any risk of damage to the current probe. This experiment, 
which will be quick and straightforward to conduct, can be undertaken after 
agreement from the probe manufacturers. 
 Single or multi-use – It is unclear at this stage whether the probe is intended for single 
or multi-use. Data presented here has shown potential for multi-use since reliable 
spectra were recorded over an 18 month period. However, this will require that the 
probe is packaged in such as way that it can be reliably sterilised between patients and 
that the probe constituents are adequately protected from this process. Again this 
 186 
should be relatively straightforward to achieve as with other multi-use endoscopic 
instruments. However, the decision will need to reflect a number of factors e.g. sales 
projections, probe build costs and sale price (which are currently confidential). 
 Manufacturing – There needs to be an established mechanism for reproducing 
identically built probes to high standards. During this Doctorate there have been 
significant issues reproducing multiple identical probes which can acquire reliable 
spectral signals. This possibly represents the largest current barrier to in vivo use 
since probes must be straightforward to manufacture and able to record spectra within 
carefully defined tolerance limits. 
 CE marking – this is the mandatory legal conformity mark necessary for products 
placed on the European market. It confirms that the manufacturer has ensured that the 
product is not only safe but also functions in a way so as to achieve its intended 
purpose. 
 Commercial support – There needs to be a mechanism for funding a future clinical 
trial. This will most likely involve a commercial collaboration. 
 
After addressing these factors a carefully planned clinical trial will need to be undertaken. 
The design of the trial must address the following: 
 
 The aims of the trial must be clearly defined. A small feasibility study will be 
necessary to demonstrate probe performance in vivo and to build further foundation to 
support a larger multi-centre trial. Prior to a large, randomised trial, a significant in 
vivo spectral dataset will be required to generate a robust classification model. Later 
trials will need to evaluate the potential of RS to alter clinical management - this 
could be achieved by recording whether mucosal sites detected as abnormal by RS 
(and subsequently proven to be abnormal histologically) were detectable using 
standard endoscopic imaging. 
 A careful power calculation based on the data presented here, is required to evaluate 
the numbers of spectra which must be measured from each pathological tissue type in 
vivo. 
 Which patients should be included? Should it be all-comers with Barrett’s or should 
inclusion be limited to those with a history of dysplastic disease. The latter would 
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slow the rate of data acquisition and also prevent generation of data from patients with 
non-dysplastic segments, so is probably impracticable. 
 A technique for ensuring that probe spectra can be correlated with the current gold 
standard (consensus expert histology) must be established. Huang et. al. have 
described the use of an ER cap to ensure that probe and biopsy sites match. However, 
this requires that all patients are scoped using an ER cap, despite not necessarily 
needing therapeutic intervention. Alternatively, a double lumen scope could be used 
so that the probe and the biopsy forceps are passed simultaneously through the scope. 
This would enable a Raman measurement to be immediately followed by a biopsy at 
the corresponding site. However, slight adjustment by the endoscopist to allow for the 
different positions of the instrument channels would be necessary. 
 Assessment of cost-benefit in conjunction with a health economist. 
 
 
8.3.2 Alternative Potential Future Projects Utilising Oesophageal RS 
 
The ability of RS to provide rapid, reproducible, cheap, highly accurate and objective 
diagnoses of a range of oesophageal pathologies could be utilised in a variety of ways. In 
addition to this Doctorate investigating the potential for endoscopic diagnosis, other potential 
uses of oesophageal RS which require further investigation are as follows. 
 
 Correlation of Raman signal with biomarkers of malignant progression. Laboratory, 
and potentially probe based systems, may have the power to detect subtle differences 
in non-dysplastic Barrett’s or LGD which correlate with an increased likelihood of 
disease progression. Whilst completing this Doctorate I supervised an MSc student at 
Cranfield University who began to correlate Raman spectral signals with early 
neoplastic molecular changes. A summary of this work is included in Appendix XI. 
 Assessment of the ability of RS to detect eosinophilic oesophagitis. In this thesis 
tissue was collected from patients with Barrett’s oesophagus and / or oesophageal 
adenocarcinoma. Further testing could assess patients presenting with dysphagia to 
assess the ability of the Raman probe to detect spectral changes consistent with a 
diagnosis of eosinophilic oesophagitis. 
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 Oesophageal cancer staging using RS. The ability of RS to probe deeper tissues could 
be utilised to enable an assessment of a tumour’s depth of invasion (T-stage). 
Similarly, endoscopic ultrasound guided Raman probe assessment of para-
oesophageal lymph nodes, which lie within 1 cm of the adventitia is potentially 
feasible. This may be of particular value in the setting of T1sm1 tumours which may 
or may not be amenable to endoscopic therapy depending on the presence of absence 
of lymphatic involvement. 
 Surveillance for buried metaplasia. Buried metaplasia cannot be detected by other 
advanced imaging techniques and may be missed by random biopsy. The potential for 
diagnosis using RS requires further investigation, although the ability to detect 
cancerous elements beneath histologically normal epithelium is significantly 
promising. 
 Margin assessment during oesophagectomy – whilst this seems a logical step in view 
of the data presented in this project, this potential will need formal investigation. 
Particularly, the effects of neoadjuvant chemotherapy on Raman signal may need to 
be defined. 
 Rapid Raman mapping – promising work has reported techniques to aid histological 
interpretation of biopsies in short, clinically applicable timescales (see Chapter 2). 
Further on-going work is required to translate this promising technique into the 
clinical environment. 
 Potential for screening – spectral cytopathology (SCP) can accurately assess large 
quantities of oesophageal cells in short timescales.[252-254; 259; 260] During a 
British Society of Gastroenterology Travelling Fellowship to Boston, I initiated a 
collaboration investigating the potential for oesophageal SCP. Early results of a proof 
of principal study are included in Appendix XII. Further ongoing work is required to 
determine whether this technology could be combined with the Cytosponge test in 
order to detect Barrett’s, dysplasia or cancer in asymptomatic patients. 
 
8.4 Conclusions 
 
Raman spectroscopy is a highly sophisticated technique with a well established ability to 
accurately discriminate oesophageal pathology.[35; 43; 49; 191; 206; 209; 212; 237; 261] 
The potential for endoscopic application of RS has recently been recognised and several 
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small scale in vivo studies have been undertaken in the oesophagus.[197; 206; 209; 212] 
However, these have suffered from significant limitations including: a need for long 
(clinically unacceptable) acquisition times; measurement of spectra only after extrusion of 
endoscopic light; an inability to detect early superficial pre-malignant disease; or a lack of 
sufficient diagnostic accuracy. 
 
This translational research thesis has evaluated a novel confocal Raman probe which was 
built following a multi-unit collaboration. It has been designed to fit through the instrument 
channel of a standard medical endoscope and has been shown to measure reliable spectra in 
conjunction with both white light endoscopy and narrow band imaging. 
 
The confocal, short focal length design has facilitated interrogation of the epithelium 
enabling accurate discrimination between LGD and HGD / IMC. However, in addition the 
probe has demonstrated the ability to detect invasive cancer beneath histologically benign 
epithelium. 
 
Endoscopists can usually distinguish normal squamous mucosa from Barrett’s oesophagus 
using standard white light endoscopy. However, identifying and grading dysplastic lesions 
and early tumours is more troublesome - it is in this setting that endoscopic RS has a potential 
clinical role. The current clinical division between endoscopic surveillance or treatment 
occurs between LGD and HGD. That is to say, LGD and non-dysplastic Barrett’s is surveyed, 
whereas HGD typically necessitates early treatment. In this thesis the Raman probe has been 
shown to distinguish HGD/adenocarcinoma from NDB/LGD and normal squamous 
oesophagus with a sensitivity of 86% and a specificity of 88%. These diagnostic accuracies 
were obtained using clinically applicable (1 s) spectral acquisition times. It must also be 
considered that these figures rely on the assumption that the ‘gold standard’ - the consensus 
histological diagnosis of two expert pathologists - is entirely accurate. 
 
There are two main clinical settings in which oesophageal RS could potentially be utilised 
during endoscopy. These will be addressed in turn: 
 
1. To maximise the detection of dysplasia during endoscopic surveillance of patients 
with Barrett’s oesophagus and minimise the number of biopsies required. The premise 
for this is that random quadrantic biopsies every 2 cm can miss up to 57% of 
 190 
dysplasia.[22] Use of endoscopic RS could replace the need for multiple random 
biopsies by enabling targeted biopsies to be taken from sites with neoplastic spectral 
signatures. 
 
Using RS to guide biopsies during surveillance could reduce the overall number of 
biopsies taken, diminish histological processing and reporting costs, minimise the risk 
of bleeding from biopsy sites, and potentially decrease the incidence of missed 
neoplasia. 
However, the diagnostic accuracies achieved may not be sufficient to support the use 
of endoscopic RS in Barrett’s surveillance at present. Histology is able to identify 
advanced neoplastic tissue with high levels of accuracy - although histological 
disagreement between HGD and LGD, and between NDB and LGD is common, it is 
very rare for histologists to misclassify HGD or adenocarcinoma as non-dysplastic 
Barrett’s. In addition, pathologists often tend to over-call diagnoses to minimise 
missed pathology, meaning that LGD and ‘indefinite for dysplasia’ samples are over-
diagnosed, but rarely missed. In order for endoscopic RS to be of value to clinicians 
during Barrett’s surveillance it must demonstrate a high sensitivity for detecting all 
neoplastic disease (including LGD, HGD and cancer). If a sensitivity value of 95% is 
deemed mandatory ROC curves show that the specificity of the model falls to around 
50% (Figure 8-2). This may however, allow for a reduction in the number of biopsies 
required, so called ‘targeted biopsying’. 
Perhaps a greater obstacle to the use of endoscopic RS in Barrett’s surveillance 
reflects the fact that it remains a point measurement technique. This will probably 
limit its use in this setting (as has so far been the case with confocal microscopy). 
Although probe based RS has the potential to provide rapid, objective diagnosis, its 
sampling area per measurement (approximately 1 mm
2
) is less than that of a point 
biopsy and therefore, as with standard biopsy regimes, ‘optical biopsy’ could 
potentially miss neoplastic disease through sampling error. In the future this limitation 
may be overcome by combination imaging with a wide-field modality such as 
molecular fluorescence imaging. Alternatively, further technological advances may 
enable real-time imaging so that future probes can scan across large areas of tissue, 
although at present this is some way off. 
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2. In patients with confirmed HGD/IMC following prior endoscopic biopsy who are 
referred for endoscopic therapy. Targeted endoscopic resection of HGD/IMC enables 
thorough staging and can completely remove the disease. Where possible, clinicians 
advise a policy of focal lesion resection followed by whole segment ablation using 
RFA.[243] However, it is often difficult to identify HGD/IMC lesions prior to 
treatment. In addition, even where there is a visible mucosal abnormality it may not 
be possible to truly define the full extent of the lesion. 
 
The advent of ER has enabled complete excision of neoplastic lesions endoscopically. 
It is essential however, that a surgical philosophy is employed to these therapies. That 
is to say, clinicians must strive for R0 (complete microscopic) resections. A Raman 
probe could be used to confirm dysplastic areas prior to targeted ER and enable 
careful assessment of the margins of the lesion to ensure that no residual disease is 
left behind following endoscopic therapy. In this setting ROC curve analysis could be 
employed to maximise sensitivity. 
 
Similarly, during endoscopic therapy a Raman probe could be used to decrease the 
likelihood of incorrectly excising benign disease by minimising false positive results. 
In doing so potential complications occurring during unnecessary ER could be 
avoided. 
 
Currently, endoscopic RS probably has a greater role in facilitating clinicians during 
endoscopic resection of advanced neoplasia, rather than in surveillance for all-comers with 
Barrett’s oesophagus, due to the limitations discussed above. Patients with known disease 
who are referred for therapy could be given extra endoscopy time to allow for a thorough 
Raman probe assessment, aiming to increase the accuracy and oncological quality of the 
intervention and thus potentially increasing cancer specific survival. 
 
This thesis has demonstrated the exciting potential for objective endoscopic diagnosis of 
early pre-malignant lesions in the oesophagus using a novel custom built Raman probe. 
Shorter acquisition times and further improvements in diagnostic performance are expected 
as the technology continues to move forward. However, even at current levels of diagnostic 
accuracy, the ability to provide an immediate and objective diagnosis during endoscopy (or 
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surgery) could have a significant impact on patient care. Further multi-probe testing is 
required to ensure consistency, optimise system calibration, and define engineering 
tolerances. However, an in vivo clinical trial is feasible in the near future. 
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Appendix I 
 
 
7th Edition of the AJCC Cancer Staging: Oesophagus and Oesophagogastric 
Junction[264] 
 
T0 No evidence of primary tumour 
Tis High-grade dysplasia 
T1 Tumour invades lamina propria or submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades adventitia 
T4a Resectable cancer invades adjacent structures such as pleura, pericardium, 
diaphragm 
T4b Unresectable cancer invades adjacent structures such as aorta, vertebral body, 
trachea 
 
N0 No regional lymph node metastases 
N1 1 to 2 positive regional lymph nodes 
N2 3 to 6 positive regional lymph nodes 
N3 7 positive regional lymph nodes 
 
M0 No distant spread 
M1 Distant spread 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Systematic inspection using high definition endoscope +/- NBI 
Gold standard biopsy protocol 
High dose PPI 
Review by expert pathologist 
 
Barrett’s without 
dysplasia 
BOSS trial 
OR 
Repeat OGD 2 years 
OR 
Discharge (e.g. elderly with 
significant comorbidity) 
LGD 
Multifocal 
HGD in long-
segment Barrett’s 
Repeat OGD in 6 
months 
Focal HGD 
IMC (+/- 
T1sm1) cancer 
Endoscopic Barrett’s oesophagus 
Flat lesion Nodular 
EMR + staging CT, 
EUS +/- PET-CT 
If LGD persists 
repeat OGD 6/12 
 
If regressed – begin 
biennial surveillance  
Discussion in MDT +/- referral to tertiary unit 
HGD 
Oesophagectomy 
Fit with long 
life-
expectancy 
High 
operative 
risk 
EMR 
Endoscopic surveillance initially 2 monthly 
Ablate whole segment 
Discuss surgery 
Repeat 2 monthly 
EMR until flat 
 
Oesophagectomy 
EMR + staging CT, EUS 
+/- PET-CT to confirm 
no submucosal invasion 
Fit with long 
life-
expectancy 
Patient 
preference or 
unfit 
Repeat 2 monthly 
EMR until flat 
NB/ Following EMR-confirmed IMC, consideration must 
also be given to the following: 
- Presence of lymphovascular invasion 
- Grade of tumour differentiation 
Appendix II 
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Appendix III 
 
Raman Peak ID Table 
 
Key:-   - deformational vibrations ;  - stretching vibrations; s - symmetric stretching 
vibrations; as - asymmetric stretching vibrations. 
 
 Assignment Author Tissue/Substance 
207 Calcium carbonate Wentrup-Byrne 1995 Cholesterol 
275 CCC Cassanas 1991 Lactic acid 
350 Ribose, cytosine Hartman 1973  
370 CCC Cassanas 1991 Lactic acid 
385 Cytosine Hartman 1973  
400 Silica Mahadevan-Jansen 
1998a 
Fibre probe on cervix 
424 CCC Barry 1992 Human strateum corneum 
425 CCO Cassanas 1991 Lactic acid 
429 Calcium hydroxyapatite Yu 1996  
430 Cholesterol Yu 1996  
430 δ(OPO) Wentrup-Byrne 1997a Human tooth 
435 Ribose Hartman 1973  
451 O-P-O symmetric bend Nie 1990 Chicken leg bone 
481 Glycogen Kendall C Sigma Aldrich G0885 
492 s (SiOSi) Frank 1994 silicone gel 
500 Cytosine, guanine & 
disulphide 
Hartman 1973  
500-550 Disulphide (S-S) stretch Gnaidecka 1998 Protein 
505  (S-S) Fredericks  1995 Bovine serum albumin 
507 Disulphide Schrader 1995 Nails 
509 Disulphide (S-S) Ozaki 1988  
510 Disulphide (C-S-S-C 
gauche-gauche-gauche) 
Gnaidecka 1998 Protein 
518 Glucose Goetz 1995  
525 Disulphide (C-S-S-C 
gauche-gauche-trans) 
Gnaidecka 1998 Protein 
526  (S-S) Edwards 1995 Strateum corneum 
526  (S-S) Barry 1992 Human strateum corneum 
528  (S-S) Yu 1996 Protein 
529 Desmosine & 
isodesmosine (amino 
acids) 
Manoharan 1996 Elastin 
530-1  (S-S) Edwards 1995 Callus, psoriatic plaque 
533 COC deformation 
(glycosidic ring) 
Maquelin 2000  
533 Glucose Chaiken 2000 Blood 
540 Disulphide (C-S-S-C 
trans-gauche-trans) 
Gnaidecka 1998 Protein 
540 OCO Cassanas 1991 Lactic acid 
547 Cholesterol Yu 1996 Protein 
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553 Glucose Chaiken 2000 Blood 
556  (S-S) Manfait 2000  
574 Tryptophan Siebinga 1992 Eye lens 
575 Cytosine, guanine & 
disulphide 
Hartman 1973  
576 Glycogen Kendall C Sigma Aldrich G0885 
587 Calcium hydroxyapatite Yu 1996 Protein 
591 Apatite Nie 1990 Human tooth enamel 
591 δ(OPO) Wentrup-Byrne 1997a Human tooth 
600 (CH) wagging Barry 1992 Human strateum corneum 
607 Cholesterol Yu 1996 Protein 
618 Phenylalanine(amino 
acid) 
Frank 1994 Collagen 
620 Phenylalanine(amino 
acid) 
Frank 1994 Diseased breast tissue 
620 Phenylalanine Yu 1996  
620-2  (C-S) Edwards 1995 Callus, psoriatic plaque 
622 Phenylalanine Puppels 1999  
623  (C-S) Barry 1992 Human strateum corneum 
623  (C-S) Edwards 1995 Strateum corneum 
624 Adenine Mahadevan-Jansen 1996 DNA (Z), RNA(Z) 
625 Guanine in the C3' 
endo/syn form 
Mahadevan-Jansen 1996 DNA (Z) 
626 Phenylalanine Mahadevan-Jansen 1995  
626  Mahadevan-Jansen 
1998a 
Cervix tissue 
626 Silica Mahadevan-Jansen 
1998a 
Fibre probe on cervix 
637 Ribose & disulphide Hartman 1973 Protein 
640 Guanine Mahadevan-Jansen 1996 RNA(Z) 
642 Thymine Mahadevan-Jansen 1996 DNA (A), RNA (A) 
643  (C-S), amide IV Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
643 Tyrosine Yu 1996  
644 Tyrosine Puppels 1999  
644  (C-S), Amide IV Barry 1992 Human strateum corneum 
650 C-COH Cassanas 1991 Lactic acid 
665 Thymine Mahadevan-Jansen 1996 DNA (B) 
668 Guanine in the C3' 
endo/anti form 
Mahadevan-Jansen 1996 DNA (A), RNA (A) 
669 (C-S) Fredericks  1995 Bovine Serum albumin 
669 (C-S) Maquelin 2000  
669 Thymine Puppels 1999  
670 Breathing of aromatic 
ring of purine bases 
(guanine  & adenine) 
Mahadevan-Jansen 1996 DNA 
670 Guanine Mahadevan-Jansen 1996 DNA (C) 
670 Guanine Hartman 1973  
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670 Thymine & guanine Puppels 1991  
681 Guanine breathing ring Puppels 1991  
682 Guanine in the C2' 
endo/anti form 
Mahadevan-Jansen 1996 DNA (B) 
692 Creatine (O-C=O) 
deformation 
Dou 1996  
704 Calcium carbonate Wentrup-Byrne 1995 Cholesterol 
709 Glycogen Kendall C Sigma Aldrich G0885 
700 Cholesterol Schrader 1995 Brain 
701 Cholesterol Yu 1996  
710 Adenine Hartman 1973  
710 s (Si-C) Frank 1994 silicone gel 
720 Nucleotides Schrader 1995 Breast cancer in mouse 
720 C-N vibration Mahadevan-Jansen 1996 Phospholipid membrane 
722 Adenine Hartman 1973  
724-7 Adenine Mahadevan-Jansen 1996 DNA (A), DNA(B), 
RNA(A) 
725 C-S Siebinga 1992 Eye lens 
725 CH2 rocking Maquelin K  
727 =C-H in plane bend Frank 1994 Breast tissue, lipid 
727 C-C stretch, proline Frank 1995 Normal breast tissue 
727 =C-H in plane bend Frank 1994b  
728 C-C stretch, proline Frank 1995 Oleic acid methyl ester 
729 Adenine breathing ring Puppels 1991  
729 Adenine Mahadevan-Jansen 1996 DNA (Z), RNA(Z) 
730  Pilotto 2001 DL-Lactic acid (C3H6O3) 
742-748 O-P-O Mahadevan-Jansen 1996 DNA (Z), RNA(Z) 
743 in bovine albumin Kendall C Sigma Aldrich A2153 
746 (CH2) Barry 1992 Human strateum corneum 
748 Thymine Mahadevan-Jansen 1996 DNA (B) 
749 Thymine breathing ring Puppels 1991  
750 OCO Cassanas 1991 Lactic acid 
750 Cholesterol Feld 1995 Carotid artery 
759 Tryptophan (amino 
acid) 
Yu 1996  
759 Tryptophan (amino 
acid) 
Nie 1990 Human eye lens 
760 Tryptophan (amino 
acid) 
Erckens 1997 Rabbit & human cornea & 
Rabbit aqueous humour 
760 Tryptophan & tyrosine Erckens 1997 Rabbit lens 
760 Tryptophan (amino 
acid) 
Hartman 1973  
760 Tryptophan (amino 
acid) 
Ozaki 1988  
760 Tryptophan (amino 
acid) 
Miura 1995  
761 Glycogen Kendall C Sigma Aldrich G0885 
762 Collagen Kendall C Sigma Aldrich C7774 
770 Breathing of aromatic Mahadevan-Jansen 1996 DNA 
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ring of pyrimidine bases 
(cytosine & thymine) 
777 Thymine Mahadevan-Jansen 1996 DNA (A), RNA (A) 
780 Cytosine Mahadevan-Jansen 1996 DNA (A), RNA (A) 
780 Nnucleotides Schrader 1995 Breast cancer in mouse 
780 Uracil ring Maquelin 2000  
782 Cytosine ring breathing Mahadevan-Jansen 1996 DNA (B) 
785 O-P-O Mahadevan-Jansen 1996 DNA (C) 
787 Cytosine & uracil Hartman 1973  
788 Thymine, cytosine, O-P-
O 
Puppels 1991 DNA 
790 s O-P-O Puppels 1999 DNA 
790 Acetone (C-C-C) stretch Dou 1996  
800  Wang 1993 pyruvate 
806-813 (809) s O-P-O Mahadevan-Jansen 1996 DNA (A) 
811 Nucleotides Schrader 1995 Breast cancer in mouse 
814 s O-P-O Manfait 2000 DNA 
814 s O-P-O Mahadevan-Jansen 1996 RNA (A) 
814 C-C stretch, backbone Frank 1995 Type I collagen (human 
placenta) 
814 C-C stretch, backbone Frank 1994a Collagen 
814 C-C stretch, backbone 
in collagen 
Kendall C Sigma Aldrich C7774 
815 Phosphate Hartman 1973  
816 C-C Proline ring Fendel 1988 Collagen type I, normal 
skin dermis 
817 C-C stretch, backbone Frank 1995 Infiltrating ductal 
carcinoma 
817 C-C stretch, backbone Frank 1994a Diseased breast tissue 
818 Haemoglobin Mahadevan-Jansen 1995  
818  Mahadevan-Jansen 
1998a 
Cervix tissue 
818 Silica Mahadevan-Jansen 
1998a 
Fibre probe on cervix 
819 Tyrosine Liu CH 1992a  
820 Structural protein Manoharan 1998 Breast 
825-830 Tyrosine (amino acid) Mahadevan-Jansen 1996 Histones 
825-842 O-P-O Mahadevan-Jansen 1996 DNA (B) 
826 in bovine albumin Kendall C Sigma Aldrich A2153 
827 (CCH) aliphatic Barry 1992 Human strateum corneum 
828 Tyrosine (amino acid) Kendall C Sigma Aldrich T8909 
830 C-COOH stretch Wang 1993 Lactate 
830 C-COOH stretch Pilotto 2001 DL-Lactic acid (C3H6O3) 
CH3-CHOH-COOH 
830 C-COOH stretch Wicksted 1995 Lactate 
830 Tyrosine (amino acid) Nie 1990 Human eye lens 
830 Tyrosine (amino acid) Mahadevan-Jansen 1996  
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830 Tyrosine (amino acid) Hartman 1973  
830 Tyrosine (amino acid) Miura 1995  
830 C-COOH Cassanas 1991 Lactic acid 
832 Tryptophan & tyrosine Erckens 1997 Rabbit lens 
832 Tyrosine Puppels 1999  
832 Tyrosine Ozaki 1988  
833 as O-P-O Puppels 1999 DNA 
833 Ribose phosphate 
 
Greve 1996  
835 as O-P-O Mahadevan-Jansen 1996 DNA (B) 
840 Tyrosine (amino acid) Frank 1994a  
840 Glucose Chaiken 2000  
840-860 Polysaccharides Shim 1996  
840-860 Polysaccharides Gnaidecka 1997a  
840-880 Glucose Chaiken 2000 Blood 
846 Tyrosine (amino acid) Kendall C Sigma Aldrich T8909 
847 Glucose Mahadevan-Jansen 
1998a 
Sigma 
849  Frank 1994a Breast 
850 Proline Liu CH 1992a  
850 Tyrosine (amino acid) Mahadevan-Jansen 1996  
850 Tyrosine (amino acid) Miura 1995  
850  Kendall C Bovine albumin Sigma 
Aldrich A2153 
850 (CCH) aromatic Barry 1992 Human strateum corneum 
850-3 (CCH) aromatic Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
853 Tyrosine (amino acid) Nie 1990 Human eye lens 
853 Tyrosine (amino acid) Puppels 1999 DNA 
853 Glycogen Kendall C Sigma Aldrich G0885 
854-6 Tyrosine (amino acid) Mahadevan-Jansen 1996 Histones 
855 Tyrosine Ozaki 1988  
855 C-C stretch Proline ring Frank 1994a Collagen 
855 C-C stretch, proline Frank 1995 Type I collagen (human 
placenta) 
856 Proline Nie 1990 Chicken leg bone 
856  Mizuno 1994 Polysaccharides in glioma 
grade III (human brain 
tissue) 
856 CC strectch, COC 
stretch, 1,4 glycosidic 
link 
Maquelin 2000  
856 C-C stretch collagen 
backbone & Proline ring 
Frank 1994a Diseased breast tissue 
856 C-C stretch, proline Frank 1995 Infiltrating ductal 
carcinoma (breast) 
856 (CC) skeletal 
vibrations, keratotic 
Carter 1998 Healthy human skin 
dermis 
856 C-C stretch collagen Lucassen 1998  
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backbone & Proline ring 
856 Tryptophan & tyrosine Erckens 1997 Rabbit lens 
856 C-C stretch Proline ring 
in collagen 
Kendall C Sigma Aldrich C7774 
857 Tyrosine Yu 1996  
858 C-C stretch in elastin Kendall C Sigma Aldrich E1625 
859 C-C Proline ring Fendel 1988 Collagen type I, normal 
skin dermis 
860 Collagen Redd 1993 Fibrocystic human breast 
tissue 
 
860 Lactate Erckens 1997 Human aqueous humour 
865 Ribose, Tryptophan 
(amino acid) 
Hartman 1973 Protein 
866 Lactic acid Pilotto 2001 DL-Lactic acid (C3H6O3) 
CH3-CHOH-COOH 
868 C-C stretch, 
hydroxyproline 
Frank 1995 Oleic acid methyl ester 
870 C-C stretch, 
hydroxyproline 
Frank 1995 Normal breast tissue 
870 Proline (amino acid) Feld 1995 Malignant breast tissue 
870  Frank 1994b Breast 
872 C-C stretch of 4-
hydroxyproline in 
collagen 
Kendall C Sigma Aldrich C7774 
873 hydroxyproline Nie 1990 Chicken leg bone 
874 C-C stretch, 
hydroxyproline 
Frank 1995 Type I collagen (human 
placenta) 
874 C-C stretch of 4-
hydroxyproline 
Frank 1994a Collagen 
876 C-C stretch, 
hydroxyproline 
Frank 1995 Infiltrating ductal 
carcinoma (breast) 
876 C-C stretch of 4-
hydroxyproline 
Frank 1994a Diseased breast tissue 
879 Tryptophan (amino 
acid) 
Nie 1990 Human eye lens 
880 Tryptophan (amino 
acid) 
Ozaki 1988  
880 Tryptophan (amino 
acid) 
Miura 1995  
880 Tryptophan (amino 
acid) 
Frank 1994a  
880 Tryptophan (amino 
acid) 
Erckens 1997 Rabbit & human cornea 
880 Tryptophan & tyrosine Erckens 1997 Rabbit lens 
880 Tryptophan (amino 
acid) 
Erckens 1997 Rabbit aqueous humour 
883 CH2 rocking, Edwards 1995 Strateum corneum, 
883 (CH2) Barry 1992 Human strateum corneum 
885 Ribose, Tryptophan 
(amino acid) 
Hartman 1973 Protein 
890 Structural protein Manoharan 1998 Breast 
890  Frank 1994b Breast 
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890-1 CH2 rocking, Edwards 1995 Callus, psoriatic plaque 
892 CH2 rocking,  collagen 
hydroxyproline 
Lucassen 1998 Skin 
893  Kendall C Bovine albumin Sigma 
Aldrich A2153 
895 DNA backbone Puppels 1999 DNA 
896 Proline Kendall C Sigma Aldrich T8449 
915 Ribose Hartman 1973 Protein 
917 Deoxyribose (CH2 
deformation) 
Mahadevan-Jansen 1996 DNA (B) 
920 Glucose Mahadevan-Jansen 
1998a 
Sigma 
920 C-C stretch in elastin Kendall C Sigma Aldrich E1625 
920 Lactic acid Pilotto 2001 DL-Lactic acid (C3H6O3) 
920 C-C stretch Proline ring Frank 1994a Diseased breast tissue, 
collagen 
920 C-C Proline ring Frank 1995 Type I collagen (human 
placenta) 
& infiltrating ductal 
carcinoma (breast) 
920 C-C stretch Proline ring 
in collagen 
Kendall C Sigma Aldrich C7774 
921 C-C Proline ring Fendel 1988 Collagen type I, normal 
skin dermis 
921 C-C stretch Proline ring Mahadevan-Jansen 1996 Collagen 
925 DNA backbone Puppels 1999 DNA 
928 DNA backbone, α helix Puppels 1991 Protein 
928-940 C-C Proline, valine Mahadevan-Jansen 
1998a 
 
930 Tryptophan (amino 
acid) 
Hartman 1973 Protein 
930 rCH3 Cassanas 1991 Lactic acid 
931 CH3 rocking,  collagen 
proline 
Lucassen 1998 Skin 
931 (CH3), (C-C) -helix Barry 1992 Human strateum corneum 
932 Skeletal C-C, α helix Puppels 1999 DNA 
932-5 CH3 rocking,  C-C 
stretch α helix keratin 
Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
934 C-C stretch, backbone Frank 1994a Collagen 
934 C-C Proline ring Frank 1995 Type I collagen (human 
placenta) 
935-945 (C-C) skeletal 
vibrations, α helix 
Mahadevan-Jansen 1998 -helix protein secondary 
structure 
935 Collagen Redd 1993 Fibrocystic human breast 
tissue 
936 C-C stretch backbone, 
hydroxyproline & 
collagen 
Caspers 1998 Skin 
936 C-C stretch, backbone 
in collagen 
Kendall C Sigma Aldrich C7774 
937 Glycogen Kendall C Sigma Aldrich G0885 
937 C-C stretch, backbone Frank 1994a Diseased breast tissue 
937 C-C Proline ring Frank 1995 Infiltrating ductal 
carcinoma (breast) 
937 -helix Schrader 1995 nails 
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938 (C-C) skeletal 
vibrations, 
keratotic 
Carter 1998 Healthy human skin 
dermis 
938 Peptide backbone 
stretch 
Yu 1996  
938 C-C backbone Mahadevan-Jansen 1996 Collagen 
939 C-C-N stretching Fredericks  1995 Bovine Serum albumin 
940 C-C-N stretching in 
bovine albumin 
Kendall C Sigma Aldrich A2153 
940 (C-C) of proline and 
valine 
Gniakeda 1997 Normal human skin 
940 Triple helix vibrations Fendel 1988 Collagen type I, normal 
skin dermis 
941 C-C stretch Ozaki 1988 Protein 
944 (C-C) Baraga 1992a Asian skin 
950 4-hydroxyproline Feld 1995 Malignant breast tissue 
955 Hydroxyapatite Manoharan 1992  
956 Carotenoids Mizuno 1994 Human brain tissue, 
acoustic neuroma 
956 (CH3), (CCH) 
olefinic 
Barry 1992 Human strateum corneum 
960 Calcification - 
hydroxyapatite 
Mizuno 1994 Human brain tissue, 
central neurocytoma 
960 Calcification - 
hydroxyapatite 
Clarke 1987 Aortic valve leaflets & 
coronary artery segments 
960 P-O symmetric stretch Nie 1990 Chicken leg bone 
960 P-O symmetric stretch Baraga 1992a Atherosclerotic plaque 
calcified salts 
960 Hydroxyapatite, P-O 
symmetric stretch 
Yu 1996 Calcified plaque 
960 Cholesterol Keller 1994  
961 Apatite Nie 1990 Human tooth enamel 
961 Υs(PO) of PO43-in 
apatite 
Wentrup-Byrne 1997a Human tooth 
961 Phosphate groups Rava 1991 Calcified atherosclerotic 
plaque 
966 Hydroxyapatite Clarke 1987 Calcified plaque 
966 Desmosine & 
isodesmosine (amino 
acids) 
Manoharan 1996 Elastin 
966 Triple helix vibrations Fendel 1988 Collagen type I, normal 
skin dermis 
968 C-OH Manfait 2000  
972 =C-H out of plane 
deformation 
Frank 1994a Breast tissue 
972 C-C Proline ring Frank 1995 Normal breast tissue, Oleic 
acid methyl ester 
972 =C-H out of plane 
deformation 
Frank 1994b Breast 
975 Ribose Hartman 1973 Protein 
975 Deoxyribose (CH2 
deformation) 
Mahadevan Jansen 1996 DNA (B) 
978 Symmetric phosphate 
ion stretching 
Mahadevan Jansen A Phospholipids, glucose-1-
phosphate 
978 Symmetric phosphate 
ion stretching 
Mahadevan Jansen A Human cervix 
978 Phosphorylated proteins Mahadevan Jansen 1995 Human cervical biopsies 
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and nucleic acids 
982 CH2 rocking Edwards 1995 Strateum corneum 
1000-1100 Glucose Chaiken 2000 Blood 
1000-1150 C-C skeletal vibrations Mahadevan Jansen 1996 Phospholipid membrane, 
hydrophobic chains 
1000-1250 Phosphate groups Sajid J 1997 DMPC 
(dimyristoylphosphatidych
oline), a typical lipid, brain 
1000-1200 C-C stretch – lipids Carter 1998 Healthy human skin 
1000 Phenylalanine in bovine 
Albumin 
Kendall C Sigma Aldrich A2153 
1001 Phenylalanine(amino 
acid) 
Kendall C Sigma Aldrich T8324 
1001 Phenylalanine(amino 
acid) 
Feld 1995 Malignant breast tissue 
1001  Lieber 2000 Ovary 
1001-1004 Phenyl ring breathing 
mode 
Shim 1996  
1002 υ(C-C) aromatic ring Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
1002 (C-C) skeletal 
vibrations, β sheet 
Mahadevan-Jansen 1996 -sheet protein secondary 
structure 
1002 Phenylalanine(amino 
acid) 
Yu 1996  
1002 Phenylalanine(amino 
acid) 
Frank 1994a  
1002 Phenylalanine(amino 
acid) 
Frank 1994a Collagen 
1002 Hydroxyproline, 
tyrosine 
Frank 1995 Type I collagen (human 
placenta) 
1002 (CC) aromatic ring Barry 1992 Human strateum corneum 
1003 (CC) aromatic ring 
stretch of phenylalanine 
residue in keratin 
Carter 1998 Healthy human skin 
1003 Phenylalanine(amino 
acid) breathing mode 
Mizuno 1994 Human brain tissue, 
protein 
1003 C-N stretch Erckens 1997 Urea 
1003 C-N stretch of urea Wicksted 1995 Urea 
1003 C-N stretch of urea Lucassen 1998  
1004 Phenylalanine(amino 
acid) 
Erckens 1997 Rabbit lens, aqueous 
humour, cornea & human 
cornea 
1004 Aromatic ring 
(breathing mode) 
Gniakeda 1997 Normal human skin 
1004 Phenylalanine(amino 
acid) 
Maquelin 2000  
1004 Phenylalanine(amino 
acid) 
Puppels 1999  
1004 Phenylalanine(amino 
acid) 
Puppels 1991  
1004 Phenylalanine(amino 
acid) 
Frank 1994a Diseased breast tissue 
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1004 Phenylalanine(amino 
acid) 
Frank 1995 Infiltrating ductal 
carcinoma (breast) 
1004 Phenylalanine(amino 
acid) + Trp aromatic 
ring 
Fredericks  1995 Bovine Serum albumin 
1004 Carotenoid Redd 1993a Beta carotene, Human 
breast carcinoma 
1004 
8.5 Phenylalanine in 
collagen 
Kendall C Sigma Aldrich C7774 
1004 P-O symmetric stretch Nie 1990 Chicken leg bone 
1005 
8.6 Carotenoid 
Redd 1993a Normal human breast 
tissue 
1005 Beta carotene Frank 1995 Breast 
1005 
8.7 Carotenoid 
Redd 1993b Human breast tissue 
Renal cell carcinoma 
(1003) 
1005 Phenylalanine(amino 
acid) 
Hartman 1973 Protein 
1006 C-N stretch of urea Wicksted 1995 Urea, rabbit aqueous 
humour 
1006 Phenylalanine, amino 
acid 
Mahadevan-Jansen 1998 Collagen, histones 
1006 Phenylalanine, amino 
acid 
Ozaki 1988 Protein 
1006 Carotenoids Mizuno 1994 Human brain tissue, 
acoustic neuroma 
1008 C-N stretch Wang 1993 Urea NH2-CO-NH2 
1008 Carotenoids Redd 1993b Carotenoids in normal 
colon 
1010 C-N stretch Erckens 1997 Human aqueous humour 
1013 Urea N-C-N stretch Dou 1996  
1014 Tryptophan (amino 
acid) 
Mahadevan-Jansen 1998  
1015 Tryptophan (amino 
acid) 
Hartman 1973 Protein 
1016 Tryptophan – amino 
acid 
Manoharan 1995 DNA in water 
1017 DNA backbone C-O 
stretch 
Puppels 1999  
1030 Collagen Kendall C Sigma Aldrich C7774 
1031 Proline Yu 1996  
1031 (CC) skeletal cis 
conformation 
Barry 1992 Human strateum corneum 
1031-32 υ(C-C) keratin Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
1032 Phenylalanine(amino 
acid) 
Erckens 1997 Rabbit & human cornea 
Rabbit lens Rabbit 
aqueous humour 
1032 Phenylalanine(amino 
acid) 
Puppels 1999  
1032 proline Frank 1995 Type I collagen (human 
placenta) 
1034  Lieber 2000 Ovary 
 235 
1035 Ribose, 
Phenylalanine(amino 
acid) 
Hartman 1973 Protein 
1035 C-C skeletal cis Lucassen 1998  
1043 Proline Frank 1995 Infiltrating ductal 
carcinoma (breast) 
1043 Formalin artefact Frank 1994a breast tissue 
1046 Lactic acid Pilotto 2001 DL-Lactic acid (C3H6O3) 
CH3-CHOH-COOH 
1048 Glycogen Kendall C Sigma Aldrich G0885 
1050 C-CH3 Cassanas 1991 Lactic acid 
1050 CO stretch, CCC trans 
skeletal stretch 
Carter 1998 Healthy human skin 
dermis 
1057 DNA backbone C-O 
stretch 
Puppels 1999  
1060 OD Cassanas 1991 Methyl lactate 
1061 Lipid Caspers 1998 Strateum corneum 
1062 υ(C-C) skeletal trans 
conformation lipid 
Edwards 1995 Strateum corneum 
1062 (CC) skeletal trans 
conformation 
Barry 1992 Human strateum corneum 
1064 C-C stretch Sajid 1997  
1065 C-O stretch & C-O-C 
sym. stretch - 
phospholipids 
Mizuno 1994 Human brain tissue 
1066 C-C stretch Frank 1994b Breast 
1066 C-C stretch Frank 1994a breast tissue 
1066 Proline Frank 1995 Normal breast tissue 
1066 C-O, C-O-C stretch Ozaki 1988 Phospholipids 
1066 Lipid Gnaidecka 1998  
1066  Lieber 2000 Ovary 
1067 Proline Frank 1995 Oleic acid methyl ester 
1069 Hydroxyapatite shifted 
due to environment 
Mahadevan Jansen A Human cervix 
1070 Symmetric phosphate 
ion stretching 
Mahadevan Jansen A Glucose -1-phosphate, 
collagen 
1070 Symmetric phosphate 
ion stretching 
Mahadevan Jansen A Human cervix 
1070 Collagen/elastin Mahadevan Jansen 1995  
1070  Utzinger 2001 Cervix 
1070 Phosphate / carbonate Baraga 1992a Atherosclerotic plaque 
1070 Phosphate / carbonate Yu 1996  
1071 apatite Nie 1990 Human tooth enamel 
1071 Υas(PO) Wentrup-Byrne 1997a Human tooth 
1072 P-O asymmetric stretch Nie 1990 Chicken leg bone 
1074  Manoharan 1994 Adipose tissue 
1074 Triglycerides Baraga 1992a Adipose tissue from 
human aorta 
1078 C-N stretch Alfano 1991 Benign breast tissue 
1078-1090 C-C, C-O stretch in 
lipids. C-C, PO2 stretch 
Shim 1996  
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in nucleic acids 
1079 C-C stretch Frank 1994a Breast tissue 
1079  Frank 1995 Normal breast tissue 
1079 C-C stretch Frank 1994b Breast 
1080 C-C stretch & PO2- 
sym. stretch - 
phospholipids 
Mizuno 1994 Human brain tissue 
1082 υ(C-C) skeletal random 
conformation lipid 
Edwards 1995 Strateum corneum 
1082  Frank 1995 Oleic acid methyl ester 
1082 PO2- vibration in 
phospholipids and 
nucleic acids 
Gniakeda 1997 Normal human skin 
1082 
8.8 Lipid 
Redd 1993a Normal human breast 
tissue, Lipid (TPE) 
1082 Lipid Redd 1993 Human breast tissue 
1082 Lipid Lucassen 1998  
1082  Gnaidecka 1998 Protein 
1082 (CC) skeletal random 
conformation 
Barry 1992 Human strateum corneum 
1083 Glycogen Kendall C Sigma Aldrich G0885 
1084 Lactic acid Pilotto 2001 DL-Lactic acid (C3H6O3) 
CH3-CHOH-COOH 
1085 Calcium carbonate Wentrup-Byrne 1995 Cholesterol 
1085 C-C stretch Yu 1996 Lipid 
1085 Phenylalanine(amino 
acid) 
Hartman 1973 Protein 
1085 Phosopholipids Feld 1995 Malignant breast tissue 
1086 C-C stretch, PO2 stretch Ozaki 1992 Phospholipids 
1087 Symmetric stretching of 
phosphate groups of the 
polynucleotide chain 
Sajid 1997 DNA 
1090 CO Cassanas 1991 Lactic acid 
1090 PO-2 Mahadevan-Jansen 1998 DNA (C) 
1091 PO-2 Mahadevan-Jansen 1998 DNA (B) 
1094 DNA O-P-O Puppels 1999  
1094 DNA O-P-O Puppels 1991  
1095 s of two ionised 
phosphate oxygens in 
the diphosphate ester 
Mahadevan-Jansen 1998 DNA (B) 
1095 PO-2 Mahadevan-Jansen 1998 DNA (Z), RNA(Z) 
1095 CC stretch, COC 
deformation 1-4 
glycosidic link 
Maquelin 2000  
1099 PO-2 Mahadevan-Jansen 1998 DNA (A), RNA(A) 
1100 Formalin Keller 1994 Formalin 
1100 PO2 stretch Hartman 1973 Protein 
1100 s of two ionised 
phosphate oxygens in 
the diphosphate ester 
Mahadevan-Jansen 1998 DNA (A) 
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1100 Lipid disorganised Gnaidecka 1998  
1100-1110 (C-C) skeletal vibrations Mahadevan-Jansen 1998 Unordered protein 
secondary structure 
1104 C-C stretch lipid Yu 1996  
1108 Desmosine & 
isodesmosine (amino 
acids) 
Manoharan 1996 Elastin 
1118  Frank 1995 Normal breast tissue 
1119  Frank 1995 Oleic acid methyl ester 
1119 C-C stretch Frank 1994a Breast tissue 
1119 C-C stretch Frank 1994b Breast 
1122 C-C stretch lipid Yu 1996  
1123 Glycogen Kendall C Sigma Aldrich G0885 
1123 Glucose Mahadevan-Jansen 
1998a 
Sigma 
1125  Hartman 1973  
1125  Frank 1995 Infiltrating ductal 
carcinoma (breast) 
1126 C-N stretch Puppels 1999 Protein 
1126 C-C stretch - 
phospholipids 
Mizuno 1994 Human brain tissue 
1126 (CC) skeletal trans 
conformation 
Barry 1992 Human strateum corneum 
1127 υ(C-C) skeletal trans 
conformation lipid & 
keratin 
Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
1127 Lipids Caspers 1998 Strateum corneum 
1127  Frank 1995 Type I collagen (human 
placenta) 
1128 C-C stretch Sajid 1997  
1128 Heme vibrational mode Shim 2000  
1129 C-C stretch, lipid Carter 1998 Healthy human skin 
strateum corneum & 
epidermal membrane 
1130 Trans C-C stretch – 
phospholipids 
Mizuno 1994 Human brain tissue, 
glioma grade III 
1130 Lipid Carter 1998 Healthy human skin 
strateum corneum & 
epidermal membrane 
1130 C-C stretch, lipid Gnaidecka 1998  
1130 C-O stretch glucose Dou 1996  
1130 Low density 
lipoproteins 
Yu 1996  
1131 Lactic acid Pilotto 2001 DL-Lactic acid (C3H6O3) 
1135 CO, rCH3 Cassanas 1991 Lactic acid 
1150 Carotenoid Brennan 1997a Human artery 
1150 C=C Carotenoid Keller 1994 Food 
1150 Cholesterol Feld 1995 Carotid artery 
1155 C-C stretch, (COH) Lucassen 1998  
1155 (CC), (COH) Barry 1992 Human strateum corneum 
1156 CN stretch Fredericks  1995 Bovine Serum albumin 
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1156 Carotenoid Frank 1994a  
1156 Carotenoid Redd 1993a Human breast carcinoma, 
Beta carotene 
1157 
8.9 Carotenoid 
Redd 1993a Normal human breast 
tissue 
1157 Carotenoid Redd 1993b Human breast tissue 
Renal cell carcinoma 
(1155) 
1157 Carotenoid Mizuno 1994 Human brain tissue, 
acoustic neurinoma, beta 
carotene 
1158 Carotenoid Feld 1995 Carotid artery 
1158 Carotenoid Redd 1993b Carotenoids in normal 
colon 
1158 NH2 rocking vibration Wicksted 1995 Urea 
1159 C-N Siebinga 1992 Protein in eye lens 
1160 Carotenoid Larrson 1974 Blood plasma 
1162 Ribose Hartman 1973  
1166  Frank 1995 Type I collagen (human 
placenta) 
1167  Frank 1995 Infiltrating ductal 
carcinoma (breast) 
1172 (CC) Barry 1992 Human strateum corneum 
1175 C-O stretching Mahadevan 1995 Human cervical biopsies 
1176 Tyrosine, Phenylalanine Puppels 1999 Protein 
1180  Utzinger 2001 Cervix 
1180 Tyrosine Manoharan 1998 Breast 
1180 Tyrosine Miura 1995  
1180 Cytosine, guanine, 
adenine 
Hartman 1973  
1197 Carotenoid Frank 1994a  
1200-1700 Collagen Wentrup-Byrne 1997a Dentine 
1205 Tyrosine + 
Phenylalanine 
Kendall C Bovine albumin, Sigma 
Aldrich A2153 
1206 4-hydroxyproline 
(amino acid), tyrosine 
Frank 1994a Diseased breast tissue 
1206 4-hydroxyproline 
(amino acid) 
Frank 1994a Collagen 
1206 Hydroxyproline, 
tyrosine 
Frank 1995 Type I collagen (human 
placenta) 
& infiltrating ductal 
carcinoma (breast) 
1207 Tyrosine Nie 1990 Human eye lens 
1207 Tyrosine + 
Phenylalanine (amino 
acid) 
Fredericks  1995 Bovine Serum albumin 
1207  Lieber 2000 Ovary 
1208 Thymine Mahadevan-Jansen 1998 DNA (B) 
1210 hydroxyproline Nie 1990 Chicken leg bone 
1210  Utzinger 2001 Cervix 
1210 Tryptophan, 
phenylalanine 
Hartman 1973  
1211 Tyrosine, 
Phenylalanine, Thymine 
Puppels 1999 Protein 
1226-1243 Amide III - (C-N) Miura 1995 β pleated sheet protein 
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secondary structure in β-
Poly-L-alanine 
1227 Heme vibrational mode Shim 2000  
1227-1247 Amide III (C-N stretch, 
N-H in plane bending) 
-sheet 
Mahadevan-Jansen 1998 -sheet protein secondary 
structure 
1230 Uracil in RNA Yazdi 1999 Cultured breast cells 
1230-1240 Amide III -sheet Carey 1982  
1230-1245 Amide III - (C-N) Miura 1995 β pleated sheet protein 
secondary structure in β-
Poly-L-glutamate 
1234 Antisymmetric 
stretching of phosphate 
groups of the 
polynucleotide chain 
Sajid 1997 DNA 
1235-1270 Amide III (C-N stretch, 
N-H in plane bending) 
unordered 
Mahadevan-Jansen 1998  
1237 Amide III Nie 1990 Human eye lens 
1238 Amide III, random coil Erckens 1997 Rabbit & human cornea 
1238 Amide III in elastin Kendall C Sigma Aldrich E1625 
1238 Cytosine, uracil, Amide 
III 
Hartman 1973  
1239 Thymine Mahadevan-Jansen 1998 DNA (A), RNA (A) 
1240 Amide III - (C-N) Miura 1995 β pleated sheet protein 
secondary structure in β-
Poly-L-lysine 
1240 Vibration of pyrimidine 
bases (cytosine & 
thymine) 
Mahadevan-Jansen 1996 DNA 
1240 Amide III (C-N) Alfano 1991 Benign breast tumour 
1240 Amide III Frank 1994a  
1240 Amide III in collagen Kendall C Sigma Aldrich C7774 
1240 Amide III - (C-N) Liu CH 1992a Uterus cancer 
1240 Amide III Keller 1994 Caractous lens 
1240 Thymine Puppels 1999 Protein 
1240-1260 Amide III unordered Carey 1982  
1243 Amide III Keller 1994 Liver - collagen 
1243 Amide III Nie 1990 Chicken leg bone 
1243 Amide III Erckens 1997 Rabbit lens 
1243-48 Amide III - (C-N) Miura 1995 irregular protein secondary 
structure in β-Poly-L-
lysine pH4 
1244 (CH2) wagging, (CN) 
amide III disordered 
Barry 1992 Human strateum corneum 
1245 CO, OH Cassanas 1991 Lactic acid 
1245 Amide III, random coil Mizuno 1994 Human brain tissue, 
glioma grade III 
1245 Keratotic Carter 1998 Healthy human skin 
dermis 
1245  Utzinger 2001 Cervix 
1245 Amide III: keratin, 
disordered collagen 
Lucassen 1998  
1245-1305 Amide III (C-N stretch, Mahadevan-Jansen 1998 Histones 
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N-H in plane bending) 
1246 Amide III Fredericks  1995 Bovine Serum albumin 
1246 Amide III (C-N) Mahadevan 1995 Collagen & DNA 
1246 Amide III (C-N) Mahadevan 1995 Human cervix precancer 
1246 Amide III (C-N 
stretching vibrations) 
Mahadevan 1995 Human cervical biopsies 
1246 Amide III (C-N 
stretching vibrations) 
Liu CH 1992a  
1246 Amide III (C-N 
stretching vibrations) 
Gnaidecka 1998 Protein 
1247 Amide III Frank 1995 Type I collagen (human 
placenta) 
& infiltrating ductal 
carcinoma (breast) 
1247 Amide III Frank 1994a Diseased breast tissue 
1247  Keller 1994 Neutrogena sarcoma 
(brain) - collagen 
1247 Amide III Frank 1994a Collagen 
1247 Amide III - (C-N) Liu CH 1992a Endometrium cancer 
1247 Collagen Redd 1993 Fibrocystic human breast 
tissue 
 
1248 Amide III Manoharan 1998 Breast 
1248 PO2- vibration in 
phospholipids and 
nucleic acids 
Gniakeda 1997 Normal human skin 
1248 Amide III (C-N stretch, 
N-H in plane bending) 
Mahadevan-Jansen 1998 Collagen 
1249 Amide III - (C-N) Miura 1995 irregular protein secondary 
structure in β-Poly-L-
glutamate pH 11 
1250 Cytosine, uracil, Amide 
III 
Hartman 1973  
1250 Amide III Brennan 1997a Human artery 
1250 Amide III Ozaki 1992  
1250 Cytosine Mahadevan-Jansen 1998 DNA (B) 
1250 Amide III Fendel 1988 Collagen type I, normal 
skin dermis 
1252 Amide III Baraga 1992b Aorta 
1253 Amide III random coil 
protein 
Schrader 1995 Breast cancer in mouse 
1254 Adenine Puppels 1991 Protein 
1254 Amide III (C-N stretch, 
N-H in plane bending) 
Mahadevan-Jansen 1998 Elastin 
1255 Cytosine Puppels 1999 Protein 
1256 Glycogen Kendall C Sigma Aldrich G0885 
1258-1304 Amide III (C-N stretch, 
N-H in plane bending) 
Mahadevan-Jansen 1998 -helix protein secondary 
structure 
1260-1310 Amide III (C-N stretch, 
N-H in plane bending) 
Miura 1995 -helix protein secondary 
structure 
1259 Amide III Frank 1994a Silicone gel 
1260 Tyrosine Miura 1995 Unordered protein 
secondary structure 
1260 Structural protein Manoharan 1998 Breast 
1260 Symmetric CH3 Frank 1994a Silicone gel 
 241 
deformation 
1260 Amide III Nie 1990 Chicken leg bone 
1260 Amide III Feld 1995 Malignant breast tissue 
1260-1280 Amide III Fredericks  1995 Bovine Serum albumin 
1261 Lipid Manoharan 1994  
1262 Amide III - (C-N) Liu CH 1992a Benign or normal cervix 
1262 Amide III - (C-N) Liu CH 1992a Benign or normal uterus 
1262 Amide III - (C-N) Liu CH 1992a Benign or normal 
endometrium 
1262 Amide III - (C-N) Liu CH 1992a Benign or normal ovary 
1264 Amide III in collagen Kendall C Sigma Aldrich C7774 
1265-1300 Amide III (C-N stretch, 
N-H in plane bending) 
Carey 1982 -helix protein secondary 
structure 
1265-1348 Amide III - (C-N) Miura 1995 -helix protein secondary 
structure in α-Poly-L-
alanine 
1265 =C-H in plane 
deformation 
Frank 1994b Breast 
1265 =C-H in plane 
deformation 
Frank 1994a breast tissue 
1265 Amide III Frank 1995 Normal breast tissue 
1267 =C-H in plane 
deformation 
Keller 1994  
1267 Amide III Frank 1995 Infiltrating ductal 
carcinoma (breast) 
1267  (=C-H) Mahadevan-Jansen 1998 Phospholipid membrane 
1267  (=C-H) Keller 1994 Coronary Artery, 
unsaturated fatty acids 
1267 Amide III Frank 1994a Lymph node 
1267 Amide III Frank 1994a Diseased breast tissue 
1267 Amide III Frank 1994a Collagen 
1268 Amide III Frank 1995 Oleic acid methyl ester 
1268 Amide III - (C-N)  and 
(NH) in bovine 
albumin 
Kendall C Sigma Aldrich A2153 
1269 Amide III Frank 1995 Type I collagen (human 
placenta) 
1269 Amide III -helix Mizuno 1994 Human brain tissue 
1270  Utzinger 2001 Cervix 
1270 Amide III - (C-N) Liu CH 1992a Endometrium cancer 
1271 Amide III - (C-N)  and 
(NH) 
Gniakeda 1997 Normal human skin 
1271 Amide III (C-N stretch, 
N-H in plane bending) 
Mahadevan-Jansen 1998 Collagen 
1273 Amide III Fendel 1988 Collagen type I, normal 
skin dermis 
1274 (NH) wagging, (CN) 
amide III -helix 
Barry 1992 Human strateum corneum 
1280 Amide III Clarke 1993 Phospholipid membrane 
1290 Amide III - (C-N) Miura 1995 -helix protein secondary 
structure in α-Poly-L-
glutamate 
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1295 Amide III - (C-N) Miura 1995 -helix protein secondary 
structure in α-Poly-L-
lysine 
1296 (CH2) Barry 1992 Human strateum corneum 
1296 Keratotic Carter 1998 Healthy human skin 
dermis 
1296 (CH2) Edwards 1995 Strateum corneum 
1297 Lipid Carter 1998 Healthy human skin 
strateum corneum & 
epidermal membrane 
1300 (C-C) (C-N) Alfano 1991 Benign breast tissue 
1300 Amide III Sajid 1997 Bovine insulin 
1300 C-H bending Liu CH 1992a Lipid 
1300 Phospholipids - CH2 
twist and wagging 
Mizuno 1994 Human brain tissue 
1300 Lipids – fatty acids Manoharan 1998 Breast 
1300 CH Cassanas 1991 Lactic acid 
1300 Adenine , cytosine Hartman 1973  
1302 Lipid Redd 1993a Lipid (TPE) 
1302 Lipid Redd 1993b Human breast tissue 
1302 
8.10 Lipid 
Redd 1993a Normal human breast 
tissue 
1302 Lipid Redd 1993 Human breast tissue 
1303 CH2 twisting Frank 1994b Breast 
1303 Triglycerides Baraga 1992a Adipose tissue from 
human aorta 
1303 Adenine Puppels G  
1303  CH2 Mahadevan-Jansen 1998 Phospholipid membrane 
1303 CH2 twisting Frank 1994a Normal breast tissue 
1303 CH3CH2 twisting Frank 1994a Diseased breast tissue 
1303 CH3CH2 twisting Frank 1995 Normal breast tissue & 
infiltrating ductal 
carcinoma 
1304 CH3CH2 twisting Frank 1995 Oleic acid methyl ester 
1306 Lipid Redd 1993b Human colon 
1309 CH2 twisting & 
wagging in lipids 
Gniakeda 1997 Normal human skin 
1310-16 Δ(CH2) Edwards 1995 Callus, psoriatic plaque 
1316 Histidine Kendall C Sigma Aldrich T8776 
1316 Guanine Mahadevan-Jansen 1998 DNA (Z), RNA(Z) 
1317 CH2 twisting Redd 1993a Skin 
1318 Guanine Mahadevan-Jansen 1998 DNA (A), RNA (A) 
1319 CH3CH2 twisting Frank 1995 Type I collagen (human 
placenta) 
1319 CH3CH2 twisting Frank 1994a Collagen 
1320 Guanine Hartman 1973  
1321 in bovine albumin Kendall C Sigma Aldrich A2153 
1322 C-H Siebinga 1992  
1325 Tryptophan (amino 
acid) ring vibrations 
Liu 1992a  
1325 Nucleic acid ring 
vibrations 
Feld 1995  
1330 Tryptophan (amino 
acid) (C-C) 
Liu 1992a Cervix cancer 
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1330 Tryptophan (amino 
acid) (C-C) 
Liu 1992a Uterus cancer 
1330 Tryptophan (amino 
acid) (C-C) 
Liu 1992a Ovary cancer 
1330 C-H Mahadevan Jansen 
1998a 
Nucleic acid bases & 
DNA, phospholipids 
1330 C-H Mahadevan Jansen 
1998a 
Human cervix precancer 
1330  Utzinger 2001 Cervix 
1330 DNA Yazdi 1999 Cultured breast cells 
1330 CH Cassanas 1991 Lactic acid 
1333 Glycogen Kendall C Sigma Aldrich G0885 
1333 Guanine Mahadevan Jansen 1998 DNA (B) 
1334 CH deformation Maquelin 2000  
1335 Nucleic acids Manoharan 1995 Colon 
1335 Adenine Mahadevan Jansen 1998 DNA (A), RNA (A) 
1337 Nucleic acid, purine 
bases (adenine, guanine) 
Boustany 1999 Colon 
1337 Nucleic acid, purine 
bases (adenine, guanine) 
Fodor 1985  
1337 Purine bases (adenine, 
guanine) 
Manoharan 1995 DNA in water 
1337 Adenylates Boustany 1999 Colon mucosa 
1338 Tryptophan, amino acid Mahadevan Jansen 1998  
1339 Adenine Mahadevan Jansen 1998 DNA (B) 
1339-41  Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
1340 Tryptophan (amino 
acid) 
Erckens 1997 Rabbit & human cornea 
1340 Tryptophan (amino 
acid) 
Erckens 1997 Rabbit aqueous humour 
1340 Nucleic acid Feld 1995 Colon  adenocarcinoma 
1343 CH3CH2 wagging Frank 1994a Diseased breast tissue 
1343 CH3CH2 wagging Frank 1994a Collagen 
1343 CH3CH2 wag Frank 1995 Type I collagen (human 
placenta) 
& infiltrating ductal 
carcinoma (breast) 
1343  Wicksted 1995 Rabbit aqueous humour 
1343 Adenine Hartman 1973  
1350 Glucose Mahadevan-Jansen 
1998a 
Sigma 
1358  Redd 1993 Normal renal parenchyma 
& renal cell carcinoma 
1359  Redd 1993 Hepatocellular carcinoma 
1360  Redd 1993 Normal hepatic 
parenchyma 
1360  Redd 1993a Myoglobin 
1360  Erckens 1997 Human aqueous humour 
1361 Tryptophan Mahadevan-Jansen 1998  
1365 Guanine, tryptophan Hartman 1973  
1372 Lipid Redd 1993 Human colon 
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1375  Redd 1993a Myoglobin 
1376 Thymine, guanine, 
adenine 
Puppels 1991  
1377 Glycogen Kendall C Sigma Aldrich G0885 
1380 CH3 OH Cassanas 1991 Lactic acid 
1385 (CH3) symm Barry 1992 Human strateum corneum 
1400 Uracil, adenine Hartman 1973  
1400  Utzinger 2001 Cervix 
1401 Symmetric CH3 
bending in proteins 
Mahadevan 1995  
1410 OH Cassanas 1991 Methyl lactate 
1412 Antisymmetric CH3 
deformation 
Frank 1994a Silicone gel 
1420 OH, CO Cassanas 1991 Lactic acid 
1421 (CH3) Barry 1992 Human strateum corneum 
1421 Guanine, adenine Puppels 1991  
1438 (CH2) scissoring Barry 1992 Human strateum corneum 
1438 CH2 deformation Shim 1996  
1439 CH2 scissoring 
deformation 
Frank 1994a breast tissue 
1439 CH3, CH2 deformation Frank 1995 Normal breast tissue 
1439 CH2 deformation McCreery 1995 Human breast biopsy 
1439 CH2 deformation due to 
lipids and proteins 
Mizuno 1994 Human brain tissue 
1439 CH2 scissoring 
deformation 
Frank 1994b Breast 
1440 Lipid Manohran 1994  
1441 CH2 bending Feld 1995 Fibrous atherosclerotic 
plaque 
1441 Lipid Keller 1994 Liver 
1442 CH3, CH2 deformation Frank 1995 Oleic acid methyl ester 
1442 Lipid Redd 1993b Human breast tissue 
Colon tissue 
1442 
8.11 Lipid 
Redd 1993a Normal human breast 
tissue 
1442 Lipids – fatty acids Manoharan 1998 Normal breast tissue 
1443 elastin Kendall C Sigma Aldrich E1625 
1444 Lipid Redd 1993a Lipid (TPE) 
1444 Triglycerides Baraga 1992a Adipose tissue from 
human aorta 
1445 (CH2) or (CH3) Liu CH 1992a Cervix cancer 
1445 (CH2) or (CH3) Liu CH 1992a Uterus cancer 
1445 (CH2) or (CH3) Liu CH 1992a Benign or normal cervix 
1445 (CH2) or (CH3) Liu CH 1992a Benign or normal 
endometrium 
1445 (CH2) or (CH3) Liu CH 1992a Benign or normal ovary 
1445 (CH2) or (CH3) Alfano 1991 Human breast tissue. 
Benign and Malignant 
tumours 
1445 CH2 deformation Frank 1994a breast tissue 
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1445 CH2 bending mode Manoharan 1998 Normal breast tissue 
1445 CH3CH2 deformation 
in collagen 
Kendall C Sigma Aldrich C7774 
1447 CH3CH2  bending 
modes in bovine 
albumin 
Kendall C Sigma Aldrich A2153 
1448 CH2 deformation Nie 1990 Chicken leg bone 
1448 Deoxyribose Mahadevan-Jansen 1998 DNA (B) 
1448-9 Δ(CH2) scissoring Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
1449 CH2 deformation Frank 1994a Lymph node 
1450 Glucose Chaiken 2000 Blood 
1450 CH bending Erckens 1997 Rabbit & human cornea 
1450 CH bending Erckens 1997 Rabbit aqueous humour 
1449 CH3CH2  bending 
modes 
Fredericks  1995 Bovine Serum albumin 
1450 CH3CH2 deformation Frank 1994a Diseased breast tissue 
1450 CH2 bending Brennan 1995 Human artery 
1450 CH2 bending mode Manoharan 1998 Diseased breast tissue 
1450 (CH2) or (CH3) Liu CH 1992a Endometrium cancer 
1450  Liu CH 1992a Elastin & collagen 
1450 CH3, CH2 deformation Frank 1995 Infiltrating ductal 
carcinoma 
1451 C-H bend Baraga 1992a Normal human aorta 
1451 CH3, CH2 deformation Frank 1995 Type I collagen (human 
placenta) 
1451 CH3CH2 deformation Frank 1994a Collagen 
1451 CH2 bending Ozaki 1988  
1451-1454 CH2 bending Mahadevan Jansen 
1998a 
Histones 
1452 Structural protein Manoharan 1998 Breast 
1452 (CH2) scissoring in 
lipids & (CH2) (CH3) 
in proteins 
Gniakeda 1997 Normal human skin 
1452 CH2 bending Feld 1995 Malignant breast tissue 
1452 CH2 in plane bending Rava 1991 Normal aorta 
1453 (CH2) or (CH3) Liu CH 1992a Ovary cancer 
1453 (CH2) or (CH3) Liu CH 1992a Benign or normal uterus 
1453 C-H bending modes Baraga 1992b Aorta 
1454 CH3 bending CH2 
scissors 
Mahadevan Jansen 
1998a 
Elastin & collagen & 
phospholipids 
1454 CH3 bending CH2 
scissors 
Mahadevan Jansen 
1998a 
Human cervix 
1454 CH3 asymmetric 
bending of proteins 
Mahadevan 1995  
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1454  Utzinger 2001 Cervix 
1455 CH3 Cassanas 1991 Lactic acid 
1455 Glycogen Kendall C Sigma Aldrich G0885 
1455 CH2 deformation Frank 1994b Breast 
1456 CH3 bending in elastin Kendall C Sigma Aldrich E1625 
1456  Lieber 2000 Ovary 
1457  Pilotto 2001 DL-Lactic acid (C3H6O3) 
CH3-CHOH-COOH 
1458 Nucleic acid Feld 1995 Colon  adenocarcinoma 
1460 Pentose sugar vibration 
due to  CH2 
Mahadevan-Jansen 1998 DNA 
1462 Deoxyribose Mahadevan-Jansen 1998 DNA (B) 
1475 CH3 Cassanas 1991 Lactic acid 
1480 Vibration of purine 
bases (adenine & 
guanine) 
Mahadevan-Jansen 1996 DNA 
1480 DNA Yazdi 1999 Cultured breast cells 
1485 Nucleic acids Manoharan 1995 Colon 
1485 Purine bases Manoharan 1995 DNA in water 
1485 Nucleic acid, purine 
bases (adenine, guanine) 
Boustany 1999 Colon 
1485 Nucleic acid, purine 
bases (adenine, guanine) 
Fodor 1985  
1487 Nucleic acid Manoharan 1995 Colon 
1491 Formalin Frank 1994a  
1500-1650 Heme Ozaki 1988  
1509 Phenylalanine Fredericks 1995 Bovine Serum albumin 
1510 Adenine, guanine Puppels 1991  
1512  Lieber 2000 Ovary 
1517 Carotenoid Frank 1994b  
1520-1670 Tryptophan & tyrosine Yazdi 1999 Cultured breast cells 
1520 C=C Carotenoid Keller 1994 Food 
1520 Carotenoid Larrson 1974 Blood plasma 
1522 Carotenoid Feld 1995 Carotid artery 
1523 Carotenoid Redd 1993 Human breast tissue 
Renal cell carcinoma 
1523 
8.12 Carotenoid 
Redd 1993a Normal human breast 
tissue 
1524 Carotenoid Mizuno 1994 Human brain tissue, 
acoustic neuroma 
1525 Carotenoid Redd 1993a Beta carotene 
1525 Carotenoid Redd 1993a TS Human breast carcinoma 
1525 Carotenoid Redd 1993a Human breast carcinoma 
1528 Carotenoid Manoharan 1994 Carotenoids in normal 
 247 
colon 
1529 Carotenoid Redd 1993b Carotenoids in normal 
colon 
1540 Amide II Sajid 1997 Bovine insulin 
1541 Tyrosine Siebinga 1992  
1547 Tryptophan Nie 1990 Human eye lens 
1550 Tryptophan Hartman 1973  
1552 (NH), (CN) Amide II Barry 1992 Human strateum corneum 
1553 Tryptophan Mahadevan-Jansen 1998  
1554  Frank 1994b Type I collagen (human 
placenta) & infiltrating 
ductal carcinoma (breast) 
1555 Tryptophan Manoharan 1995 DNA in water 
1556 Tryptophan Fredericks  1995 Bovine Serum albumin 
1570 Vibration of purine 
bases (adenine & 
guanine) 
Mahadevan-Jansen 1996 DNA 
1570 nucleotides Schrader 1995 Breast cancer in mouse 
1575 Guanine, adenine 
tryptophan 
Hartman 1973  
1576 Nucleic acid Feld 1995 Colon  adenocarcinoma 
1577 Guanine, adenine Puppels 1991  
1580 nucleotides Schrader 1995 Breast cancer in mouse 
1580 DNA Yazdi 1999 Cultured breast cells 
1580  Utzinger 2001 Cervix 
1585 Nucleic acid, purine 
bases (adenine, guanine) 
Boustany 1999 Colon 
1585 Nucleic acid, purine 
bases (adenine, guanine) 
Fodor 1985  
1585 υ(C-O) olefinic Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
1585 (C=C) olefinic Barry 1992 Human strateum corneum 
1593 Purine bases Manoharan 1995 DNA in water 
1600  Hartman 1973  
1602 Phenylalanine Siebinga 1992  
1602 Tyrosine Manoharan 1995 Tyrosine, colon 
adenocarcinoma 
1606 Phenylalanine Fredericks  1995 Bovine Serum albumin 
1607 Phenylalanine in bovine 
albumin 
Kendall C Sigma Aldrich A2153 
1610 Tyrosine Boustany 1999 Colon mucosa 
1610 Tyrosine Spiro 1987 Protein bands 
1612 C=C stretching Manoharan 1995 Benzene 
 
1616 Tyrosine Fredericks 1995 Bovine Serum albumin 
1617 Tyrosine, phenylalanine Puppels 1991  
1620 Tryptophan, tyrosine, 
phenylalanine, uracil 
Hartman 1973  
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1620 Tryptophan Boustany 1999 Colon mucosa 
1620 Tryptophan Spiro 1987 Protein bands 
1622 Tryptophan Manoharan 1995 DNA in water 
1637 Amide I (C=O) Frank 1994a Diseased breast tissue 
1637 Amide I (C=O) Frank 1994a Collagen 
1640 OH bending Erckens 1997 Water 
1642 Amide I (C=O) Mahadevan-Jansen 1998 Collagen 
1648-1661 Amide I (C=O) Mahadevan-Jansen 1998 Histones 
1645 Bending mode  Water 
1645 Amide I (C=O stretch) Miura 1995 -helix protein secondary 
structure in α-Poly-L-
lysine 
1645-1660 Amide I (C=O stretch) Carey 1982 -helix protein secondary 
structure 
1665-1680 Amide I (C=O stretch) Carey 1982 -sheet protein secondary 
structure 
1660-1670 Amide I (C=O stretch) Carey 1982 Unordered protein 
secondary structure 
1645-1655 Amide I (C=O stretch) Miura 1995 -helix protein secondary 
structure 
1665-1680 Amide I (C=O stretch) Miura 1995 -sheet protein secondary 
structure 
1655-1665 Amide I (C=O stretch) Miura 1995 Unordered protein 
secondary structure 
1654-1662 Amide I (C=O stretch) 
-helix 
Mahadevan-Jansen 1998 -helix protein secondary 
structure 
1665-1680 Amide I (C=O stretch) Mahadevan-Jansen 1998 -sheet protein secondary 
structure 
1654-1685 Amide I (C=O stretch) Mahadevan-Jansen 1998 Unordered protein 
secondary structure 
1650 Amide I Baraga 1992a Normal human aorta 
1650 lipid Boustany 1999 Colon mucosa 
1650 Pyrimidine bases 
(cytidine, thymidine) ? 
Manoharan 1995 DNA in water 
1650 C=C lipid bands Boustany 1999 Colon 
1650 Amide I (C=O) 
 
Sajid 1997 Bovine insulin 
1650  Wang 1993 Ascorbate 
1650  Erckens 1997 Rabbit aqueous humour 
1650 Amide I (C=O stretch) 
(C=O) 
Brennan 1994 Human artery 
1650-1666 C=C vibration cis-
isomer in fatty acid 
chain 
Mahadevan-Jansen 1998 Phospholipid membrane 
1651 Amide I, (C=O) Alfano 1991 Benign breast tissue and 
malignant tumours 
1651-1664 Amide I, (C=O) Carter 1998 Healthy human skin 
1651 Amide I, (C=O) in 
collagen 
Kendall C Sigma Aldrich C7774 
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1651 Amide I, (C=O stretch) Liu CH 1992a Ovarian cancer 
1651-4 υ(C-O) Amide I, α helix Edwards 1995 Strateum corneum, Callus, 
psoriatic plaque 
1652 Lipid Redd 1993a Zhe Chuan 
Feng, Kwok to Yue, 
Gansler TS 
Lipid (TPE) 
1652 Lipid Redd 1993 Human breast tissue 
1652 Amide I Miura 1995 -helix protein secondary 
structure in α-Poly-L-
glutamate 
1652 (C=O) Amide I -helix Barry 1992 Human strateum corneum 
1653 Lipid Redd 1993 Human breast tissue 
Human colon 
1653 
8.13 Lipid 
Redd 1993a Normal human breast 
tissue 
1653 Amide I protein Mizuno 1994  
1653 Amide I (C=O stretch) 
in bovine albumin 
Kendall C Sigma Aldrich A2153 
1654 -helix Schrader 1995 nails 
1654 C=C stretch Olefinic McCreery 1994 Breast biopsy tissue 
1654 C=C stretch Frank 1994a Breast tissue 
1654 Amide I Frank 1995 Normal breast tissue 
1654 C=C stretch Frank 1994b Breast 
1655 C=C stretch of 
unsaturated fatty acid 
chains 
Baraga 1992b Aorta 
1655 Amide I Frank 1995 Oleic acid methyl ester 
1655 Amide I protein (C=O 
stretch) 
Keller 1994 Coronary Artery 
1655 Amide I (C=O stretch) Frank 1994a Lymph node 
1655 Amide I (C=O stretch) Liu 1992a Endometrial cancer 
1655 Amide I (C=O stretch) Miura 1995 -helix protein secondary 
structure in α-Poly-L-
alanine 
1656 Amide I (C=O stretch) Mahadevan Jansen 
1998a 
Collagen 
1656 Amide I (C=O stretch) Mahadevan Jansen 1996 Human cervix 
1656 Amide I (C=O stretch) Mahadevan Jansen 1995  
1656  Utzinger 2001 Cervix 
1656 Amide I (C=O stretch) Liu 1992a Benign or normal 
endometrium 
1656 Amide I (C=O stretch) Miura 1995 irregular protein secondary 
structure in β-Poly-L-
glutamate pH 11 
1657 Amide I (C=O stretch) Liu 1992a Cervical cancer 
1657 Lipids – fatty acids Manoharan 1998 Breast 
1657 Lipids Manoharan 1995 Colon 
1657 Amide I (C=O stretch) Feld 1995 Malignant breast tissue 
1657 Amide I Frank 1995 Infiltrating ductal 
carcinoma (breast) 
1657 Amide I (C=O stretch) Frank 1994a Diseased breast tissue 
1658 Amide I (C=O stretch) Ozaki 1992  
1658 Amide I Baraga 1992b Aorta 
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1659 Amide I, (C=O) Alfano 1991 Benign breast tumours 
1659 Amide I (C=O stretch) Liu CH 1992a Benign or normal ovary 
1659 Amide I (C=O stretch) Liu CH 1992a Benign or normal cervix 
1659 Amide I (C=O stretch) Liu CH 1992a Benign or normal uterus 
1659 Amide I (C=O stretch) Liu CH 1992a Uterus cancer 
1659 Amide I (C=O stretch) ά 
helical 
Mizuno 1994 Human brain tissue 
1659 Amide I (C=O stretch) Fredericks 1995 Bovine Serum albumin 
1659 Amide I (C=O stretch) Greve 1996  
1661 Amide I (C=O) in 
elastin 
Kendall C Sigma Aldrich E1625 
1661 Amide I (C=O) Gniakeda 1997 Normal human skin 
1662 Nucleic acid Feld 1995 Colon  adenocarcinoma 
1662 Triglycerides Baraga 1992a Adipose tissue from 
human aorta 
1662 Nucleic acids Manoharan 1996 Colon 
1664 Amide I (C=O stretch) Carter 1998 Healthy human skin 
1664  Lieber 2000 Ovary 
1665 Amide I (C=O stretch) Miura 1995 irregular protein secondary 
structure in β-Poly-L-
lysine pH 4 
1665 Amide I (C=O stretch) Frank 1994a Collagen 
1665 Amide I Frank 1995 Type I collagen (human 
placenta) 
1665 Amide I (C=O stretch) Keller 1994 Liver - collagen 
1665 Carbonyl vibration 
mode 
Feld 1995 Fibrous atherosclerotic 
plaque 
1666 C=O stretching modes 
of pyrimidine bases 
Sajid 1997 DNA 
1667 Structural protein Manoharan 1998 Malignant breast 
1668 Amide I (C=O stretch) Mahadevan-Jansen 1998 Elastin 
1669 Amide I (C=O stretch) Nie 1990 Human eye lens 
1669 Protein Schrader 1995 Breast cancer in mouse 
1669 Amide I (C=O stretch) Miura 1995 β pleated sheet protein 
secondary structure in β-
Poly-L-alanine 
1669 Amide I (C=O stretch) Rava 1991 Normal aorta 
1670-1680 C=C vibration trans-
isomer in fatty acid 
chain 
Mahadevan-Jansen 1998 Phospholipid membrane 
1670 Amide I Nie 1990 Chicken leg bone 
1670 Amide I (C=O stretch) Mahadevan-Jansen 1998 Pure protein - β pleated 
sheet 
1670 Amide I (C=O stretch) Mahadevan-Jansen 1998 Collagen 
1670 Amide I (C=O stretch) Frank 1994a  
1670 Amide I (C=O stretch) Erckens 1997 Rabbit lens 
1670 Amide I (C=O stretch) Miura 1995 β pleated sheet protein 
secondary structure in β-
Poly-lysine 
1672 Amide I (C=O stretch) Miura 1995 β pleated sheet protein 
secondary structure in β-
Poly-L-glutamate 
1683 Amide I (C=O stretch) Mahadevan-Jansen 1998 Bound protein - regular 
uncharacterised secondary 
structure 
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1717 C=O stretching modes 
of purine bases 
Sajid 1997 DNA 
1725  Wang 1993 Lactate 
1725 C=0 Cassanas 1991 Lactic acid 
1726 Lactate Goetz 1995  
1736 ester stretching mode 
C=O 
Sajid 1997 DMPC 
(dimyristoylphosphatidych
oline), a typical lipid 
1740 (C=O) -lipid Keller 1994 Food, coronary artery 
1743  Frank 1995 Oleic acid methyl ester, 
normal human breast tissue 
1743 C=O stretch Frank 1994a Breast tissue 
1743 C=O stretch Frank 1994b Breast 
1743 (C=O) lipid Barry 1992 Human strateum corneum 
1747 C=0 stretch Baraga 1992b Aorta 
1750 C=O Fendel 1988 Normal skin dermis 
1752 Triglycerides Baraga 1992a Adipose tissue from 
human aorta 
1768 (COO) Barry 1992 Human strateum corneum 
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Appendix IV 
 
Initial Probe-Spectrometer Evaluation 
Experiment 1. Temporal variation in PTFE spectra. 
 
The laser and CCD were switched on at time 0. 5 s PTFE spectra were measured at 3 minute 
intervals except for the first measurement which was made at 12 minutes (blue spectrum in 
Figure VI-1). 
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Figure VI-1. Temporal variations in PTFE spectra. 
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Figure VI-2. Temporal variation in PTFE spectral intensity at 730 cm
-1
 every 3 mintues. 
 
 
Significant variation occurred over the first 15 minutes. This is due to the laser ‘warming up’ 
and the CCD stabilising after being turned on. Following this preliminary experiment the 
system was switched on a minimum of 20 minutes before spectral measurements were taken. 
 
Experiment 2. Switching the laser ‘on’ and ‘off’. 
 
After the laser had ‘warmed up’ the effect of repeatedly switching the laser off for short 
periods between measurements was evaluated (Figure VI-3). A series of PTFE spectra were 
measured; the laser was switched off for 2 minutes between each measurement. Consistent 
spectra were recorded (Figure VI-3). 
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Figure VI-3. PTFE spectra. The laser was switched off for two minutes between each measurement. 
 
Experiment 3. Effect of disconnecting the laser source. 
 
The effect of disconnecting the Raman probe from the laser source between each 
measurement was evaluated. Figure VI-4 shows that consistent spectra were measured. 
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Figure VI-4. PTFE spectra. Between each measurement the probe was disconnected 
from the laser source. 
 
Experiment 4. Does repositioning of the probe on the PTFE / green 
glass between readings effect spectral measurement? 
 
Between measurements the probe was removed from contact with the PTFE and green glass 
standards. Repeat measurements assessed any variation produced by probe contact and probe 
angle. Figures VI-5 and VI-6 show the effects. Although peak position was consistent, 
variation in intensity was marked. Adequate contact between the probe and the standards was 
found to be the significant source of this variation. 
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Figure VI-5. PTFE spectra. Between each measurement the probe was moved and then 
repositioned. 
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Figure VI-6. Green glass spectra. Between each measurement the probe was moved and 
then repositioned. 
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Experiment 5. Can the probe acquire Raman spectra from a tissue 
phantom? 
 
Prior to taking measurements from human oesophageal tissue, spectra were acquired using 
the probe-spectrometer system from a porcine tissue phantom. A 830 nm monochromatic 
laser was used to excite the tissue for 1, 5, and 10 seconds. 
 
Figure VI-7 shows 5 s porcine tissue spectra measured by passage of the Raman probe 
through a Perspex mapping grid positioned on the surface of the tissue. Note the lipid peaks 
detected when measuring a lipid-rich portion of porcine tissue (gold spectrum). No evidence 
of tissue disruption was observed. 
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Figure VI-7. Five second spectra measured from adjacent grid positions across a 
porcine tissue phantom. 
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For comparison, spectra measured randomly from the porcine phantom (without the use of 
the grid) are plotted below (Figure VI-8). 
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Figure VI-8. Porcine tissue spectra measured at random across the surface of the tissue. 
 
Experiment 6. Effect of saline / water lavage. 
 
Comparison of mean spectra following lavage with saline and spectroscopic grade water. I 
needed to ensure that removing blood from tissue by washing with water or saline would not 
cause major spectral disruption. The control was not washed. The spectral differences below 
may reflect the effects of other variables including tissue contact and probe pressure which 
were not controlled in this experiment. 
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Figure VI-9. Mean 5 s porcine tissue spectra measured before and after lavage with 
water and lavage with saline. 
 
 
Experiment 7. Comparison of Current and Original Prototype Probe 
 
The background signal measured using the Raman probe was compared to that of an earlier 
prototype probe (Figure VI-10). Both probes were used in conjunction with the same laser 
source and spectrometer. Although the background shapes were similar, the intensity of 
background signal recorded using the prototype probe was considerably higher than with the 
current confocal design. 
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Figure VI-10. Air background spectra acquired in 5 s with the current confocal probe 
and the earlier prototype probe. 
 
 
Ex vivo oesophageal tissue spectra were acquired from three patients using the prototype 
probe. Mean 5 s tissue spectra for 3 pathologies are illustrated in Figure VI-11. Mean 5 s 
spectra for each pathology acquired using the current probe are also illustrated for 
comparison. The prototype probe was not used for further tissue measurements as it was not 
designed for tissue contact (making it less amenable to endoscopic use than the current 
probe); it did not have a confocal, short focal length design, so could not interrogate 
oesophageal epithelium without significant signal interference from deeper tissues; and it 
displayed a significantly higher background signal. 
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Figure VI-11. Mean tissue spectra acquired in 5 s using the current confocal probe and 
the earlier prototype probe. The different background signal allows easy visual 
distinction between tissue measured using each of the two probes. 
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Appendix V 
 
 
Temporary Local Rules for the 830nm Laser associated with the Compact 
Raman Spectroscopy System and Raman Probe 
 
Nature of Hazards to Persons 
Innovative Photonic Solutions (IPS) Laser: Class IIIB, >350mW, λ =830nm (Serial # 1002 
Model # I0830MM0350MF-EM) 
This laser has a shutter which must be closed when the laser is not in use. 
 
Extreme care should be taken when operating these lasers to avoid potentially hazardous 
exposure to both eyes and skin. Safe use of the lasers depends on strict adherence to the 
following rules. These Rules apply to each laser equally.  
 
This laser is designed to be used with a fibre optic patchcord attached to the laser output port 
and should not be operated in an “open beam” configuration for QA measurements. The 
probes must be kept facing downwards in the jig provided at all times. More than one laser 
must NOT be operated simultaneously in “open beam” configuration. 
 
These Local Rules have been written such that the laser (and probe system) can only be used 
in Endoscopy Theatre 3 in Gloucestershire Royal Hospital. The location of the room must be 
signed off by the LPA prior to use. 
 
Controlled Area Designation and Access 
1) The room in which the laser is being used is designated a “Controlled Area”, when the 
laser is switched on. The number of persons in the Controlled Area will be kept to a 
minimum. The laser will only be used in this area. Approved warning signs will be are 
fitted to the door. The second entrance to the room (single door) will be kept locked at all 
times. The main door will be manned by an assistant stood outside to prevent anyone 
from entering the room. Prior to the single designated session of laser use on Friday 21
st
 
1400 – 1800, members of the endoscopy department will be informed of the use of the 
laser and advised that they will not be able to enter Room 3 whilst the laser is in use. 
They will be given a written handout to endorse this advice. 
2) All endoscopy equipment will be moved to the edge of the room and shiny objects will be 
covered or removed prior to use of the laser. 
 
Laser Protection Supervisor (LPS) 
3) The Laser Protection Supervisor is Prof. N. Stone. (See (18)). The role of the LPS is to 
ensure adherence to these Local Rules, that the register of Authorized Users is maintained 
and liaise with the Laser Protection Advisor (LPA) as required. 
 
Register of Authorised Users 
4) Authorised users are Dr N. Stone, Dr C.A. Kendall and Dr J. Hutchings and Dr L.M. 
Almond. They have been trained in the safe operation of the laser and will sign statements 
 263 
to the effect that they have read and understood these Local Rules. A list of the approved 
users with the authorisation signature of the Laser Protection Supervisor can be found 
below. 
5) It is the responsibility of the Authorized User to be aware of the nature of the hazards 
involved.  
6) It is the responsibility of the Authorized User to consider: 
 Location of nearest fire extinguisher – on corridor 
 Control of access to the room – see section 1 above 
 Telephone contact in case of emergencies – extension of room 8228, extension in 
an emergency 2222 
 
Protective Eyewear 
7) Protective eyewear, suitable for use with NIR diode lasers (830nm) is provided, in 
accordance with BS EN 207/208. People in the controlled area must wear protective 
eyewear. 
 
Methods of Safe Working 
8) The operator will place a sign on the outside of the laboratory door which states 
‘WARNING - LASER ON - DO NOT ENTER WITHOUT SUITABLE EYE 
PROTECTION’ when the laser is in use.  
9) The laser output port will not be routinely used in an “open beam” configuration, 
therefore the beam will be emitted from the probe tip. The probe will be kept facing 
downwards in the jig to minimize exposure risk. 
10) The laser should be positioned such that the direct ‘open beam’ is not directed towards 
the door or windows.   
11) Do not look directly into the laser or the probe 
12) The shutter must be closed or the safety cap replaced when the probe is disconnected or 
reconnected.  
13) Keep all reflective or shiny components out of the laboratory unless no alternative is 
available.  
14) When the lasers are not in use the key will be removed from the laser and stored securely 
by the nominated key holder. 
 
Custody of the Key 
15) The Laser Protection Supervisor, Prof. N. Stone, is the nominated key holder. He is 
responsible for issuing the key to Authorised Operators only (see Point 13).  
 
Adverse Incident Procedure 
16) If an actual or suspected incident should occur, in which the eyes or skin are irradiated 
with the laser beam, an examination by an ophthalmologist or dermatologist should be 
carried out within 24 hours. The Laser Protection Adviser should be contacted as soon as 
possible.  
 
Laser Protection Advisor 
17) For further advice or information contact the Laser Protection Adviser Dr Janelle Reyes-
Goddard or the Laser Protection Supervisor Professor Nicholas Stone. Biophotonics 
Research Unit. Gloucestershire Hospitals NHS Foundation Trust. 
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Signs 
18) A printed sign shall be fitted to the entrance to the Controlled Area, containing the BS 
Laser Symbol and the wording, ‘Controlled Area, Class 3B Semiconductor Lasers, = 
830 nm’. SA second sign will also fitted stating in larger type: “Please do not enter 
without knocking”. 
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Appendix VI 
 
Risk Assessment Form   
 
 
Location: 
 
Ward:/ Department: Biophotonics Research Unit 
 
Site:   Leadon House:                                Speciality:  Clinical 
Research 
Assessment number: 31 
 
 
Task: 
 
 
Raman probe measurements on patient tissue (clinical and 
research) samples in vitro 
Date of Assessment: 8
th
 July 2011 
Assessor/auditor: Max Almond 
 
 
Description of services 
and situation of the 
workplace 
 
Which service users does the task affect? 
Max Almond, Catherine Kendall, Jo Hutchings 
 
How often does the above task occur in the workplace? 
 
 Daily                 Weekly                        Monthly 
 
What time of the day does the above task generally occur? 
 
Office Hours and Evenings 
 
What is the most common type of injury following the above task 
in the workplace?  
 
N/A (No injury has ever occurred). 
 
Is there history of staff absence as a result of the above 
task in your workplace? 
 
No 
 
Provide brief description of general working and occurrences 
of the tasks that may result in harm. 
 
Use of laser probe for tissue analysis. 
Pinning out of ex vivo human tissue (using pins). 
Fixation of biopsies using formalin. 
Snap freezing of biopsies using liquid nitrogen. 
Taking biopsies from tissue specimens using biopsy forceps 
and scalpel. 
Handling human tissue. 
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Ref 
no. 
What are the Hazards? Who might be harmed 
and how? 
What are you already doing? What further action is 
necessary? 
Risk rating 
G Y O R 
 
 
 
How have the accidents 
injuries been caused  
Review sources of 
evidence for what has 
been harmed – e.g. 
incident accident forms, 
complaints,  
What do you already do to reduce the 
chance of accidents  
     
 
 
1 
Use of laser probe for 
tissue analysis. 
 
User – damage to eyes / 
skin. 
Eye protection. 
Limited laser power. 
Assessment of competency prior to 
independent use - users are not signed off 
to use the laser unless assessed by the 
LPS. 
Please refer to Biophotonics laser  Local  
Rules.  
None.     
 
2 
Pinning out of ex vivo 
human tissue (using 
pins). 
 
User – needle-stick 
injury. 
Wear gloves when handling tissue. 
Refer to needle-stick protocol. 
None.     
 
3 
Fixation of biopsies 
using formalin. 
 
User – contact with eyes 
/ skin. 
Wear gloves. 
Training 
Well ventilated room 
Store large quantities 
(large 1 L bottles) of 
formalin in the chemistry 
lab. Only keep the 
    
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minimum number of 
biopsy pots in the 
Raman lab and use the 
Chemistry Lab for 
storage.  
 
4 
Snap freezing of 
biopsies using liquid 
nitrogen. 
 
User – contact with body 
part. 
Wear gloves, face protection, long sleeves, 
apron. 
Training 
None.     
 
5 
Handling of human 
tissue. 
User + others using the 
lab. 
Carefully clean equipment after use. Wear 
gloves whilst handling tissue. 
Training 
Cross reference RA for handling tissue.  
 
None.     
 
6 
Taking biopsies from 
tissue specimens using 
biopsy forceps and 
scalpel. 
 
User. Wear gloves. 
Training as a surgeon, training for research 
None.     
 
7 
 
Loss of tissue prior to 
essential clinical 
analysis. 
Important clinical 
information may be lost. 
This could impact on 
subsequent care of the 
patient. 
Only one patient’s tissue is measured at 
one time. Tissue is taken to the pathology 
department as soon as Raman 
measurements have been taken. 
Ensure that the lab is kept clear from 
clutter to prevent samples being misplaced. 
None.     
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8 
Laser damage to the 
tissue sample 
A clinical diagnosis may 
not be possible due to 
damaged samples. This 
could impact on 
subsequent care of the 
patient.   
Measurements are carried out with a 
constant laser power at the probe tip.  
 
None     
 
9 
Inappropriate handling 
of patient identifiable 
information 
Patient identifiable 
information may be 
accessed by those other 
than the patient, clinical 
and research staff 
involved in the project. 
Patient identifiable information is stored in 
a sample database which is password 
protected and stored on an office PC. The 
database is not used on laptops/USB 
sticks. Spectra are stored with an 
anonymised patient identifier, Any 
paperwork (including stickers) with patient 
identifiable information must be disposed of 
as confidential waste. Lab books should 
not contain patient identifiable information. 
Adherence to the Trust policy on Data 
protection. Completion of e-learning on 
Data Protection, 
None     
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Appendix VIII 
 
 
PATIENT INFORMATION SHEET  
Version 1 – January 2003 
 
Early Diagnosis of Oesophageal Malignancy  
 
Lead Researchers: Prof H Barr, Dr N Stone, Dr C Kendall 
 
You are invited to take part in a research study being carried out at the Gloucestershire Royal 
Hospital. Before you decide whether you would like to participate it is important for you to 
understand why the research is being done, and what it will involve. Please take time to read 
the following information carefully and discuss it with others if you wish. Please ask us if 
there is anything unclear or if you would like further information. Please take time to decide 
whether or not you wish to take part. Thank you for reading this information. 
 
What is the purpose of the study? 
The staff of Gloucestershire Royal Hospital and scientists at Cranfield University are working 
together to find new ways of providing advanced clinical support for the local community. 
An area where we feel we can make major advances is in improving our ability to detect 
oesophageal disease, pre-cancer and cancer. 
 
Why have I been chosen? 
We will be collecting samples from many people under surveillance for Barrett's oesophagus. 
Therefore this request does not mean that your diagnosis is unsure. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to participate you will be 
given this information sheet to keep and will be asked to sign a consent form. If you decide to 
take part you are still free to withdraw at any time and without giving a reason. Your care, 
treatment or method of assessment will not be altered in any way by your decision to donate 
or otherwise.  
 
What will happen to me if I take part? 
Your doctor has explained to you that he/she will be removing some oesophagus tissue 
during the course of your care. Specialist staff within the hospital will examine this tissue and 
your care guided by what they find. If you are willing to allow us, we can use a small number 
of additional samples to help us develop new diagnostic tests. No additional procedures will 
be undertaken as a result of your consent. In addition there is no need for any lifestyle 
restrictions to participate in this study.  
 
What is being tested in this study? 
We are developing new techniques using light for the early detection of disease. Using 
advanced rapid tests we hope to be able to easily detect this disease earlier without the need 
for long uncomfortable procedures. Before these investigations can be carried out on patients, 
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it is necessary to assess its suitability with human tissue in the laboratory. The Optical 
Diagnosis Group based at the Gloucestershire Royal Hospital has over five years experience 
of working in this field. 
 
What are the possible disadvantages and risks of taking part? 
No additional procedures to your routine care will be undertaken as part of this study, 
therefore there are no associated additional risks. 
 
What are the possible benefits of taking part? 
No additional procedures to your routine care will be undertaken as part of this study, 
therefore there is no immediate clinical benefit to yourself. However, the information 
collected from this study may help us develop new techniques to improve the treatment of 
patients with Barrett’s oesophagus. 
 
Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research will be kept 
strictly confidential. If you consent to taking part in this study you will give permission for 
Dr N Stone & Dr C Kendall, from the Optical Diagnosis Group Cranfield Postgraduate 
Medical School to have access to your medical notes, where it is relevant to your taking part 
in research.  
 
What will happen to the results of the research study? 
We hope that the results will be published in scientific and medical journals. You will not be 
identified in any way in such a publication. 
 
Who is funding and organising the research? 
The research is funded by the NHS R&D Executive, Health Technology Development 
scheme (DoH & DTI) and the EPSRC. It is being carried out by Cranfield Postgraduate 
Medical School, a link between the Gloucestershire Hospitals NHS Trust and Cranfield 
University. 
 
Who has reviewed the study? 
The Gloucestershire Local Research Ethics Committee has reviewed the study. 
 
Consumers for Ethics in Research (CERES) publish a leaflet entitled ‘Medical Research and 
You’. This leaflet gives more information on medical research. A copy can be obtained from 
CERES, PO Box 1365, London N16 0BW. 
 
Thank you for your help and co-operation. If you have any questions please contact 
Professor H. Barr, Gloucestershire Royal Hospital. Tel: 08454 226679 or Dr C. Kendall 
on 08454 225715 
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Appendix IX 
 
CONSENT FORM 
 
Early Diagnosis of Oesophageal Malignancy  
 
Lead Researchers: Prof H Barr, Dr N Stone, Dr C Kendall 
 
Please initial each box 
1. I confirm that I have read and understand the information sheet, datedfor the above 
study and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being 
affected. In the event that I wish to withdraw from this study, data collection will 
cease immediately and I can request that all data collected is confidentially destroyed. 
 
3. I understand that Dr N Stone & Dr C Kendall, from the Optical Diagnosis Group 
Cranfield Postgraduate Medical School, may access sections of my medical notes, 
where it is relevant to my taking part in research. I give permission for these 
individuals to have access to my records. 
 
4. I agree to take part in this study.  
 
5. I understand that you may take additional samples during the course of my care to 
help you develop new diagnostic tests. These samples may be made available for 
research after all the procedures required for my clinical management have been 
completed. I give my consent.  
 
 
.............................……..   .....................  ...................…………… 
8.13.1.1 Name of Patient   Date   Signature 
 
.............................……..   .....................  ...................…………… 
8.13.1.2 Name of person taking consent Date   Signature 
(if different from researcher) 
 
.............................……..   .....................  ...................…………… 
8.13.1.3 Name of Researcher   Date   Signature 
 
 
1 copy for patient, 1 for researcher, 1 for hospital notes 
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Appendix X 
 
Power Calculation 
 
 
This calculation aimed to establish the number of samples needed to demonstrate a sensitivity 
of 86% (attained from the preliminary analysis) for differentiating adenocarcinoma / HGD, 
from normal squamous, non-dysplastic Barrett’s oesophagus and gastric tissue. 
 
 
TP + FN = z
2
 x (SN (1 – SN)) / W2 
 
 =>  = 1.96
2
 x (0.86 (1 – 0.86))) / 0.12 
 
 => = 185.01 
 
 NsN = 185.01/P 
 
 =>  = 185.01/0.092 
 
 = 502 
 
Where: 
SN is the sensitivity of the probe for detecting HGD/cancer from my preliminary 
analysis. 
W is the confidence interval (in this case 90%). 
P is the proportion of spectral measurements that were from homogenous cancer/HGD. 
 
This calculation determined that approximately 500 samples (NsN) would be required to 
demonstrate a sensitivity of 86% for cancer/HGD using 90% confidence intervals. This 
calculation assumes that only 9% of measured spectra will be HGD/cancer (as was the case in 
the preliminary analysis), and also that only one spectrum will be measured per biopsy. No 
allowance is made for tissue being excluded due to heterogeneity or diagnostic disagreement 
between expert pathologists. Also, the number of biopsy samples required to enable 
classification between grades of dysplasia could not be calculated here. 
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Given these limitations this power calculation was used only as a guide. The entire spectral 
dataset presented in this thesis could be used to optimise a more accurate power calculation 
prior to an in vivo study in the future. 
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Appendix IX 
 
This appendix summarises the Cranfield MSc Thesis submitted by Ms Marta Losa in August 
2011.[259] I co-designed and co-supervised this work and helped with methodology, data 
collection and interpretation of the results. 
 
Do Raman Spectroscopy Signatures Correlate with Molecular Markers of 
Progression in Barrett’s Oesophagus? 
 
 
Summary: 
 
Raman spectroscopy is a powerful analytical technique with the ability to distinguish 
oesophageal pathologies by detecting minute differences in their biochemistry. This 
technique has the potential to supersede routine histology reporting for establishing 
pathological diagnosis, however to date the link between the spectral signatures and 
underlying molecular changes has not been explored. 
 
A thorough literature review was performed to identify a range of biomarkers which are 
known to correlate with the metaplasia–dysplasia–adenocarcinoma sequence (Table IX-1).  
 
 
 
Table IX-1. Biomarkers which are known to correlate with progression from normal 
squamous oesophagus to adenocarcinoma.[259] 
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The biomarkers for further study were selected based on the following criteria: 
- Detectable at a protein level. 
- Detectable using a cheap, relatively straight-forward technique such as 
immunohistochemistry (IHC). 
- Primary antibodies must be commercially available. 
- Strong evidence as a biomarker for neoplastic progression. 
- Previously well studied and well characterised. 
 
Subsequently five biomarkers (p53, E‐cadherin, Cyclin A, CDX‐2 And hTERT) were 
selected for use in the study. 
 
Forty‐one biopsies were collected from 17 patients during routine Barrett’s surveillance 
endoscopy. Biopsies were snap frozen in liquid nitrogen and sectioned. Contiguous sections 
were obtained from each sample (Figure IX-1). 
  
 
Figure IX-1. Scheme of sections obtained from each tissue sample.[259] 
 
The sections highlighted in green in Figure IX-1 were analysed using p53 and E-cadherin 
IHC at Gloucestershire Royal Hospital (GRH). IHC analysis of CDX-2, cyclin A and hTERT 
was performed at Cranfield University (red sections). Standardised IHC protocols were 
carefully adhered to at both centres. The results of the Cranfield IHC were graded semi-
quantitatively as 0, +, ++, or +++ for each of the biomarkers (Figure IX-2). 
 
High quality Raman maps were acquired over 48 hours from two tissue samples. Maps were 
acquired using a customised Renishaw Raman System 1000 spectrometer coupled to a 
microscope. An 830 nm monochromatic laser was used for excitation and scattered light was 
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filtered and then dispersed and measured by a CCD. Figure  3-7 illustrates one of the high 
quality maps acquired using an x and y step size of 8.4 µm and an acquisition time of 30s per 
pixel. Mean spectra measured from different areas across the tissue section are illustrated in 
Figure IX-2.  
 
The two biopsies for which all Raman, histological and IHC analysis was completed both had 
a histological diagnosis of Barrett’s oesophagus. However, a slightly different pattern of 
molecular markers were identified in each sample: 
Sample 1: Cyclin A ++, CDX-2 +, hTERT ++ 
Sample 2: Cyclin A +++, CDX-2 0, hTERT +++ 
 
 
 
Figure IX-2. Example of positive results for hTERT staining in samples 1 and 2. Sample 
1 was graded ++ and sample 2 +++. Photographs on the left were taken at 10x 
magnification, and those on the right at 40x magnification.[259] 
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Figure IX-3. Mean Raman spectra acquired from different areas across two mapped 
tissue sections. Both of these sections had glandular areas – mean spectra for these areas 
are illustrated individually.[259] 
 
This was a proof of principle study aiming to refine the methodology for identifying Raman 
signatures which might correlate with molecular markers, prompting further investigation. 
Within the scope and time-restraints of the study two biopsies were chosen for high quality 
mapping. IHC for detecting 5 biomarkers, and H&E staining, were performed on sections 
from the corresponding biopsies as illustrated in figure IX-2. As stated previously, 
independent, semi-quantitative grading of IHC results was performed for three of the five 
biomarkers (Cyclin A, CDX-2, and hTERT). 
 
The mean Raman spectra from glandular areas were markedly different from squamous areas, 
consistent with previously reported studies (Figure IX-3).[34; 38; 43; 49; 245] Slight 
differences in mean spectra between the glandular areas in each sample were identified, 
which could potentially reflect biochemical differences corresponding to molecular markers 
of disease progression. However, in this study, no definite correlation could be identified. 
 Normal Squamous 
 Lamina propria 
 Glandular (sample 1) 
 Glandular (sample 2) 
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This pilot study had a number of limitations: 
 
- Grading of IHC results was based on staining across the sample as a whole. This 
could have been improved by defining an area of definite positively or negatively 
staining glands and proceeding to map that specific area. 
- Due to the pilot nature of the study, and short timescales, the numbers of samples with 
histological, IHC and Raman data available was small. 
- Biomarkers were chosen which were known to correlate with disease progression in 
Barrett’s oesophagus. It is possible that several other biomarkers have a more 
pronounced Raman signal and so may be better ‘Raman markers’ of progression. To 
identify these, a larger panel of biomarkers will need to be investigated. It may be that 
future biomarkers should be chosen based on a known biochemical structure being 
predicted to generate a significant Raman signal. 
- A larger sample size will enable multivariate classification of glandular spectra based 
on histological and molecular features. In this pilot study no statistical algorithms 
were developed to explore biomarker-Raman correlations. 
- Significant fading of IHC stains was observed in this study, perhaps due to the use of 
acetone, as opposed to formalin, fixation. Frozen (rather than formalin fixed samples 
were used here to prevent corruption of Raman signals by unwanted artefacts caused 
by formalin fixation). 
 
Although no correlations were definitely identified, this pilot study highlighted several 
potential methodological difficulties which must be addressed prior to further studies. A 
potential Raman-histology-biomarker classification model has been proposed which will 
require further study, with much greater sample sizes. Also, alternative techniques for 
biomarker identification could be employed to enable more specific and quantitative data to 
be acquired. A much larger group of biomarkers will also need to be evaluated. A PhD 
position at the Biophotonics Research Unit has been recently advertised to investigate 
Raman-biomarker correlations further. 
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Appendix XII 
 
Spectral Cytopathology of Oesophageal Cells 
 
Introduction: 
 
A small proof of principle study assessing the potential for spectral cytopathology (SCP) of 
oesophageal cells was performed in collaboration with Professor Max Diem and his research 
group in Northeastern University, Boston. This research followed a BSG travelling 
fellowship where I visited Professor Diem’s team and proposed a role for SCP in the 
oesophagus. 
 
The ability to reliably and rapidly detect Barrett’s oesophagus and / or neoplasia from 
samples of oesophageal cells could potentially lead to a screening test for these conditions. 
SCP is a novel technique which uses infrared spectroscopy to probe molecular differences in 
cell types potentially enabling objective diagnostic discrimination. Several studies have 
reported the success of SCP in diagnosing neoplasia from other sites including the oral cavity 
and the cervix but to date SCP of oesophageal cells has not been attempted.[252-254; 260] 
 
Aims: 
 
A proof of principle study to assess the potential for SCP of oesophageal cells to discriminate 
normal squamous, Barrett’s oesophagus and neoplasia. 
 
Ethics: 
 
Ethical approval for this study was provided by the Glouceseter Research Ethics Committee. 
 
Methods:  
 
Oesophageal brushings were taken during endoscopy from patients with Barrett’s oesophagus 
with and without neoplasia. Samples were fixed in ThinPrep and transported to Boston. There 
they were vortexed off the brushes, filtered to remove debris and deposited onto Kevley low-
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e slides. Infrared (IR) spectral data maps from a  2 mm x 2 mm spot were acquired at 4 cm
-1
 
resolution and 6.25 μm pixel size with 2 scans per pixel. 
 
Data were processed using PapMap (which excluded spectral data which were not acquired 
from cells) and PCA. 
 
Results: 
 
Three samples were used for this preliminary analysis in order to ascertain whether SCP was 
a suitable approach for studying Barrett’s Esophagus. 
 
2 samples were taken from an area of normal squamous oesophagus and 1 from an area of 
Barrett’s. 25 individual cells from each of the following samples were used for PCA. Mean 
absorption spectra for each sample are illustrated (Figure XII-1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure XII-1. Mean absorption spectra for each sample. 
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PC loadings and PC scores plots are illustrated in Figures XII-2 and XII-3 respectively. 
 
 
 
Figure XII-2. illustrates PC loadings 1-4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure X-3A PC scores plot 1 vs. 2. 
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Figure X-3B PC scores plot 1 vs. 3. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure X-3C PC scores plot 1 vs. 4. 
 
 
Conclusions: 
 
These data show that SCP of oesophageal cells is feasible. Although PCA was not conclusive 
it is likely that more cells from a larger sample pool may yield a better result. Also, some of 
the cells from the Barrett’s sample were in fact squamous which will have hindered spectral 
discrimination.  
 
PC1 
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P
C
3
 
P
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ThinPrep solution did not appear to induce spectral artefacts. However, in future formalin 
fixation would be preferable. In addition, sample collection must be modified using larger 
more robust brushes in order to maximize the collection of whole oesophageal cells. 
 
A firm amide I peak was present at 1652 cm
-1
. More detailed biochemical analysis will be 
undertaken through further testing. 
 
An international collaboration has been initiated between the Biophotonics Research Unit in 
Gloucester and the Department of Medical Diagnostics in Northeastern University, Boston. 
There is agreement that there is a clear clinical need for oesophageal SCP and further sample 
collection is currently in progress. 
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Appendix XIII 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20 PC loadings following PCA on a three group (normal squamous; NDB/LGD; 
HGD/adenocarcinoma) classification model. 
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Appendix XIV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCA was performed on the spectra acquired in the presence of endoscopic white light, 
NBI and after exclusion of all ambient light. PC loads 1-20 are plotted. No obvious 
Raman peaks are visible. Most of the PC loads represent spectral noise. 
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Appendix XV 
 
 
Grants, prizes, awards, publications and presentations October 
2010 – October 2012 
 
 
Grants 
 Royal College of Surgeons of England Research Training Fellowship. October 2011. 
 Three Counties Oesophageal Research Training Fellowship October 2010. 
 
 
Prizes 
 
 First prize for best presentation of original research at the International Laser Europe 
Conference, London, May 2012. 
 Translational Medicine Meeting Oral Presentation Prize. Gloucestershire Royal 
Hospital. March 2012. 
 Winner of the West Midlands Surgical Society prize for best oral presentation. 
Worcester, November 2011. 
 Winner of the best poster prize at the West Midlands Surgical Society. Worcester, 
November 2011. (2
nd
 author). 
 Winner of the Royal Society of Medicine Prize (Surgery Section) for best presentation 
of laboratory research. London, September 2011. 
 Winner of the Twort Prize for best oral presentation at the 5th International Barrett’s 
Symposium, London. April 2011. 
 Nominated for The Royal Society of Medicine Trainee of the Year Award 2012. 
Decision takes place November 2012. 
 
 
Awards 
 
 The British Society of Gastroenterology John Bennett Travelling Research Fellowship 
This funded a trip to Harvard University, Boston and the Mayo Clinic, Rochester. 
 
I organised the travelling fellowship myself. It included the following: 
 
o Observation and discussion of complex upper GI endoscopy and Barrett’s 
related research at Massachusetts General Hospital under the supervision of 
Professor W. Brugge (Director of Endoscopy, Harvard Medical School); and 
at the Mayo Clinic, Rochester under the supervision of Professor Ken Wang 
(Professor of Gastroenterology). Clinical cases included diagnostic and 
therapeutic EUS, ERCP including pancreatic stenting and spyglass, confocal 
microscopy, chromoendoscopy, EMR, ESD, cryotherapy, RFA and APC 
ablation, and EUS guided pseudocyst drainage and necrosectomy. 
o Presentation and initiation of a collaboration with a group at Northeastern 
University, Boston, working on oesophageal spectral cytopathology using 
Raman and infra-red spectroscopy. This included analysis of oesophageal 
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brushings I had taken from patients in the UK and is part of an on-going 
collaboration. 
o Participation on the biannual Harvard Medical School Advanced Therapeutic 
Endoscopy course - included performing EUS-guided pseudocyst drainage on 
porcine stomachs as well as CM, EUS + FNA, 360 RFA and EMR in 
anaesthetized pigs. 
 
Publications 
 
1. Almond LM, Hutchings, Barr H, Day J, Stone N, Kendall CA. Fibre-optic Raman 
Spectroscopic Analysis in the Upper Gastrointestinal Tract. Spectroscopy Europe, 2011. 
23(3): 6-12. 
2. Almond LM, Hutchings, Shepherd N, Barr H, Stone N, Kendall CA. Raman 
spectroscopy: a potential tool for early objective diagnosis of neoplasia in the 
oesophagus. Journal of Biophotonics. 2011. 4(10): 685-95. 
3. Almond LM, Bowley DM, Karandikar SS, Roy-Choudhury SH. Role of CT 
colonography in symptomatic assessment, surveillance and screening. Int J Colorectal 
Dis. 2011 Aug; 26(8):959-66. 
4. Almond LM, Bowley DM, Hendrickse C, Karandikar SS, Roy-Choudhury SH. CT 
Colonography following Colorectal Cancer Resection: a ‘one-stop’ assessment of 
metachronous mucosal lesions, local recurrence and distant metastases. Radiology, 2011; 
260: 302-303. 
5. Petal K, Almond LM. Transient Auditory Dysfunction – A Description and Study of 
Prevalence. Accepted for publication by ENT Journal. In Print. 
6. Lloyd G, Hutchings J, Almond LM et. al.. Assessing the performance of spectroscopic 
models for cancer diagnostics using cross-validation and permutation testing. Proc. SPIE, 
2012. 8219, 821-9. 
7. Almond LM, Hutchings J, Kendall C et. al.. Preclinical evaluation of a Raman 
spectroscopic probe for endoscopic classification of oesophageal pathologies. Proc. 
SPIE, 2012. 8219, 90-7. 
8. Almond LM, Barr H. Advanced endoscopic imaging in Barrett's oesophagus. IJS. 2012; 
10(5):236-41. 
9. Barr H, Almond LM. The Future of Upper Gastrointestinal Cancer. Frontline 
Gastorenterology. 2012; 3:i24-i27. 
10. Williamson JML, Almond LM et. al.. Current management of Barrett’s oesophagus. Br J 
Hosp Med (Lond). 2012; 73(5):271-7. 
11. Green S, Almond LM, Jankowski J et. al.. Surgery versus radical endotherapies for early 
cancer and high grade dysplasia in Barrett's oesophagus. Cochrane Syst. Rev. In Print. 
12. Kallaway C,Almond LM et. al.. Advances in the clinical application of Raman 
Spectroscopy. Submitted to TCRT, June 2012. Under review. 
13. Torrence AW, Almond LM et. al.. Has The Introduction of Integrated Positron-Emission 
Tomography and Computed Tomography (PET-CT) Improved The Staging, Survival or 
Early Recurrence In Oesophageal Cancer? Submitted to BJS. 2012. Under review. 
14. Almond LM, Dwerryhouse S, Shepherd N, Barr H. Endoscopic Eradication of Early 
Barrett’s Neoplasia. Submitted to BJS. 2012. Under review. 
15. Almond LM et. al.. Assessment of a custom-built Raman spectroscopic probe for 
diagnosis of early oesophageal neoplasia. Submitted to JBO. 2012. Accepted subject to 
minor revisions. 
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Invited Articles 
 
1. Almond LM. Shining Light on the Path to Cancer. The Nursing Times. Invited after 
winning 1st prize at the International Barrett’s Symposium sponsored by Heartburn 
Cancer Awareness Support. http://www.nursingtimes.net/nursing-practice/clinical-
specialisms/gastroenterology/winning-oesophageal-cancer-presentation-shines-light-on-
the-disease/5029108.article. 
 
 
Book Chapters 
 
1. Almond LM, Barr H, Jankowski J. Barrett’s Oesophagus. Under review by editors 
Professor Michael Griffin and Professor Simon Raimes. Elsevier Publishing. For 
inclusion in 5
th
 Edition, A Companion to Specialist Surgical Practice: Oesophagogastric 
Surgery. 
2. Almond LM, Barr H. Endoscopic Detection and Eradication of Dysplastic Barrett’s 
Oesophagus. Accepted for publication by InTech publishing group. In print. 
3. Almond LM, Barr H. Prevention of Oesophageal Cancer. Commissioned by Wiley-
Blackwell publishing for the GI Oncology Handbook edited by Professor Jankowski and 
Dr Hawk. In Print. 
 
Published Abstracts: 
 
1. CT colonography after resection for colorectal cancer: safe & feasible. British Journal of 
Surgery, 2011, 98(S3): 80-217 
2. Almond LM, Hutchings J, Kendall C, Stone N, Day J, Shepherd N, Barr H. Towards real-
time ‘biochemical endoscopy’ for diagnosis of early barrett's neoplasia. Gut, 
2011;60:A167-A168 
3. Almond LM, Torrence A, Wadley M. Pre-operative PET-CT reduces early recurrence of 
oesophageal carcinoma following oesophagectomy. British Journal of Surgery, 2011, 
98(S3): 1–79 
4. Almond LM, Barr H et. al.. Prospects for Raman Spectroscopy for Real-time Endoscopic 
and Intra-operative Diagnosis of Cancer and Pre-cancerous Change. 
5. Almond LM, Barr H. Endoscopic Resection offers prolonged survival from High grade 
Dysplasia and Intramucosal Cancer in Barrett’s Oesophagus. British Journal of Surgery, 
2011, 98(S3): 1–79 
6. Almond LM, Hutchings J, Kendall C, Stone N, Day J, Shepherd N, Barr H. Mapping of 
the distal oesophagus using fibre-optic Raman Spectroscopy. British Journal of Surgery, 
2011, 98(S3): 1–79 
7. CT colonography after resection for colorectal cancer: safe & feasible. British Journal of 
Surgery, 2011, 98(S3): 80-217 
8. Almond LM, Hutchings J. Towards Endoscopic Detection of Oesophageal Neoplasia 
using fibre-optic Raman Spectroscopy. Gut 2012. (In Print). 
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National / International Oral Presentations 
 
1. Almond LM, Hutchings J, Kendall C, Stone N, Day J, Shepherd N, Barr H. Towards 
Endoscopic Detection and Targeting of Oesophageal Neoplasia using near-infrared 
spectroscopy. European Society of Esophagology. 2011 
2. Almond LM, Hutchings J, Kendall C, Stone N, Day J, Shepherd N, Barr H. Endoscopic 
Detection of Oesophageal Dysplasia using Light. 5th International Barrett’s Symposium. 
Winner of Twort prize. 2011 
3. Almond LM, Torrence A, Wadley M. Pre-operative PET-CT reduces early recurrence of 
oesophageal carcinoma following oesophagectomy. Presented at ASGBI International 
Surgical Congress, ‘21st Century Surgery’, 2011. 
4. Almond LM, Barr H. Endoscopic Resection offers prolonged survival from High grade 
Dysplasia and Intramucosal Cancer in Barrett’s Oesophagus. Presented at ASGBI 
International Surgical Congress, ‘21st Century Surgery’, 2011. 
5. Almond LM, Hutchings J, Kendall C, Stone N, Day J, Shepherd N, Barr H. Mapping of 
the distal oesophagus using fibre-optic Raman Spectroscopy. Presented at ASGBI 
International Surgical Congress, ‘21st Century Surgery’, 2011. 
6. Almond LM, Hutchings J, Kendall C, Stone N, Day J, Shepherd N, Barr H. Towards 
Endoscopic Detection and Targeting of Early Barrett’s Neoplasia using Fibre-Optic 
Raman Spectroscopy. Royal Society of Medicine, 2011. Winner of 1
st
 prize (surgery 
section) for best presentation of laboratory research. 
7. Almond LM. Potential for Oesophageal Cancer Screening using Spectral Cytopathology? 
Presented at Northeastern University, Boston, US, 2011. 
8. Almond LM. Inaugural John Bennett Travelling Oesophageal Fellowship Award 
Presentation. DDF (AUGIS / BSG). Liverpool, 2012. 
 
 
International Poster Presentations 
 
1. Almond LM, Hutchings, Kendall CA, Day J, Shepherd NA, Stone N, Barr H. Towards 
real-time ‘biochemical endoscopy’ for diagnosis of early Barrett’s neoplasia. BSG, 
Birmingham, 2011. 
2. Almond LM, Hutchings, Kendall CA, Day J, Shepherd NA, Stone N, Barr H. Towards 
Endoscopic Detection of Oesophageal Neoplasia using fibre-optic Raman Spectroscopy. 
DDF, Liverpool, 2012. 
 
 
Courses 
 
1. The 4th mattu Oesophago-Gastric Cancer Symposium. Guildford. December 2011. 
2. Harvard University Advanced Therapeutic Endoscopy Course. Boston, US. November 
2011. 
3. Royal College of Surgeons Research Methods Course. London. November 2011. 
4. ERCP Workshop. Birmingham, November 2011. 
5. Endoscopic Mucosal Resection course. Gloucestershire Royal Hospital. May 2011. 
6. Good Clinical Practice course. University of Birmingham. November 2010. 
7. Essentials for New Clinical Research Staff. Bath. October 2010. 
 
 
